Lysosomal storage disorder biomarkers and methods of use thereof

Specific lipid and protein biomarkers for LSDs allow for accurate assessment and personalized treatment, addressing the neurological aspects of these disorders and improving patient outcomes.

JP2024156744AInactive Publication Date: 2024-11-06DENALI THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024119466
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-10-08
Filing Date
2024-07-25
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for new biomarkers for lysosomal storage disorders (LSDs) to evaluate patients and therapies, as existing research has not adequately addressed the neurological components of these diseases, which often lead to severe symptoms and early death.

Method used

The use of specific lipid biomarkers such as bis(monoacylglycero)phosphate (BMP), GM2 ganglioside, GM3 ganglioside, GD3 ganglioside, GD1a/b gangliosides, and Glucosylceramide (GlcCer), along with soluble triggering receptor 2 (sTREM2) and neurofilament light chain (Nf-L), to detect and monitor LSDs, allowing for treatment adjustment and therapeutic efficacy assessment.

Benefits of technology

These biomarkers provide a means to accurately assess LSD severity and treatment effectiveness, enabling personalized treatment regimens that can reduce lipid and protein accumulation, thereby improving patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156744000047
    Figure 2024156744000047
  • Figure 2024156744000048
    Figure 2024156744000048
  • Figure 2024156744000049
    Figure 2024156744000049
Patent Text Reader

Abstract

To provide a method of detecting one or more biomarkers in a subject having a lysosomal storage disorder.SOLUTION: The method comprises: 1) measuring the concentration of a combination of two or more lipids in a sample from the subject, wherein the combination of lipids is selected from the group consisting of: a) a bis (monoacylglycero) phosphate (BMP); b) a GM2 ganglioside and / or a GM3 ganglioside; c) a GD3 ganglioside; d) a GD1a / b ganglioside; and e) a glucosylceramide (GlcCer); 2) measuring the concentration of GlcCer in a sample from the subject; 3) measuring the concentration of neurofilament light chain (Nf-L) in a sample from the subject; and / or 4) measuring the concentration of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in a sample from the subject.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application Serial No. 62 / 777,599, filed December 10, 2018, U.S. Provisional Application Serial No. 62 / 860,039, filed June 11, 2019, U.S. Provisional Application Serial No. 62 / 869,387, filed July 1, 2019, and U.S. Provisional Application Serial No. 62 / 912,253, filed October 8, 2019. The entire contents of the above-mentioned applications are incorporated herein by reference. [Background technology]

[0002] Lysosomal storage disorders (LSDs) are relatively rare genetic metabolic diseases resulting from defects in lysosomal function. LSDs are typically caused by the deficiency of a single enzyme involved in the breakdown of metabolic products in lysosomes. The accumulation of products resulting from the lack of enzymatic activity can affect various organ systems and lead to severe symptoms and early death. The majority of LSDs also have a significant neurological component, ranging from progressive neurodegeneration and severe cognitive impairment to epilepsy, behavioral, and psychiatric disorders. Although much research has been done to investigate the molecular mechanisms underlying LSDs and to develop new treatments, further exploration is still needed. In particular, new LSD biomarkers are needed, for example, for use in evaluating patients and therapies, and for screening drugs for therapeutic activity. Summary of the Invention [Means for solving the problem]

[0003] Accordingly, certain embodiments described herein provide a method for detecting one or more biomarkers in a subject having a lysosomal storage disorder (LSD), the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: a) bis(monoacylglycero)phosphate (BMP), b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) Glucosylceramide (GlcCer) measuring, 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is a mucopolysaccharidosis (MPS) disorder; 3) measuring the concentration of neurofilament light chain (Nf-L) in a sample from the subject; and / or 4) measuring the concentration of soluble triggering receptor expressed on bone marrow cells 2 (sTREM2) in a sample from the subject; The present invention provides a method comprising:

[0004] Certain other embodiments of the invention are directed to a method for treating LSD in a subject, the method comprising: 1) administering LSD treatment to subjects; 2) a) a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: i) BMP; ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer, A combination selected from the group consisting of: b) GlcCer in a sample from a subject, wherein the LSD is an MPS disorder; c) Nf-L in a sample from the subject, and / or d) sTREM2 in samples from subjects Measuring the concentration of, and 3) adjusting the dosage of the LSD treatment based on the concentration of the selected lipid(s) / protein(s) in the sample from the subject compared to the control value. The present invention provides a method comprising: [Brief description of the drawings]

[0005] [Figure 1] Brain HS / DS(GAG) accumulation in IDS KO mice compared to age-matched controls. For each age group, wild type (WT) is shown on the left and IDS KO is shown on the right. [Figure 2-1] Lysosomal lipids (GM2, GM3, BMP, and GlcCer) accumulate in the brains of IDS KO mice compared to their age-matched controls. In Figures 2B-2D, for each age group, the bar representing WT is shown on the left and the bar representing IDS KO is shown on the right. [Figure 2-2] Lysosomal lipids (GM2, GM3, BMP, and GlcCer) accumulate in the brains of IDS KO mice compared to their age-matched controls. In Figures 2B-2D, for each age group, the bar representing WT is shown on the left and the bar representing IDS KO is shown on the right. [Figure 2-3] Lysosomal lipids (GM2, GM3, BMP, and GlcCer) accumulate in the brains of IDS KO mice compared to their age-matched controls. In Figures 2B-2D, for each age group, the bar representing WT is shown on the left and the bar representing IDS KO is shown on the right. [Figure 2-4] Lysosomal lipids (GM2, GM3, BMP, and GlcCer) accumulate in the brains of IDS KO mice compared to their age-matched controls. In Figures 2B-2D, for each age group, the bar representing WT is shown on the left and the bar representing IDS KO is shown on the right. [Diagram 3] Elevated levels of BMPs observed in the serum of IDS KO mice compared to their age-matched controls. For each age group, the bar representing wild type (WT) is shown on the left and the bar representing IDS KO is shown on the right. [Figure 4]Elevated levels of lysosomal lipids (Gd1a / b, GM3, BMP and GlcCer) observed in the CSF of IDS KO mice compared to their age-matched controls. For each age group, the bar representing wild type (WT) is shown on the left and the bar representing IDS KO is shown on the right. [Diagram 5] Peripheral administration of ETV:IDS (4 weeks of treatment) corrects GAG accumulation in (A) the brain and (B) the CSF in IDS KO mice. Graphs show mean ± SEM and p-values: one-way ANOVA with Dunnett's multiple comparison test; *p0.05, **p0.01, ***p0.001, ****p0.0001. [Figure 6] Peripheral administration of ETV:IDS (4 weeks of treatment) corrects lysosomal lipid (ganglioside) accumulation in IDS KO brain. Graphs show mean ± SEM and p-values: One-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 7] Peripheral administration of ETV:IDS (4 weeks of treatment) corrects lysosomal lipid (GlcCer) accumulation in IDS KO brain. Graphs show mean ± SEM and p-values: One-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 8] Peripheral administration of ETV:IDS (4 weeks of treatment) corrects lysosomal lipid (BMP) accumulation in IDS KO brain. Graphs show mean ± SEM and p-values: One-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 9-1] Heatmap showing lipid levels in the brain of IDS KO mice treated with vehicle, ETV:IDS or elaplace (idursulfase). Fold change compared to WT. [Figure 9-2] Same as above. [Figure 9-3] Same as above. [Figure 9-4] Same as above. [Figure 9-5] Same as above. [Figure 10] Peripheral administration of ETV:IDS corrects TREM2 accumulation in IDS KO brain. Graphs show mean ± SEM and p-values: One-way ANOVA with Dunnett's multiple comparison test; ****p0.0001. [Figure 11] Peripheral administration of ETV:IDS reduces the accumulation of CSF soluble TREM2 (sTrem2) levels in IDS KO;TfRmu / huKI mice. [Figure 12-1] HS / DS(GAG) accumulation in serum (FIG. 12A), brain (FIG. 12B), and CSF (FIG. 12C) in IDS KO mice treated with vehicle or 3, 10, 20, or 40 mg / kg ETV:IDS. [Figure 12-2] HS / DS(GAG) accumulation in serum (FIG. 12A), brain (FIG. 12B), and CSF (FIG. 12C) in IDS KO mice treated with vehicle or 3, 10, 20, or 40 mg / kg ETV:IDS. [Figure 12-3] HS / DS(GAG) accumulation in serum (FIG. 12A), brain (FIG. 12B), and CSF (FIG. 12C) in IDS KO mice treated with vehicle or 3, 10, 20, or 40 mg / kg ETV:IDS. [Figure 13-1] Peripheral administration of ETV:IDS corrects the accumulation of GM3 (FIG. 13A), GlcCer (FIG. 13B), and BMP (FIG. 13C) in the brains of IDS KO mice treated with 3, 10, 20, or 40 mg / kg ETV:IDS compared to vehicle-treated IDS KO mice. Graphs show mean±SEM and p-values: one-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 13-2]Peripheral administration of ETV:IDS corrects the accumulation of GM3 (FIG. 13A), GlcCer (FIG. 13B), and BMP (FIG. 13C) in the brains of IDS KO mice treated with 3, 10, 20, or 40 mg / kg ETV:IDS compared to vehicle-treated IDS KO mice. Graphs show mean±SEM and p-values: one-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 13-3] Peripheral administration of ETV:IDS corrects the accumulation of GM3 (FIG. 13A), GlcCer (FIG. 13B), and BMP (FIG. 13C) in the brains of IDS KO mice treated with 3, 10, 20, or 40 mg / kg ETV:IDS compared to vehicle-treated IDS KO mice. Graphs show mean±SEM and p-values: one-way ANOVA with Dunnett's multiple comparison test; *p≦0.05, **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 14] Administration of ETV:IDS reduces the levels of individual GAG species (D0S0, D0A0, and D0a4) in the brain (A) and CSF (B) from IDS KO mice compared to vehicle-treated IDS KO mice. Graphs show mean ± SEM and p-values: one-way ANOVA with Dunnett's multiple comparison test; **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 15-1] FIG. 1 shows a schematic diagram of a CNS cell sorting protocol for the isolation of enriched populations of neurons, astrocytes, and microglial cells. [Figure 15-2] FIG. 1 shows a flow chart of a representative gating scheme used to isolate enriched populations. [Figure 15-3]Representative FACS gates for the sorting procedure described in Figure 15B are shown. Starting from the top left to the bottom right: forward (FSC) and side (SSC) scatter determines cells from debris, live cells are positively gated, exclusion of CD31 positive endothelial cells is confirmed, EAAT2 positive astrocytes are subgated from CD11b microglia, Thy1 positive neurons are subgated from EAAT2 positive astrocytes, and final removal of O1 oligodendrocyte cells in CD11b microglia, EAAT2 astrocytes, and Thy1 neuronal cell populations determine the final sorting criteria. [Figure 16] Principal component analysis using log-transformed CPM expression values ​​from the top 500 genes with highest variance. Principal components 1 and 2 account for 48% and 26% of the variance between samples, respectively. [Figure 17-1] Figure 1 shows the expression of given cell-specific markers in purified neurons, astrocytes, microglia, and input cell suspensions as determined by RNA-Seq. Columns are genes specific to cell types: (endo.) endothelium, (oligo.) oligodendrocytes; expression values ​​per gene are shown as the number of standard deviations (z-score) away from its mean; n=4 mice. [Figure 17-2] The expression of the top 20 enriched genes for each cell type as determined by fold enrichment >5.0 and FDR <0.01 is listed and shown. Heatmap expression values ​​are plotted as gene-level z-scores. Input cells were single cell suspensions from dissociated brains. [Figure 17-3] Figure 1 shows qRT-PCR data generated from isolated cell populations of neurons, astrocytes, and microglia. Gene classes are grouped on the x-axis: (Astro) astrocytes, (MG) microglia, (Neu) neurons, (Oligo) oligodendrocytes, and (Endo) endothelial cells; n=5 mice. Graphs show mean ± SEM. [Figure 18-1]GAG levels in microglia, astrocytes, and neurons isolated from IDS KO;TfRmu / huKI mice compared to TfRmu / huKI controls (n=3-5 mice per group). All data are shown as mean ± SEM; unpaired Student's t-test p≦0.05*, 0.001***. [Figure 18-2] Vehicle-treated TfRmu / huKI and IDS KO treated with ETV:IDS (40 mg / kg); Distribution of ETV:IDS in FACS-enriched neuronal, astrocyte, and microglial cell populations 2 hours post-dosing in TfRmu / huKI mice; n=4 mice per group. Graphs show mean ± SEM; Two-way ANOVA with Sidak's test; **p≦0.01, ***p≦0.001, and ****p≦0.0001. [Figure 19] Reduced GAG accumulation in neurons, astrocytes, and microglia from IDS KO;TfRmu / huKI mice administered 40 mg / kg ETV:IDS intravenously once weekly for 4 weeks. Data are shown as mean ± SEM; one-way ANOVA with Tukey's multiple comparison test, *p≦0.05, **p≦0.01, ****p≦0.0001. [Figure 20] Decreased ganglioside accumulation in neurons, astrocytes, and microglia from IDS KO;TfRmu / huKI mice administered 40 mg / kg ETV:IDS intravenously once weekly for 4 weeks. Data are shown as mean ± SEM; one-way ANOVA with Tukey's multiple comparison test, *p≦0.05, **p≦0.01, ****p≦0.0001. [Figure 21] Decreased glucosylceramide accumulation in neurons, astrocytes, and microglia from IDS KO;TfRmu / huKI mice dosed with 40 mg / kg ETV:IDS intravenously once weekly for 4 weeks. Data are shown as mean ± SEM; one-way ANOVA with Tukey's multiple comparison test, *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001. [Figure 22]Reversion of BMP alterations in neurons, astrocytes, and microglia from IDS KO;TfRmu / huKI mice treated with 40 mg / kg ETV:IDS intravenously once weekly for 4 weeks. Data are shown as mean ± SEM; one-way ANOVA with Tukey's multiple comparison test, *p≦0.05, **p≦0.01, ****p≦0.0001. [Figure 23] H&E staining (upper panels) and MALDI MS images (middle and lower panels) of coronal brain sections of wild-type and IDS KO;TfRmu / huKI mice after four weekly doses of vehicle, idursulfase, or ETV:IDS. The middle panel shows the distribution of the signal at m / z 1382.816, which corresponds to GM2(d36:1), and the lower panel shows the distribution of the signal at m / z 1179.738, which corresponds to GM3(d36:1). Images show the relative intensity of each signal from 0 to 100%. [Figure 24] Immunofluorescence images of brain tissue from TfRmu / huKI and IDS KO;TfRmu / huKI mice treated with vehicle, ETV:IDS, or idursulfase. Brain tissue was stained for DAPI and CD68. Magnification was 20x, and images represent the hippocampus (upper panel), cortex (middle panel), and striatum (lower panel). [Diagram 25] Table of cell type-specific enriched gene sets; information in the table corresponds to the heatmap in FIG. 17B. Expression of the top 20 genes for each cell type as determined by fold enrichment >5.0 and FDR <0.01 is listed in ascending order of p-value. The average log fold change (logFC.avg) is relative to the other two "outer" populations, and the three rightmost columns show the average expression of genes within each cell population; n=4 mice. [Figure 26-1]Scatter plots of Nf-L concentrations in wild-type and IDS knockout mice at 3, 6, and 9 months of age. Nf-L levels in serum and CSF of 9-month-old mice are shown in Figures 26A and 26B, respectively. In CSF of mouse cohorts at different ages is shown in Figure 26C. Data are shown as mean + / - SEM with p-values ​​obtained by unpaired t-test analysis. [Figure 26-2] Scatter plots of Nf-L concentrations in wild-type and IDS knockout mice at 3, 6, and 9 months of age. Nf-L levels in serum and CSF of 9-month-old mice are shown in Figures 26A and 26B, respectively. In CSF of mouse cohorts at different ages is shown in Figure 26C. Data are shown as mean + / - SEM with p-values ​​obtained by unpaired t-test analysis. [Figure 26-3] Scatter plots of Nf-L concentrations in wild-type and IDS knockout mice at 3, 6, and 9 months of age. Nf-L levels in serum and CSF of 9-month-old mice are shown in Figures 26A and 26B, respectively. In CSF of mouse cohorts at different ages is shown in Figure 26C. Data are shown as mean + / - SEM with p-values ​​obtained by unpaired t-test analysis. [Figure 27] Peripheral administration of ETV:IDS (13 weekly doses of 1 mg / kg or 3 mg / kg) reduces neurofilament light chain (Nf-L) levels in IDS knockout mice. Data are shown as mean + / - SEM with p-values ​​obtained by unpaired t-test analysis (*p<0.05; ***p<0.001; error bars = SEM). [Figure 28] Peripheral administration of ETV:IDS (13 weekly doses of 1 mg / kg or 3 mg / kg) reduces accumulation of GAG levels in liver and urine of IDS knockout mice. Urinary GAG levels were normalized to creatinine. Data are presented as mean + / - SEM with p-values ​​obtained by unpaired t-test analysis (****p<0.0001; error bars=SEM). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0006] As described herein, a series of biomarkers associated with LSD have been identified. In particular, as described in the Examples, a series of secondary lysosomal lipids have been shown to accumulate in the brain, CSF and serum from LSD mouse models. Also, triggering receptor expressed on myeloid cells 2 (TREM2) and neurofilament light chain (Nf-L) have been shown to accumulate in brain tissue from these mice. Notably, this secondary lipid accumulation and TREM2 accumulation can be ameliorated by application of LSD treatment (e.g., ETV:IDS). Based on these findings, these lipids / proteins can be used as biomarkers for purposes including, but not limited to, evaluating subjects with such disorders, evaluating the effectiveness of a given treatment, developing and / or modifying treatment regimens (e.g., adjusting dosing), and in methods for screening drugs for therapeutic activity.

[0007] Accordingly, certain embodiments described herein provide a method for detecting one or more biomarkers in a subject having an LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, where the LSD is an MPS disorder; and / or 3) measuring the concentration of sTREM2 in a sample from the subject; The present invention provides a method comprising:

[0008] Certain embodiments described herein also include a method of detecting one or more biomarkers in a subject having an LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample from the subject; and / or 4) measuring the concentration of sTREM2 in a sample from the subject The present invention provides a method comprising:

[0009] Certain embodiments described herein also include a method of assessing the efficacy of a treatment in a subject having an LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject (i.e., a sample obtained from the subject after administration of a treatment), the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, where the LSD is an MPS disorder; and / or 3) measuring the concentration of sTREM2 in a sample from the subject; Including, A reduction in the concentration of the selected lipid / protein in a sample from the subject compared to the concentration of the lipid(s) / protein in a sample obtained from the subject prior to administration of the treatment correlates with treatment efficacy.

[0010] Certain embodiments described herein include a method for assessing the efficacy of a treatment in a subject having an LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject (i.e., a sample obtained from the subject after administration of a treatment), the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample from the subject; and / or 4) measuring the concentration of sTREM2 in a sample from the subject Including, A reduction in the concentration of the selected lipid(s) / protein(s) in a sample from the subject compared to the concentration of the lipid(s) / protein(s) in a sample obtained from the subject prior to administration of the treatment correlates with treatment efficacy.

[0011] Certain embodiments described herein include a method of identifying a subject having an LSD as a candidate for treatment, comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, where the LSD is an MPS disorder; and / or 3) measuring the concentration of sTREM2 in a sample from the subject; Including, Methods are provided in which subjects are identified as candidates or non-candidates for treatment based on the concentration of the selected lipid(s) / protein(s) in the sample compared to a control value. For example, a concentration of the selected lipid(s) / protein(s) in the sample from the subject that is at least as high as the control value identifies the subject as a candidate for treatment.

[0012] Certain embodiments described herein also include a method of identifying a subject having an LSD as a candidate for treatment, comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer measuring, 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample from the subject; and / or 4) measuring the concentration of sTREM2 in a sample from the subject Including, Methods are provided in which subjects are identified as candidates or non-candidates for treatment based on the concentration of selected lipid(s) / protein(s) in a sample compared to a control value. For example, a concentration of selected lipid(s) / protein(s) in a sample from a subject that is at least as high as a control value identifies the subject as a candidate for treatment.

[0013] In some embodiments, the methods described herein further comprise applying LSD treatment to the subject.In some embodiments, the methods described herein further comprise adjusting the treatment regimen of the subject.For example, dosage can be increased or decreased, dosage frequency can be increased or decreased, or alternative therapy can be applied based on the comparison of the concentration of each selected lipid / protein with control value.

[0014] Accordingly, certain embodiments described herein are methods for treating LSD in a subject, the methods comprising: 1) administering LSD treatment to subjects; 2) a) a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: i) BMP; ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3 ganglioside, iv) GD1a / b gangliosides, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in a sample from a subject, wherein the LSD is an MPS disorder; and / or c) sTREM2 in samples from subjects Measuring the concentration of, and 3) adjusting the dosage of the LSD treatment based on the concentration of the selected lipid(s) / protein in a sample from the subject compared to a control value. In certain embodiments, the method includes administering an adjusted dosage of the LSD treatment to the subject, the dosage adjustment being based on the concentration of the selected lipid(s) / protein compared to the control value. In certain embodiments, the method includes applying a higher dosage of the LSD treatment to the subject than the original LSD treatment dosage (step 1) if the concentration of the selected lipid(s) / protein is higher than the control value. In certain embodiments, the method includes applying a lower dosage of the LSD treatment to the subject than the original LSD treatment dosage (step 1) if the concentration of the selected lipid(s) / protein is lower than the control value.

[0015] Certain embodiments described herein also include a method for treating LSD in a subject, the method comprising: 1) administering LSD treatment to subjects; 2) a) a combination of two or more lipids in a sample from a subject, the combination of lipids comprising: i) BMP; ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3 ganglioside, iv) GD1a / b gangliosides, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in a sample from a subject, wherein the LSD is an MPS disorder; c) Nf-L in a sample from the subject, and / or d) sTREM2 in samples from subjects Measuring the concentration of, and 3) adjusting the dosage of the LSD treatment based on the concentration of the selected lipid(s) / protein(s) in a sample from the subject compared to a control value. In certain embodiments, the method includes administering an adjusted dosage of the LSD treatment to the subject, where the dosage adjustment is based on the concentration of the selected lipid(s) / protein(s) compared to the control value. In certain embodiments, the method includes applying a higher dosage of the LSD treatment to the subject than the original LSD treatment dosage (step 1) if the concentration of the selected lipid(s) / protein(s) is higher than the control value. In certain embodiments, the method includes applying a lower dosage of the LSD treatment to the subject than the original LSD treatment dosage (step 1) if the concentration of the selected lipid(s) / protein(s) is lower than the control value.

[0016] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of sTREM2 in a sample from a subject with an LSD.

[0017] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of Nf-L in a sample from a subject with LSD.

[0018] As described herein, the concentration of GlcCer can be measured in a sample from a subject having an LSD. In such an embodiment, the LSD is an MPS. Thus, in certain embodiments, the methods described herein include measuring or having measured the concentration of GlcCer in a sample from a subject having an LSD, where the LSD is an MPS. In certain other embodiments, GlcCer is measured in combination with other lipids / proteins as described herein. In such an embodiment, the LSD can be any LSD, for example, an LSD as described herein.

[0019] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of a combination of two or more lipids in a sample from a subject with an LSD.

[0020] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of one or more combinations of lipids and the concentration of sTREM2 in a sample from a subject with an LSD.

[0021] In certain embodiments, the methods described herein include determining the concentration and / or concentration of one or more combinations of lipids in a sample from a subject having an LSD. Measuring or having measured the concentration of Nf-L.

[0022] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of sTREM2 and the concentration of Nf-L in a sample from a subject with an LSD.

[0023] In certain embodiments, the methods described herein include measuring, or having measured, the concentration of one or more combinations of lipids, the concentration of sTREM2, and the concentration of Nf-L in a sample from a subject with an LSD.

[0024] Certain embodiments described herein are directed to a method for treating LSD in a subject, the method comprising administering an LSD treatment to the subject, the subject receiving: 1) an elevated concentration of a combination of two or more lipids compared to a control, the combination of lipids being: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer an elevated concentration selected from the group consisting of: 2) elevated concentrations of GlcCer, where the LSD is an MPS disorder; and / or 3) Elevated levels of sTREM2 The present invention provides a method comprising:

[0025] Certain embodiments described herein are directed to a method for treating LSD in a subject, the method comprising administering an LSD treatment to the subject, the subject receiving: 1) an elevated concentration of a combination of two or more lipids compared to a control, the combination of lipids being: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) GlcCer an elevated concentration selected from the group consisting of: 2) elevated concentrations of GlcCer, where LSD is an MPS disorder; 3) elevated levels of Nf-L, and / or 4) Elevated levels of sTREM2 The present invention provides a method comprising:

[0026] Certain embodiments described herein are directed to a method of treating LSD in a subject, the method comprising: 1) obtaining or having obtained a sample from a subject; 2) In the sample, a) A combination of two or more lipids in a sample compared to a control, the lipid / protein combination being: i) BMP; ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3 ganglioside, iv) GD1a / b gangliosides, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in the sample compared to a control, wherein the LSD is an MPS disorder, and / or c) sTREM2 in samples compared to controls detecting or having detected an elevated concentration of 3) diagnosing the subject with LSD if elevated concentrations of the selected lipids / proteins are detected; and 4) administering an effective amount of LSD treatment to the diagnosed subject; The present invention provides a method comprising:

[0027] Certain embodiments described herein are directed to a method of treating LSD in a subject, the method comprising: 1) obtaining or having obtained a sample from a subject; 2) In the sample, a) A combination of two or more lipids in a sample compared to a control, the lipid / protein combination being: i) BMP; ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3 ganglioside, iv) GD1a / b gangliosides, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in the sample compared to the control, where the LSD is an MPS disorder; c) Nf-L in the sample compared to the control, and / or d) sTREM2 in samples compared to controls detecting or having detected an elevated concentration of 3) diagnosing the subject with LSD if elevated concentrations of the selected lipids / proteins are detected; and 4) administering an effective amount of LSD treatment to the diagnosed subject; The present invention provides a method comprising:

[0028] In certain embodiments, the subject has, or has been determined to have, an elevated concentration of sTREM2.

[0029] In certain embodiments, the subject has, or has been determined to have, elevated concentrations of Nf-L.

[0030] In certain embodiments, the subject has, or has been determined to have, an elevated concentration of GlcCer.

[0031] In certain embodiments, the subject has, or has been determined to have, elevated concentrations of a combination of two or more lipids.

[0032] In certain embodiments, the subject has, or has been determined to have, elevated levels of one or more lipids and elevated levels of sTREM2.

[0033] In certain embodiments, the subject has, or has been determined to have, elevated levels of one or more lipids and elevated levels of Nf-L.

[0034] In certain embodiments, the subject has, or has been determined to have, elevated levels of Nf-L and elevated levels of sTREM2.

[0035] In certain embodiments, the subject has, or has been determined to have, elevated levels of one or more of a lipid, an elevated level of Nf-L, and an elevated level of sTREM2.

[0036] Certain embodiments also provide an LSD treatment for use in the methods described herein.

[0037] Certain embodiments provide for the use of an LSD treatment to prepare a medicament for use in the methods described herein.

[0038] Biomarkers for Lysosomal Storage Disorders As described herein, a series of biomarkers for LSD have been identified. In particular, these biomarkers include the accumulation of certain lipids (i.e., BMP, GlcCer, GD3, GD1a / b, GM2 and GM3) in subjects with LSD, as well as the accumulation of TREM2, which can be measured based on sTREM2 levels, and the accumulation of Nf-L. Thus, these biomarkers can be evaluated by measuring the concentration of one or more of these lipids / proteins in samples obtained from subjects.

[0039] As used herein, the phrase "sample" or "physiological sample" is meant to refer to a biological sample obtained from a subject that contains proteins and / or lipids. Thus, the sample may be evaluated at the lipid or protein level. In certain embodiments, the physiological sample comprises tissue, cerebrospinal fluid (CSF), urine, blood, serum, or plasma. In certain embodiments, the sample comprises tissue, e.g., brain, liver, kidney, lung, or spleen. The sample may comprise a fluid. In certain embodiments, the sample comprises CSF. In certain embodiments, the sample comprises blood and / or plasma. In certain embodiments, the sample comprises serum.

[0040] TREM2 As used herein, the term "TREM2 protein" refers to the triggering receptor 2 protein expressed on myeloid cells encoded by the gene Trem2. As used herein, "TREM2 protein" refers to the native (i.e., wild-type) TREM2 protein of any vertebrate, including, but not limited to, human, non-human primate (e.g., cynomolgus monkey), rodent (e.g., mouse, rat), and other mammals. In some embodiments, the TREM2 protein is a human TREM2 protein having the sequence identified by UniprotKB accession number Q9NZC2.

[0041] The TREM2 gene encodes a 230 amino acid long protein that includes an extracellular domain, a transmembrane region, and a short cytoplasmic tail (UniProtKB Q9NZC2; see NCBI Reference Sequence: NP_061838.1). The extracellular region encoded by exon 2 consists of a single type V Ig-SF domain that contains three potential N-glycosylation sites. The putative transmembrane region contains a charged lysine residue. The cytoplasmic tail of TREM2 lacks signaling motifs and is thought to signal through the signaling adaptor molecules DAP12 / TYROBP and DAP10. TREM2 is found on the surface of osteoclasts, immature dendritic cells, and macrophages. In the central nervous system, TREM2 is expressed exclusively in microglia.

[0042] TREM2 can be cleaved by a disintegrin and metalloproteinase (ADAM) protease (e.g., ADAM10 and ADAM17), which results in the release of soluble TREM2 (sTREM2) into the extracellular environment. As described herein, elevated levels of TREM2 indicate downstream pathology in subjects with LSDs. Thus, TREM2 or sTREM2 levels can be measured using assays known in the art or described herein. For example, assays for detecting and measuring levels of protein expression include, for example, Western blot analysis, immunofluorescence, immunohistochemistry (e.g., of tissue arrays), mesoscale discovery (MSD) methods, and the like. In certain methods described herein, the concentration of TREM2 can be measured in a sample from a subject having or suspected of having an LSD. In certain methods described herein, the concentration of sTREM2 can be measured in a sample from a subject having or suspected of having an LSD.

[0043] In some embodiments, the concentration of sTREM2 in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In some embodiments, the concentration of sTREM2 is elevated at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In some embodiments, elevated sTREM2 concentrations are observed in tissue samples, e.g., brain. In some embodiments, elevated sTREM2 concentrations are observed in CSF. In some embodiments, elevated sTREM2 concentrations are observed in serum.

[0044] In certain other embodiments, a subject with an LSD is administered an effective LSD treatment that reduces the concentration of sTREM2 in a sample from the subject compared to a control (e.g., the same subject before receiving the treatment). In certain embodiments, the concentration of sTREM2 is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to the control. In certain embodiments, reduced sTREM2 concentration is observed in a tissue sample, e.g., brain. In certain embodiments, reduced sTREM2 concentration is observed in CSF. In certain embodiments, reduced sTREM2 concentration is observed in serum.

[0045] Nf-L As used herein, the term "Nf-L" refers to the neurofilament light chain (also referred to as neurofilament light chain polypeptide, neurofilament light polypeptide, and neurofilament light protein) encoded by the gene NEFL. As used herein, "Nf-L protein" refers to the native (i.e., wild-type) Nf-L protein of any vertebrate, including, but not limited to, human, non-human primate (e.g., cynomolgus monkey), rodent (e.g., mouse, rat), and other mammals. In some embodiments, the Nf-L protein is a human Nf-L protein having a sequence identified in UniprotKB Accession No. P07196.

[0046] As described herein, elevated levels of Nf-L indicate downstream pathology in subjects with LSD. Thus, Nf-L levels can be measured using assays known in the art or described herein. For example, assays for detecting and measuring levels of protein expression include, for example, Western blot analysis, immunofluorescence, immunohistochemistry (e.g., tissue array), mesoscale discovery (MSD) methods, etc. In certain methods described herein, the concentration of Nf-L can be measured in samples from subjects with or suspected of having LSD.

[0047] In some embodiments, the concentration of Nf-L in a sample from a subject with LSD is elevated compared to a control (e.g., a healthy control subject without LSD). In some embodiments, the concentration of Nf-L is elevated at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In some embodiments, elevated Nf-L concentration is observed in a tissue sample, e.g., brain. In some embodiments, elevated Nf-L concentration is observed in CSF. In some embodiments, elevated Nf-L concentration is observed in serum.

[0048] In certain other embodiments, the subject with LSD is administered an effective LSD treatment that reduces the concentration of Nf-L in a sample from the subject compared to a control (e.g., the same subject before receiving the treatment). In certain embodiments, the concentration of Nf-L is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to the control. In certain embodiments, the reduced Nf-L concentration is observed in a tissue sample, e.g., the brain. In certain embodiments, the reduced Nf-L concentration is observed in the CSF. In certain embodiments, the reduced Nf-L concentration is observed in serum.

[0049] Lipids As described herein, elevated levels of BMP, GlcCer, GD3, GD1a / b, GM2 and / or GM3 indicate downstream pathology in subjects with LSD. Thus, in certain methods described herein, the concentration of at least one BMP, GlcCer, GD3, GD1a / b, GM2 and / or GM3 can be measured in a sample from a subject with or suspected of having an LSD. The concentrations of these lipids can be measured (e.g., by mass spectrometry) using assays known in the art or described herein.

[0050] Bis(monoacylglycero)phosphate (BMP) refers to a class of anionic phospholipids. BMP is concentrated in the inner membrane of multivesicular endosomes and lysosomes, and is believed to play a role in glycosphingolipid degradation and cholesterol transport (see Kobayashi et al., Nat. Cell Biol. 1 (1999) 113-118). Specific BMP species are described herein (see, for example, Examples and Figures).

[0051] In certain embodiments, the concentration of at least one BMP species in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In certain embodiments, the BMP is a BMP species described herein, e.g., in the Examples or Figures. For example, in certain embodiments, the BMP is BMP(44:12), BMP(36:2), BMP(di20:4), BMP(di22:6) or BMP(di18:1). In certain embodiments, the concentration of at least one BMP is elevated by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In certain embodiments, the elevated BMP concentration is observed in a tissue sample, e.g., the brain. In certain embodiments, the elevated BMP concentration is observed in the CSF. In certain embodiments, the elevated BMP concentration is observed in serum.

[0052] In certain other embodiments, the subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one BMP species in a sample from the subject compared to a control (e.g., the same subject before receiving treatment). In certain embodiments, the concentration of at least one BMP is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, the reduced BMP concentration is observed in a tissue sample, for example, the brain. In certain embodiments, the reduced BMP concentration is observed in CSF. In certain embodiments, the reduced BMP concentration is observed in serum.

[0053] Glucosylceramide (GlcCer) is a sphingoglycolipid (ceramide and oligosaccharide) or oligoglycosylceramide having one or more sialic acids linked on the glycan. Specific GlcCer species are described herein (see, e.g., the Examples and Figures).

[0054] In certain embodiments, the concentration of at least one GlcCer species in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In certain embodiments, the GlcCer is a GlcCer species described herein, e.g., in the Examples or Figures. For example, in certain embodiments, GlcCer is GlcCer(d34:0), GlcCer(d34:1), GlcCer(d36:1), GlcCer(d42:1), GlcCer(d18:1,16:0), GlcCer(d18:1,18:0), GlcCer(d18:2,18:0), GlcCer(d18:1,20:0), GlcCer(d18:2,20:0), GlcCer(d18:1,22:0), GlcCer(d18:1,22:1), GlcCer(d18:2,22:0), GlcCer(d18:1,24:1) or GlcCer(d18:1,24:0). In some embodiments, GlcCer is GlcCer(d34:1), GlcCer(d36:1), GlcCer(d42:1), GlcCer(d18:1,16:0) or GlcCer(d18:1,22:0). In some embodiments, GlcCer is GlcCer(d34:0). In some embodiments, the concentration of at least one GlcCer is increased by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In some embodiments, the increased GlcCer concentration is observed in a tissue sample, e.g., brain. In some embodiments, the increased GlcCer concentration is observed in CSF. In some embodiments, the increased GlcCer concentration is observed in serum.

[0055] In certain other embodiments, a subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one GlcCer species in a sample from the subject compared to a control (e.g., the same subject prior to treatment). In certain embodiments, the concentration of at least one GlcCer is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, reduced GlcCer concentrations are observed in tissue samples, e.g., brain. In certain embodiments, reduced GlcCer concentrations are observed in CSF. In certain embodiments, reduced GlcCer concentrations are observed in serum.

[0056] Gangliosides are a type of glycosphingolipid. Specific GD3 species are described herein (see, e.g., the Examples and Figures).

[0057] In some embodiments, the concentration of at least one GD3 species in a sample from a subject with LSD is elevated compared to a control (e.g., a healthy control subject without LSD). In some embodiments, the GD3 is a GD3 species described herein, for example, in the Examples or Figures. For example, in some embodiments, the GD3 is GD3(d34:1), GD3(d36:1), GD3(d38:1), GD3(d39:1), GD3(d40:1), GD3(d42:2) or GD3(d42:1). In some embodiments, the GD3 is GD3(d34:1), GD3(d36:1) or GD3(d39:1). In some embodiments, the GD3 is GD3(d34:1) or GD3(d36:1).

[0058] In some embodiments, the concentration of at least one GD3 is increased by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to control.In some embodiments, the increased GD3 concentration is observed in tissue samples, for example, brain.In some embodiments, the increased GD3 concentration is observed in CSF.In some embodiments, the increased GD3 concentration is observed in serum.

[0059] In certain other embodiments, the subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one GD3 species in a sample from the subject compared to a control (e.g., the same subject before receiving treatment). In certain embodiments, the concentration of at least one GD3 is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, the reduced GD3 concentration is observed in a tissue sample, e.g., the brain. In certain embodiments, the reduced GD3 concentration is observed in the CSF. In certain embodiments, the reduced GD3 concentration is observed in serum.

[0060] Gangliosides GD1a and GD1b are glycosphingolipids. Specific GD1a / b are described herein (see, e.g., the Examples and Figures).

[0061] In some embodiments, the concentration of at least one GD1a / b species in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In some embodiments, the GD1a / b is a GD1a / b species described herein, e.g., in the Examples or Figures. For example, in some embodiments, the GD1a / b is GD1a / b(d36:1) or GD1a / b(d38:1).

[0062] In some embodiments, the concentration of at least one GD1a / b is increased by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In some embodiments, the increased GD1a / b concentration is observed in a tissue sample, for example, the brain. In some embodiments, the increased GD1a / b concentration is observed in CSF. In some embodiments, the increased GD1a / b concentration is observed in serum.

[0063] In certain other embodiments, the subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one GD1a / b species in a sample from the subject compared to a control (e.g., the same subject before receiving treatment). In certain embodiments, the concentration of at least one GD1a / b is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, the reduced GD1a / b concentration is observed in a tissue sample, e.g., the brain. In certain embodiments, the reduced GD1a / b concentration is observed in the CSF. In certain embodiments, the reduced GD1a / b concentration is observed in serum.

[0064] Ganglioside monosialyl 2 (GM2) is a glycosphingolipid. Specific GM2 species are described herein (see, e.g., the Examples and Figures).

[0065] In certain embodiments, the concentration of at least one GM2 species in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In certain embodiments, the GM2 is a GM2 species described herein, e.g., in the Examples or Figures. For example, in certain embodiments, the GM2 species is GM2(d38:1) or GM2(d36:1). In certain embodiments, the concentration of at least one GM2 is elevated by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In certain embodiments, the elevated GM2 concentration is observed in a tissue sample, e.g., brain. In certain embodiments, the elevated GM2 concentration is observed in CSF. In certain embodiments, the elevated GM2 concentration is observed in serum.

[0066] In certain other embodiments, a subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one GM2 species in a sample from the subject compared to a control (e.g., the same subject before undergoing treatment). In certain embodiments, the concentration of at least one GM2 is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, the reduced GM2 concentration is observed in a tissue sample, e.g., brain. In certain embodiments, the reduced GM2 concentration is observed in CSF. In certain embodiments, the reduced GM2 concentration is observed in serum.

[0067] Like GM2, ganglioside monosialyl 3 (GM3) is also a class of glycosphingolipid. Specific GM3 species are described herein (see, e.g., the Examples and Figures).

[0068] In certain embodiments, the concentration of at least one GM3 species in a sample from a subject with an LSD is elevated compared to a control (e.g., a healthy control subject without an LSD). In certain embodiments, the GM3 is a GM3 species described herein, e.g., in the Examples or Figures. For example, in certain embodiments, the GM3 species is GM3(d34:1), GM3(d36:1), GM3(d38:1), GM3(d40:1), GM3(d41:1), GM3(d42:2), GM3(d42:1), GM3(d43:0), GM3(d44:1) or GM3(d44:2). In certain embodiments, the GM3 species is GM3(d34:1), GM3(d36:1) or GM3(d38:1). In some embodiments, the concentration of at least one GM3 is increased by at least about 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to a control. In some embodiments, the increased GM3 concentration is observed in a tissue sample, for example, the brain. In some embodiments, the increased GM3 concentration is observed in CSF. In some embodiments, the increased GM3 concentration is observed in serum.

[0069] In certain other embodiments, the subject with LSD is administered an effective LSD treatment that reduces the concentration of at least one GM3 in a sample from the subject compared to a control. In certain embodiments, the concentration of at least one GM3 is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more compared to a control. In certain embodiments, the reduced GM3 concentration is observed in a tissue sample, for example, the brain. In certain embodiments, the reduced GM3 concentration is observed in the CSF. In certain embodiments, the reduced GM3 concentration is observed in serum.

[0070] Measurement of TREM2, Nf-L, lipids, and lipid combinations As used herein, the term "combination of two or more lipids" refers to two or more lipids, where at least two of the lipids are from different classes, and the classes are selected from a) BMP, b) GlcCer, c) GD3 ganglioside, d) GD1a / b ganglioside, and e) GM2 and / or GM3 ganglioside.

[0071] In certain embodiments, a combination of two or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2, and GM3 is evaluated or has been evaluated. In certain embodiments, the combination comprises a BMP. In certain embodiments, the combination comprises GlcCer. In certain embodiments, the combination comprises GD3. In certain embodiments, the combination comprises GD1a / b. In certain embodiments, the combination comprises GM2. In certain embodiments, the combination comprises GM3. In certain embodiments, the combination comprises a BMP and GlcCer. In certain embodiments, the combination comprises a BMP and GD3. In certain embodiments, the combination comprises a BMP and GD1a / b. In certain embodiments, the combination comprises a BMP and GM2. In certain embodiments, the combination comprises a BMP and GM3. In certain embodiments, the combination comprises GlcCer and GD3. In certain embodiments, the combination comprises GlcCer and GD1a / b. In some embodiments, the combination comprises GlcCer and GM2. In some embodiments, the combination comprises GlcCer and GM3. In some embodiments, the combination comprises GD3 and GD1a / b. In some embodiments, the combination comprises GD3 and GM2. In some embodiments, the combination comprises GD3 and GM3. In some embodiments, the combination comprises GD1a / b and GM2. In some embodiments, the combination comprises GD1a / b and GM3. In some embodiments, the combination does not consist of GM2 and GM3.

[0072] In certain embodiments, a combination of three or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2, and GM3 is evaluated or has been evaluated. In certain embodiments, the combination includes BMP, GlcCer, and GD3. In certain embodiments, the combination includes BMP, GlcCer, and GD1a / b. In certain embodiments, the combination includes BMP, GlcCer, and GM2. In certain embodiments, the combination includes BMP, GlcCer, and GM3. In certain embodiments, the combination includes BMP, GD3, and GD1a / b. In certain embodiments, the combination includes BMP, GD3, and GM2. In certain embodiments, the combination includes BMP, GD3, and GM3. In certain embodiments, the combination includes BMP, GD1a / b, and GM2. In certain embodiments, the combination includes BMP, GD1a / b, and GM3. In certain embodiments, the combination includes BMP, GD1a / b, and GM3. In certain embodiments, the combination includes BMP, GD1a / b, and GM3. In certain embodiments, the combination includes BMP, GM2, and GM3. In some embodiments, the combination includes GlcCer, GD3, and GD1a / b. In some embodiments, the combination includes GlcCer, GD3, and GM2. In some embodiments, the combination includes GlcCer, GD3, and GM3. In some embodiments, the combination includes GlcCer, GD1a / b, and GM2. In some embodiments, the combination includes GlcCer, GD1a / b, and GM3. In some embodiments, the combination includes GlcCer, GM2, and GM3. In some embodiments, the combination includes GD3, GD1a / b, and GM2. In some embodiments, the combination includes GD3, GD1a / b, and GM3. In some embodiments, the combination includes GD3, GM2, and GM3. In some embodiments, the combination includes GD1a / b, GM2, and GM3.

[0073] In certain embodiments, a combination of four or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2, and GM3 is evaluated or has been evaluated. In certain embodiments, the combination includes BMP, GlcCer, GD3, and GD1a / b. In certain embodiments, the combination includes BMP, GlcCer, GD3, and GM2. In certain embodiments, the combination includes BMP, GlcCer, GD3, and GM3. In certain embodiments, the combination includes BMP, GlcCer, GD1a / b, and GM2. In certain embodiments, the combination includes BMP, GlcCer, GD1a / b, and GM3. In certain embodiments, the combination includes BMP, GlcCer, GM2, and GM3. In certain embodiments, the combination includes BMP, GD3, GD1a / b, and GM2. In certain embodiments, the combination includes BMP, GD3, GD1a / b, and GM3. In some embodiments, the combination includes BMP, GD3, GM2, and GM3. In some embodiments, the combination includes BMP, GD1a / b, GM2, and GM3. In some embodiments, the combination includes GlcCer, GD3, GD1a / b, and GM2. In some embodiments, the combination includes GlcCer, GD3, GD1a / b, and GM3. In some embodiments, the combination includes GlcCer, GD3, GM2, and GM3. In some embodiments, the combination includes GlcCer, GD1a / b, GM2, and GM3. In some embodiments, the combination includes GD3, GD1a / b, GM2, and GM3.

[0074] In certain embodiments, a combination of five or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2, and GM3 is evaluated or has been evaluated. In certain embodiments, the combination includes BMP, GlcCer, GD3, GD1a / b, and GM2. In certain embodiments, the combination includes BMP, GlcCer, GD3, GD1a / b, and GM3. In certain embodiments, the combination includes BMP, GD3, GD1a / b, GM2, and GM3. In certain embodiments, the combination includes BMP, GlcCer, GD3, GM2, and GM3. In certain embodiments, the combination includes BMP, GlcCer, GD1a / b, GM2, and GM3. In certain embodiments, the combination includes GlcCer, GD3, GD1a / b, GM2, and GM3. In certain embodiments, the combination includes BMP, GlcCer, GD1a / b, GM2, and GM3.

[0075] In certain embodiments, combinations of BMP, GlcCer, GD3, GD1a / b, GM2, and GM3 are evaluated or have been evaluated.

[0076] In some embodiments, sTREM2 is or has been evaluated. In some embodiments, sTREM2 and one or more lipids are or have been evaluated. In some embodiments, the lipid is a BMP. In some embodiments, the lipid is GlcCer. In some embodiments, the lipid is GD3. In some embodiments, the lipid is GD1a / b. In some embodiments, the lipid is GM2. In some embodiments, the lipid is GM3.

[0077] In certain embodiments, a combination of sTREM2 and two or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated. In certain embodiments, the combination of two or more lipids is a combination described herein.

[0078] In certain embodiments, a combination of sTREM2 and three or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated, in certain embodiments, the combination of three or more lipids is a combination described herein.

[0079] In some embodiments, a combination of sTREM2 and four or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated, in some embodiments, the combination of four or more lipids is a combination described herein.

[0080] In some embodiments, a combination of sTREM2 and five or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated, in some embodiments, the combination of five or more lipids is a combination described herein.

[0081] In certain embodiments, sTREM2, BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 are evaluated or have been evaluated.

[0082] In certain embodiments, Nf-L is or has been assessed.

[0083] In certain embodiments, Nf-L and sTREM2 are assessed or have been assessed.

[0084] In some embodiments, Nf-L and one or more lipids are or have been evaluated. In some embodiments, the lipid is BMP. In some embodiments, the lipid is GlcCer. In some embodiments, the lipid is GD3. In some embodiments, the lipid is GD1a / b. In some embodiments, the lipid is GM2. In some embodiments, the lipid is GM3.

[0085] In certain embodiments, a combination of Nf-L and two or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated. In certain embodiments, the combination of two or more lipids is a combination described herein.

[0086] In some embodiments, a combination of Nf-L and three or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated. In some embodiments, the combination of three or more lipids is a combination described herein.

[0087] In some embodiments, a combination of Nf-L and four or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated. In some embodiments, the combination of four or more lipids is a combination described herein.

[0088] In some embodiments, a combination of Nf-L and five or more lipids selected from the group consisting of BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 is evaluated or has been evaluated, in some embodiments, the combination of five or more lipids is a combination described herein.

[0089] In certain embodiments, Nf-L, BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 are evaluated or have been evaluated.

[0090] In certain embodiments, sTREM2, Nf-L and one or more lipids are or have been evaluated. In certain embodiments, sTREM2, Nf-L, BMP, GlcCer, GD3, GD1a / b, GM2 and GM3 are or have been evaluated.

[0091] Thus, a sample obtained from a subject having or suspected of having an LSD may be assessed for accumulation of sTREM2, Nf-L, and / or one or more lipids selected from BMP, GlcCer, GD3, GD1a / b, GM2, and GM3. Specifically, the concentrations of sTREM2 protein, Nf-L, and / or one or more lipids may be measured in a sample obtained from the subject using assays known in the art or described herein (e.g., mass spectrometry).

[0092] In certain embodiments, the protein and / or lipid concentrations are compared to the corresponding protein and / or lipid concentrations in a sample from a control subject (eg, a healthy subject without LSD).

[0093] In some embodiments, the amount of each of the selected lipids / proteins in a sample from a subject is compared to a control value determined for a healthy control or a population of healthy controls (i.e., not suffering from LSD). In some embodiments, a subject is identified as a candidate for treatment or treatment adjustment if the amount of each of the selected lipids / proteins in a sample from the subject is increased compared to the control value. In some embodiments, a subject is identified as a candidate for treatment or treatment adjustment if the amount of each of the selected lipids / proteins in a sample from the subject is increased by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more compared to the control value. In some embodiments, a subject is identified as a candidate for treatment or treatment adjustment if the amount of each of the selected lipids / proteins in a sample from the subject is increased by at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the control value. In some embodiments, healthy control values ​​for each of the selected lipids / proteins are determined by assessing the levels of each lipid / protein in a subject or population of subjects (e.g., 10, 20, 50, 100, 200, 500, 1000 or more subjects) who are all known to be free of LSD.

[0094] In some embodiments, the amount of each of the selected lipids / proteins in a sample from a subject is compared to a control value determined for a disease control or a population of disease controls (i.e., suffering from an LSD). In some embodiments, the disease control value for each of the selected lipids / proteins is determined by assessing the levels of the selected lipids / proteins in a subject or population of subjects (e.g., 10, 20, 50, 100, 200, 500, 1000 or more subjects) all known to have an LSD.

[0095] In some embodiments, a subject is identified as a candidate for treatment or treatment adjustment (e.g., increased dosage or frequency) if the amount of each of the selected lipids / proteins in a sample from the subject is at least as high as the amount of each of the selected lipids / proteins in a disease control or population of disease controls. In some embodiments, a subject is identified as a candidate for treatment or treatment adjustment if the amount of each of the selected lipids / proteins in a sample from the subject is comparable (e.g., within 20%, 10%, 5%, 4%, 3%, 2%, or 1%) to the amount of each of the selected lipids / proteins in a disease control or population of disease controls.

[0096] In some embodiments, the subject with LSD is a subject that is being treated for LSD.The level in the subject after receiving treatment is compared with the level in the same subject before the treatment (e.g., before the first application) of the treatment.The effectiveness of the treatment can be determined by the change (e.g., reduction) in the amount of selected lipid / protein.

[0097] In certain other embodiments, a subject is identified as a candidate for treatment adjustment (e.g., reduced dosage or frequency) if the amount of each of the selected lipids / proteins in a sample from the subject is lower than the amount of each of the selected lipids / proteins in a disease control or population of disease controls.

[0098] In some embodiments, the population of subjects is matched to the test subjects according to one or more patient characteristics, such as age, sex, ethnicity, or other criteria. In some embodiments, the control value is established using the same type of sample (e.g., blood or a sample containing PBMCs) from the population of subjects as is used to assess lipid / protein levels in the test subjects.

[0099] Lysosomal storage disorders As described herein, certain biomarkers associated with LSD have been identified. LSD is an inherited metabolic disease characterized by the accumulation of undigested or partially digested macromolecules, which ultimately leads to cellular dysfunction and clinical abnormalities. Classically, LSD is defined as a deficiency in lysosomal function, usually classified by the substrate that accumulates, and includes mucopolysaccharidoses. The classification of these disorders has recently been expanded to include other deficiencies or defects of proteins that lead to the accumulation of macromolecules, such as proteins required for normal post-translational modification of lysosomal enzymes, or proteins that are important for proper lysosomal transport.

[0100] In certain embodiments, the LSD is an MPS disorder (eg, Hunter Syndrome).

[0101] Therapeutic Agents Certain methods described herein involve administering a lysosomal storage disorder treatment to a subject.

[0102] As used herein, a "lysosomal storage disorder treatment" can be any therapeutic agent or therapy capable of reducing one or more symptoms (e.g., neurological symptoms) associated with a LSD. Certain lysosomal storage disorder treatments are known. For example, such treatments include, for example, hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT), substrate synthesis inhibition therapy, chaperone therapy, and gene therapy (e.g., in vivo or ex vivo).

[0103] In some embodiments, the LSD treatment comprises ERT. In some embodiments, the ERT can be a therapy designed to treat one or more neurological symptoms. As described below, the LSD therapy of certain ERT can be targeted to the brain using enzyme transport vehicle (ETV). For example, certain fusion proteins comprising ERT enzymes that can be used in the methods described herein are described in WO2019 / 070577, which is discussed below and incorporated herein by reference for all purposes.

[0104] A defined fusion protein containing an ERT enzyme Certain embodiments of fusion proteins comprising an enzyme replacement therapy (ERT) enzyme linked to an Fc polypeptide are described below; these fusion proteins can be used as LSD treatments in certain methods described herein. In some cases, the protein comprises a dimeric Fc polypeptide, with one of the Fc polypeptide monomers linked to an ERT enzyme. The Fc polypeptide can increase the enzyme half-life, and in some cases, can be modified to confer additional functional properties to the protein. Also described herein are fusion proteins that facilitate the delivery of ERT enzymes through the blood-brain barrier (BBB). These proteins include Fc polypeptides and modified Fc polypeptides that form dimers, and ERT enzymes linked to Fc regions and / or modified Fc regions. The modified Fc region can specifically bind to a BBB receptor, such as the transferrin receptor (TfR). In some embodiments, the ERT enzyme is iduronate 2-sulfatase (IDS), or a catalytically active variant or fragment of wild-type IDS, e.g., wild-type human IDS. Certain embodiments of these fusion proteins may be referred to herein as enzyme transport vehicles (ETVs) in combination with a particular enzyme, eg, ETV:IDS.

[0105] ERT enzymes In some aspects, the fusion protein described herein comprises: (i) an Fc polypeptide, which may contain modifications (e.g., one or more modifications that promote heterodimerization) or may be a wild-type Fc polypeptide; and an ERT enzyme; and (ii) an Fc polypeptide, which may contain modifications (e.g., one or more modifications that promote heterodimerization) or may be a wild-type Fc polypeptide; and optionally an ERT enzyme. In some embodiments, one or both Fc polypeptides may contain modifications that result in binding to a blood-brain barrier (BBB) ​​receptor, e.g., TfR. The ERT enzyme may be any enzyme that is deficient in LSDs. The ERT enzyme incorporated into the fusion protein is catalytically active, i.e., it retains the enzyme activity that is deficient in LSDs. In some embodiments, the ERT enzyme is an IDS that is deficient in Hunter syndrome.

[0106] In some embodiments, a fusion protein comprising an ERT enzyme and optionally a modified Fc polypeptide that binds to a BBB receptor, e.g., a TfR-binding Fc polypeptide, comprises a catalytically active fragment or variant of a wild-type IDS. In some embodiments, the IDS enzyme is a variant or catalytically active fragment of an IDS protein comprising the amino acid sequence of any one of SEQ ID NOs: 91, 92, 112, 192, and 196. In some embodiments, the catalytically active variant or fragment of an IDS enzyme has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more of the activity of the wild-type IDS enzyme.

[0107] In some embodiments, the ERT enzyme (e.g., IDS), or catalytically active variant or fragment thereof, present in the fusion protein described herein, retains at least 25% of its activity compared to its activity when not conjugated to an Fc polypeptide or a TfR-binding Fc polypeptide. In some embodiments, the ERT enzyme, or catalytically active variant or fragment thereof, retains at least 10%, or at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of its activity compared to its activity when not conjugated to an Fc polypeptide or a TfR-binding Fc polypeptide. In some embodiments, the ERT enzyme, or catalytically active variant or fragment thereof, retains at least 80%, 85%, 90%, or 95% of its activity compared to its activity when not conjugated to an Fc polypeptide or a TfR-binding Fc polypeptide. In some embodiments, fusion to an Fc polypeptide does not reduce the activity of an ERT enzyme, such as an IDS, or a catalytically active variant or fragment thereof. In some embodiments, fusion to a TfR-binding Fc polypeptide does not reduce the activity of an ERT enzyme.

[0108] I. Fc Polypeptide Engineering for Blood-Brain Barrier (BBB) ​​Receptor Binding In some aspects, the fusion protein is capable of being transported across the blood-brain barrier (BBB). Such proteins include modified Fc polypeptides that bind to BBB receptors. BBB receptors are expressed on the BBB endothelium, as well as other cell and tissue types. In some embodiments, the BBB receptor is the transferrin receptor (TfR).

[0109] The amino acid residues designated in the various Fc modifications, including those introduced into modified Fc polypeptides that bind to BBB receptors, e.g., TfR, are numbered herein using EU index numbering. Any Fc polypeptide, e.g., an IgG1, IgG2, IgG3, or IgG4 Fc polypeptide, can have a modification, e.g., an amino acid substitution, at one or more positions described herein.

[0110] The modified Fc polypeptides present in the fusion proteins described herein (e.g., that enhance heterodimerization and / or BBB receptor binding) can have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to a native Fc region sequence or a fragment thereof, e.g., a fragment at least 50 amino acids in length or at least 100 amino acids in length or more. In some embodiments, the amino acid sequence of the native Fc is the Fc region sequence of SEQ ID NO: 1. In some embodiments, the modified Fc polypeptides have at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 1-110 of SEQ ID NO: 1 or amino acids 111-217 of SEQ ID NO: 1, or a fragment thereof, e.g., a fragment at least 50 amino acids in length or at least 100 amino acids in length or more.

[0111] In some embodiments, the modified (e.g., heterodimerization and / or BBB receptor binding enhancing) Fc polypeptide comprises at least 50 amino acids, or at least 60, 65, 70, 75, 80, 85, 90 or 95 or more, or at least 100 or more amino acids, corresponding to the amino acid sequence of a native Fc region. In some embodiments, the modified Fc polypeptide comprises at least 25 contiguous amino acids, or at least 30, 35, 40 or 45 contiguous amino acids, or 50 contiguous amino acids, or at least 60, 65, 70, 75, 80, 85, 90 or 95 or more contiguous amino acids, or 100 or more contiguous amino acids, corresponding to the amino acid sequence of a native Fc region, such as SEQ ID NO:1.

[0112] In some embodiments, the domain modified for BBB receptor binding activity is a human Ig CH3 domain, such as an IgG1 CH3 domain. The CH3 domain can be from any IgG subtype, i.e., IgG1, IgG2, IgG3, or IgG4. In the context of an IgG1 antibody, the CH3 domain refers to the segment of amino acids from about position 341 to about position 447, as numbered according to the EU numbering scheme.

[0113] In some embodiments, the modified (e.g., BBB receptor binding) Fc polypeptide present in the fusion proteins described herein comprises at least one, two or three substitutions, and in some embodiments at least four, five, six, seven, eight or nine substitutions, at amino acid positions 384, 386, 387, 388, 389, 390, 413, 416, and 421 according to the EU numbering scheme.

[0114] FcRn binding site In certain aspects, a modified (e.g., BBB receptor-binding) Fc polypeptide, or an Fc polypeptide present in a fusion protein described herein that does not specifically bind to a BBB receptor, may also contain an FcRn binding site. In some embodiments, the FcRn binding site is present in an Fc polypeptide or a fragment thereof.

[0115] In some embodiments, the FcRn binding site comprises a native FcRn binding site. In some embodiments, the FcRn binding site does not comprise an amino acid change to the amino acid sequence of the native FcRn binding site. In some embodiments, the native FcRn binding site is an IgG binding site, for example, a human IgG binding site. In some embodiments, the FcRn binding site comprises a modification that alters FcRn binding.

[0116] In some embodiments, the FcRn binding site has one or more mutated, e.g., substituted, amino acid residues, which mutation(s) increase or do not substantially decrease serum half-life (i.e., decrease serum half-life by 25% or less when assayed under identical conditions, compared to an equivalent modified Fc polypeptide having a wild-type residue at the mutated position). In some embodiments, the FcRn binding site has one or more substituted amino acid residues at positions 250-256, 307, 380, 428, and 433-436 according to the EU numbering scheme.

[0117] In some embodiments, one or more residues at or near the FcRn binding site are mutated relative to the native human IgG sequence to increase the serum half-life of the modified polypeptide. In some embodiments, mutations are introduced at one, two or three of positions 252, 254, and 256. In some embodiments, the mutations are M252Y, S254T, and T256E. In some embodiments, the modified Fc polypeptide further comprises mutations M252Y, S254T, and T256E. In some embodiments, the modified Fc polypeptide comprises substitutions at one, two or all three of positions T307, E380, and N434 according to the EU numbering scheme. In some embodiments, the mutations are T307Q and N434A. In some embodiments, the modified Fc polypeptide comprises mutations T307A, E380A, and N434A. In some embodiments, the modified Fc polypeptide comprises substitutions at positions T250 and M428 according to the EU numbering scheme. In some embodiments, the modified Fc polypeptide comprises the mutations T250Q and / or M428L. In some embodiments, the modified Fc polypeptide comprises substitutions at positions M428 and N434 according to the EU numbering scheme. In some embodiments, the modified Fc polypeptide comprises the mutations M428L and N434S. In some embodiments, the modified Fc polypeptide comprises an N434S or N434A mutation.

[0118] II. Fc Polypeptides that Bind to the Transferrin Receptor This section describes the production of modified Fc polypeptides described herein that are capable of binding to the transferrin receptor (TfR) and being transported across the blood-brain barrier (BBB).

[0119] TfR-binding Fc polypeptides containing mutations in the CH3 domain In some embodiments, modified Fc polypeptides that specifically bind to TfR comprise substitutions in the CH3 domain. In some embodiments, modified Fc polypeptides comprise a human Ig CH3 domain, such as an IgG CH3 domain, that is modified for TfR binding activity. The CH3 domain can be from any IgG subtype, i.e., IgG1, IgG2, IgG3 or IgG4. In the context of IgG antibodies, the CH3 domain refers to the segment of amino acids from about position 341 to about position 447, numbered according to the EU numbering scheme.

[0120] In some embodiments, an engineered Fc polypeptide that specifically binds to TfR binds to the apical domain of TfR and can bind to TfR without blocking or otherwise inhibiting the binding of transferrin to TfR. In some embodiments, the binding of transferrin to TfR is not substantially inhibited. In some embodiments, the binding of transferrin to TfR is inhibited by less than about 50% (e.g., less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%). In some embodiments, binding of transferrin to TfR is inhibited by less than about 20% (e.g., less than about 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%).

[0121] In some embodiments, an engineered Fc polypeptide that specifically binds to TfR comprises at least two, three, four, five, six, seven, eight, or nine substitutions at positions 384, 386, 387, 388, 389, 390, 413, 416, and 421 according to the EU numbering scheme. Exemplary substitutions that may be introduced at these positions are shown in Tables 4 and 5. In some embodiments, the amino acid at position 388 and / or 421 is an aromatic amino acid, e.g., Trp, Phe, or Tyr. In some embodiments, the amino acid at position 388 is Trp. In some embodiments, the aromatic amino acid at position 421 is Trp or Phe.

[0122] In some embodiments, at least one of the following positions is substituted: Leu, Tyr, Met, or Val at position 384; Leu, Thr, His, or Pro at position 386; Val, Pro, or an acidic amino acid at position 387; an aromatic amino acid, such as Trp, at position 388; Val, Ser, or Ala at position 389; an acidic amino acid, Ala, Ser, Leu, Thr, or Pro at position 413; Thr or an acidic amino acid at position 416; or Trp, Tyr, His, or Phe at position 421. In some embodiments, the modified Fc polypeptide may include conservative substitutions of particular amino acids at one or more of the positions within the set, e.g., amino acids within the same charge category, hydrophobic category, side chain ring structure category (e.g., aromatic amino acids), or size category, and / or polar or non-polar category. Thus, for example, He may be present at position 384, 386, and / or position 413. In some embodiments, the acidic amino acid at one, two or each of positions 387, 413, and 416 is Glu. In other embodiments, the acidic amino acid at one, two or each of positions 387, 413, and 416 is Asp. In some embodiments, two, three, four, five, six, seven or all eight of positions 384, 386, 387, 388, 389, 413, 416, and 421 have an amino acid substitution as defined in this paragraph.

[0123] In some embodiments, the modified Fc polypeptide as described in the preceding two paragraphs comprises a native Asn at position 390. In some embodiments, the modified Fc polypeptide comprises a Gly, His, Gln, Leu, Lys, Val, Phe, Ser, Ala, or Asp at position 390. In some embodiments, the modified Fc polypeptide further comprises one, two, three, or four substitutions at positions including 380, 391, 392, and 415 according to the EU numbering scheme. In some embodiments, Trp, Tyr, Leu, or Gln may be present at position 380. In some embodiments, Ser, Thr, Gln, or Phe may be present at position 391. In some embodiments, Gln, Phe, or His may be present at position 392. In some embodiments, Glu may be present at position 415.

[0124] In certain embodiments, the modified Fc polypeptide comprises two, three, four, five, six, seven, eight, nine, ten or eleven positions selected from the following: Trp, Leu or Glu at position 380; Tyr or Phe at position 384; Thr at position 386; Glu at position 387; Trp at position 388; Ser, Ala, Val or Asn at position 389; Ser or Asn at position 390; Thr or Ser at position 413; Glu or Ser at position 415; Glu at position 416; and / or Phe at position 421. In some embodiments, the modified Fc polypeptide contains all of the following eleven positions: Trp, Leu, or Glu at position 380; Tyr or Phe at position 384; Thr at position 386; Glu at position 387; Trp at position 388; Ser, Ala, Val, or Asn at position 389; Ser or Asn at position 390; Thr or Ser at position 413; Glu or Ser at position 415; Glu at position 416; and / or Phe at position 421.

[0125] In some embodiments, the modified Fc polypeptide comprises a Leu or Met at position 384; a Leu, His, or Pro at position 386; a Val at position 387; a Trp at position 388; a Val or Ala at position 389; a Pro at position 413; a Thr at position 416; and / or a Trp at position 421. In some embodiments, the modified Fc polypeptide further comprises a Ser, Thr, Gln, or Phe at position 391. In some embodiments, the modified Fc polypeptide further comprises a Trp, Tyr, Leu, or Gln at position 380 and / or a Gln, Phe, or His at position 392. In some embodiments, a Trp is present at position 380 and / or a Gln is present at position 392. In some embodiments, the modified Fc polypeptide does not have a Trp at position 380.

[0126] In other embodiments, the modified Fc polypeptide comprises a Tyr at position 384; a Thr at position 386; a Glu or Val at position 387; a Trp at position 388; a Ser at position 389; a Ser or Thr at position 413; a Glu at position 416; and / or a Phe at position 421. In some embodiments, the modified Fc polypeptide comprises a native Asn at position 390. In certain embodiments, the modified Fc polypeptide further comprises a Trp, Tyr, Leu, or Gln at position 380; and / or a Glu at position 415. In some embodiments, the modified Fc polypeptide further comprises a Trp at position 380 and / or a Glu at position 415.

[0127] In additional embodiments, the modified Fc polypeptide further comprises one, two or three substitutions at positions including 414, 424, and 426 according to the EU numbering scheme. In some embodiments, position 414 is Lys, Arg, Gly, or Pro, position 424 is Ser, Thr, Glu, or Lys, and / or position 426 is Ser, Trp, or Gly.

[0128] In some embodiments, the modified Fc polypeptide comprises one or more of the following substitutions: Tyr at position 380; Thr at position 386; Trp at position 388; Val at position 389; Thr or Ser at position 413; Glu at position 415; and / or Phe at position 421 according to the EU numbering scheme.

[0129] In some embodiments, the modified Fc polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to amino acids 111-217 of any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90). In some embodiments, the modified Fc polypeptide has at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90). In some embodiments, the modified Fc polypeptide comprises amino acids at EU index positions 384-390 and / or 413-421 of any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90). In some embodiments, the modified Fc polypeptide comprises amino acids at EU index positions 380-390 and / or 413-421 of any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90). In some embodiments, the modified Fc polypeptide comprises amino acids at EU index positions 380-392 and / or 413-426 of any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90).

[0130] In some embodiments, the modified Fc polypeptide has at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 4-90, 95-98, and 103-106 (e.g., SEQ ID NOs: 34-38, 58, and 60-90), and has the following amino acids at positions numbered according to the EU index: Trp, Tyr, Leu, Gln, or Glu at position 380; Leu, Tyr, Met, or Val at position 384; Leu, Thr, His, or Pro at position 386; Val, Pro, or an acidic amino acid at position 387; For example, the amino acid further includes at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of: Trp; Val, Ser, or Ala at position 389; Ser or Asn at position 390; Ser, Thr, Gln, or Phe at position 391; Gln, Phe, or His at position 392; an acidic amino acid, Ala, Ser, Leu, Thr, or Pro at position 413; Lys, Arg, Gly or Pro at position 414; Glu or Ser at position 415; Thr or an acidic amino acid at position 416; Trp, Tyr, His or Phe at position 421; Ser, Thr, Glu, or Lys at position 424; and Ser, Trp, or Gly at position 426.

[0131] In some embodiments, the modified Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 34 to 38, 58, and 60 to 90. In other embodiments, the modified Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 34 to 38, 58, and 60 to 90, in which one, two, or three amino acids have been substituted.

[0132] In some embodiments, the modified Fc polypeptide comprises additional mutations, such as those described below, including, but not limited to, knob mutations (e.g., T366W, as numbered with reference to EU numbering), hole mutations (e.g., T366S, L368A, and Y407V, as numbered with reference to EU numbering), mutations that modulate effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered with reference to EU numbering), and / or mutations that increase serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme). By way of illustration, SEQ ID NOs: 118-191 provide non-limiting examples of modified Fc polypeptides (e.g., clones CH3C.35.20.1, CH3C.35.23.2, CH3C.35.23.3, CH3C.35.23.4, CH3C.35.21.17.2, and CH3C.35.23) having mutations in the CH3 domain that include one or more of these additional mutations.

[0133] In some embodiments, the modified Fc polypeptide comprises a knob mutation (e.g., T366W, numbered with reference to EU numbering) and has at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 118, 130, 142, 154, 166, and 178. In some embodiments, the modified Fc polypeptide comprises the sequence of any one of SEQ ID NOs: 118, 130, 142, 154, 166, and 178.

[0134] In some embodiments, the modified Fc polypeptide comprises a knob mutation (e.g., T366W, as numbered with reference to EU numbering) and a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered with reference to EU numbering) and has at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences in SEQ ID NOs: 119, 120, 131, 132, 143, 144, 155, 156, 167, 168, 179, 180, 190, and 191. In some embodiments, the modified Fc polypeptide comprises any one of the sequences in SEQ ID NOs: 119, 120, 131, 132, 143, 144, 155, 156, 167, 168, 179, and 180.

[0135] In some embodiments, the modified Fc polypeptide comprises a knob mutation (e.g., T366W, as numbered with reference to EU numbering) and a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and has at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences in SEQ ID NOs: 121, 133, 145, 157, 169, and 181. In some embodiments, the modified Fc polypeptide comprises the sequence of any one of SEQ ID NOs: 121, 133, 145, 157, 169, and 181.

[0136] In some embodiments, the modified Fc polypeptide comprises a knob mutation (e.g., T366W, as numbered with reference to EU numbering), a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered with reference to EU numbering), and a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and has at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 122, 123, 134, 135, 146, 147, 158, 159, 170, 171, 182, and 183. In some embodiments, the modified Fc polypeptide comprises the sequence of any one of SEQ ID NOs: 122, 123, 134, 135, 146, 147, 158, 159, 170, 171, 182, and 183.

[0137] In some embodiments, the modified Fc polypeptide comprises a hole mutation (e.g., T366S, L368A, and Y407V, numbered with reference to EU numbering) and has at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 124, 136, 148, 160, 172, and 184. In some embodiments, the modified Fc polypeptide comprises any one of SEQ ID NOs: 124, 136, 148, 160, 172, and 184.

[0138] In some embodiments, the modified Fc polypeptide comprises a hole mutation (e.g., T366S, L368A, and Y407V, as numbered with reference to EU numbering) and a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered with reference to EU numbering) and has at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences in SEQ ID NOs: 125, 126, 137, 138, 149, 150, 161, 162, 173, 174, 185, and 186. In some embodiments, the modified Fc polypeptide comprises a sequence of any one of SEQ ID NOs: 125, 126, 137, 138, 149, 150, 161, 162, 173, 174, 185, and 186.

[0139] In some embodiments, the modified Fc polypeptide comprises a whole mutation (e.g., T366S, L368A, and Y407V, as numbered with reference to EU numbering) and a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and has at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences in SEQ ID NOs: 127, 139, 151, 163, 175, and 187. In some embodiments, the modified Fc polypeptide comprises a sequence in any one of SEQ ID NOs: 127, 139, 151, 163, 175, and 187.

[0140] In some embodiments, the modified Fc polypeptide comprises whole mutations (e.g., T366S, L368A, and Y407V, as numbered with reference to EU numbering), mutations that modulate effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered with reference to EU numbering), and mutations that increase serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and has at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 128, 129, 140, 141, 152, 153, 164, 165, 176, 177, 188, and 189. In some embodiments, the modified Fc polypeptide comprises the sequence of any one of SEQ ID NOs: 128, 129, 140, 141, 152, 153, 164, 165, 176, 177, 188, and 189.

[0141] In some embodiments, a modified Fc polypeptide that specifically binds to TfR comprises at least two, three, four, five, six, seven, or eight substitutions at positions 345, 346, 347, 349, 437, 438, 439, and 440 according to the EU numbering scheme. In some embodiments, the modified Fc polypeptide comprises a Gly at position 437, a Phe at position 438, and / or an Asp at position 440. In some embodiments, a Glu is present at position 440. In certain embodiments, the modified Fc polypeptide comprises at least one substitution at the following positions: Phe or Ile at position 345; Asp, Glu, Gly, Ala or Lys at position 346; Tyr, Met, Leu, Ile or Asp at position 347; Thr or Ala at position 349; Gly at position 437; Phe at position 438; His Tyr, Ser or Phe at position 439; or Asp at position 440. In some embodiments, two, three, four, five, six, seven, or all eight of positions 345, 346, 347, 349, 437, 438, 439, and 440 have a substitution as defined in this paragraph. In some embodiments, the modified Fc polypeptide may include conservative substitutions of particular amino acids at one or more of the positions within the set, e.g., amino acids within the same charge class, hydrophobic class, side chain ring structure class (e.g., aromatic amino acids), or size class, and / or polar or non-polar class.

[0142] III. Additional Fc Polypeptide Mutations In some aspects, the fusion proteins described herein comprise two Fc polypeptides, each of which may comprise an independently selected modification or may be a wild-type Fc polypeptide, e.g., a human IgG1 Fc polypeptide. In some embodiments, one or both Fc polypeptides contain one or more modifications that confer binding to a blood-brain barrier (BBB) ​​receptor, e.g., the transferrin receptor (TfR). Non-limiting examples of other mutations that may be introduced into one or both Fc polypeptides include, for example, mutations to increase serum stability or serum half-life, mutations to modulate effector function, mutations to affect glycosylation, mutations to reduce immunogenicity in humans, and / or mutations to provide knob and hole heterodimerization of the Fc polypeptide.

[0143] In some embodiments, the Fc polypeptides present in the fusion protein independently have at least about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to a corresponding wild-type Fc polypeptide (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc polypeptide).

[0144] In some embodiments, the Fc polypeptide present in the fusion protein contains knob and hole mutations to promote heterodimer formation and prevent homodimer formation. Generally, the modifications introduce a protrusion ("knob") at the interface of the first polypeptide and a corresponding cavity ("hole") at the interface of the second polypeptide, where the protrusion can be located within the cavity such that heterodimer formation is promoted and homodimer formation is prevented. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A complementary depression of the same or similar size as the protrusion is created at the interface of the second polypeptide by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). In some embodiments, such additional mutations are at positions in the Fc polypeptide that do not adversely affect binding of the polypeptide to a BBB receptor, e.g., TfR.

[0145] In one exemplary embodiment of the knob and hole approach for dimerization, position 366 (numbered according to the EU numbering scheme) of one of the Fc polypeptides present in the fusion protein contains a tryptophan instead of the native threonine. The other Fc polypeptide in the dimer has a valine instead of the native tyrosine at position 407 (numbered according to the EU numbering scheme). The other Fc polypeptide may further contain a substitution in which the native threonine at position 366 (numbered according to the EU numbering scheme) is replaced with a serine, and a substitution in which the native leucine at position 368 (numbered according to the EU numbering scheme) is replaced with an alanine. Thus, one of the Fc polypeptides of the fusion proteins described herein has a T366W knob mutation and the other Fc polypeptide has a Y407V mutation, which is typically accompanied by a T366S and L368A hole mutation.

[0146] In some embodiments, modifications to enhance serum half-life may be introduced. For example, in some embodiments, one or both Fc polypeptides present in the fusion proteins described herein may contain a tyrosine at position 252, a threonine at position 254, and a glutamic acid at position 256, numbered according to the EU numbering scheme. Thus, one or both Fc polypeptides may contain M252Y, S254T, and T256E substitutions. Alternatively, one or both Fc polypeptides may contain M428L and N434S substitutions, numbered according to the EU numbering scheme. Alternatively, one or both Fc polypeptides may have an N434S or N434A substitution.

[0147] In some embodiments, one or both Fc polypeptides present in the fusion proteins described herein may contain modifications that reduce effector function (i.e., reduce the ability to induce a given biological function upon binding to an Fc receptor expressed on an effector cell that mediates the effector function). Examples of antibody effector functions include, but are not limited to, C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation. Effector functions may vary depending on the antibody class. For example, native human IgG1 and IgG3 antibodies may elicit ADCC and CDC activity upon binding to the appropriate Fc receptor present on immune system cells, and native human IgG1, IgG2, IgG3, and IgG4 may elicit ADCP function upon binding to the appropriate Fc receptor present on immune system cells.

[0148] In some embodiments, one or both Fc polypeptides present in the fusion proteins described herein may be engineered to contain other modifications for heterodimerization, such as electrostatic manipulation of contact residues within the naturally charged CH3-CH3 interface or modification of hydrophobic patches.

[0149] In some embodiments, one or both Fc polypeptides present in the fusion proteins described herein may contain additional modifications that modulate effector function.

[0150] In some embodiments, one or both Fc polypeptides present in the fusion proteins described herein may contain modifications that reduce or eliminate effector function. Exemplary Fc polypeptide mutations that reduce effector function include, but are not limited to, substitutions in the CH2 domain, e.g., at positions 234 and 235 according to the EU numbering scheme. For example, in some embodiments, one or both Fc polypeptides may contain alanine residues at positions 234 and 235. Thus, one or both Fc polypeptides may contain L234A and L235A (LALA) substitutions.

[0151] Additional Fc polypeptide mutations that modulate effector function include, but are not limited to, the following: position 329 may have a mutation in which proline is substituted with glycine or arginine, or with an amino acid residue large enough to disrupt the Fc / Fcγ receptor interface formed between proline 329 of Fc and tryptophan residues Trp87 and Trp110 of FcγRIII. Additional exemplary substitutions include S228P, E233P, L235E, N297A, N297D, and P331S according to the EU numbering scheme. Multiple substitutions may also be present, for example, L234A and L235A in the human IgG1 Fc region; L234A, L235A, and P329G in the human IgG1 Fc region; S228P and L235E in the human IgG4 Fc region; L234A and G237A in the human IgG1 Fc region; L234A, L235A, and G237A in the human IgG1 Fc region; V234A and G237A in the human IgG2 Fc region; L235A, G237A, and E318A in the human IgG4 Fc region; and S228P and L236E in the human IgG4 Fc region, according to the EU numbering scheme. In some embodiments, one or both Fc polypeptides may contain one or more amino acid substitutions that modulate ADCC, for example, substitutions at positions 298, 333, and / or 334 according to the EU numbering scheme.

[0152] Exemplary Fc Polypeptides Containing Additional Mutations As non-limiting examples, one or both Fc polypeptides present in a fusion protein described herein may include additional mutations including knob mutations (e.g., T366W as numbered according to the EU numbering scheme), hole mutations (e.g., T366S, L368A, and Y407V as numbered according to the EU numbering scheme), mutations that modulate effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A) as numbered according to the EU numbering scheme), and / or mutations that increase serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E as numbered with reference to EU numbering, or (ii) N434S with or without M428L as numbered according to the EU numbering scheme).

[0153] In some embodiments, an Fc polypeptide may have a knob mutation (e.g., T366W, as numbered according to the EU numbering scheme) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 1 and 4 to 90. In some embodiments, an Fc polypeptide having the sequence of any one of SEQ ID NOs: 1 and 4 to 90 may be modified to have a knob mutation.

[0154] In some embodiments, an Fc polypeptide can have a knob mutation (e.g., T366W as numbered according to the EU numbering scheme), a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A) as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having the sequence of any one of SEQ ID NOs: 1 and 4-90 can be modified to have a knob mutation and a mutation that modulates effector function.

[0155] In some embodiments, an Fc polypeptide may have a knob mutation (e.g., T366W, as numbered according to the EU numbering scheme), a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having the sequence of any one of SEQ ID NOs: 1 and 4-90 may be modified to have a knob mutation and a mutation that increases serum stability or serum half-life.

[0156] In some embodiments, an Fc polypeptide may have a knob mutation (e.g., T366W as numbered according to the EU numbering scheme), a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A) as numbered according to the EU numbering scheme), a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E as numbered with reference to EU numbering, or (ii) N434S with or without M428L as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having a sequence of any one of SEQ ID NOs: 1 and 4-90 may be modified to have a knob mutation, a mutation that modulates effector function, and a mutation that increases serum stability or serum half-life.

[0157] In some embodiments, an Fc polypeptide can have a whole mutation (e.g., T366S, L368A, and Y407V, numbered according to the EU numbering scheme) and at least 85% identity, at least 90% identity, or at least 95% identity to the sequence of any one of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having a sequence of any one of SEQ ID NOs: 1 and 4-90 can be modified to have a whole mutation.

[0158] In some embodiments, an Fc polypeptide can have a whole mutation (e.g., T366S, L368A, and Y407V, as numbered according to the EU numbering scheme), a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having a sequence of any one of SEQ ID NOs: 1 and 4-90 can be modified to have a whole mutation and a mutation that modulates effector function.

[0159] In some embodiments, an Fc polypeptide may have a whole mutation (e.g., T366S, L368A, and Y407V, as numbered according to the EU numbering scheme), a mutation that increases serum or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to the EU numbering scheme, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to any one of the sequences of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having a sequence of any one of SEQ ID NOs: 1 and 4-90 may be modified to have a whole mutation and a mutation that increases serum stability or serum half-life.

[0160] In some embodiments, the Fc polypeptide may have a whole mutation (e.g., T366S, L368A, and Y407V, as numbered according to the EU numbering scheme), a mutation that modulates effector function (e.g., L234A, L235A, and / or P329G (e.g., L234A and L235A), as numbered according to the EU numbering scheme), a mutation that increases serum stability or serum half-life (e.g., (i) M252Y, S254T, and T256E, as numbered with reference to EU numbering, or (ii) N434S, with or without M428L, as numbered according to the EU numbering scheme), and at least 85% identity, at least 90% identity, or at least 95% identity to any one of SEQ ID NOs: 1 and 4-90. In some embodiments, an Fc polypeptide having any one of SEQ ID NOs: 1 and 4-90 may be modified to have a whole mutation, a mutation that modulates effector function, and a mutation that increases serum stability or serum half-life.

[0161] IV. Exemplary Fusion Proteins Comprising ERT Enzymes In some aspects, the fusion protein described herein comprises a first Fc polypeptide linked to an enzyme replacement therapy (ERT) enzyme, an ERT enzyme variant, or a catalytically active fragment thereof; and a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. In some embodiments, the first Fc polypeptide and / or the second Fc polypeptide does not comprise an immunoglobulin heavy and / or light chain variable region sequence or an antigen-binding portion thereof. In some embodiments, the ERT enzyme is an IDS. In some embodiments, the first Fc polypeptide is a modified Fc polypeptide and / or the second Fc polypeptide is a modified Fc polypeptide. In some embodiments, the second Fc polypeptide is a modified Fc polypeptide. In some embodiments, the modified Fc polypeptide contains one or more modifications that promote heterodimerization with another Fc polypeptide. In some embodiments, the modified Fc polypeptide contains one or more modifications that reduce effector function. In some embodiments, the modified Fc polypeptide contains one or more modifications that increase serum half-life. In some embodiments, the modified Fc polypeptide contains one or more modifications that confer binding to a blood-brain barrier (BBB) ​​receptor, for example, the transferrin receptor (TfR).

[0162] In other aspects, the fusion protein described herein comprises a first polypeptide chain comprising a modified Fc polypeptide that specifically binds to a BBB receptor, e.g., TfR, and a second polypeptide chain comprising an Fc polypeptide that dimerizes with the modified Fc polypeptide to form an Fc dimer. The ERT enzyme can be linked to either the first or second polypeptide chain. In some embodiments, the ERT enzyme is an IDS. In some embodiments, the ERT enzyme is linked to the second polypeptide chain. In some embodiments, the protein comprises two ERT enzymes, each linked to one of the polypeptide chains. In some embodiments, the Fc polypeptide can be a BBB receptor binding polypeptide that specifically binds to the same BBB receptor as the modified Fc polypeptide in the first polypeptide chain. In some embodiments, the Fc polypeptide does not specifically bind to a BBB receptor.

[0163] In some embodiments, the fusion protein described herein comprises a first polypeptide chain comprising a modified Fc polypeptide that specifically binds to TfR, and a second polypeptide chain comprising an Fc polypeptide, wherein the modified Fc polypeptide and the Fc polypeptide dimerize to form an Fc dimer. In some embodiments, the ERT enzyme is an IDS. In some embodiments, the ERT enzyme is linked to the first polypeptide chain. In some embodiments, the ERT enzyme is linked to the second polypeptide chain. In some embodiments, the Fc polypeptide does not specifically bind to a BBB receptor, e.g., TfR.

[0164] In some embodiments, the fusion proteins described herein comprise a first polypeptide chain comprising a modified Fc polypeptide that binds TfR and comprises a T366W (knob) substitution; and a second polypeptide chain comprising an Fc polypeptide comprising T366S, L368A, and Y407V (hole) substitutions. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises a L234A and L235A (LALA) substitution. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises a M252Y, S254T, and T256E (YTE) substitution. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises a L234A and L235A (LALA) substitution and a M252Y, S254T, and T256E (YTE) substitution. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide comprises human IgG1 wild-type residues at positions 234, 235, 252, 254, 256 and 366.

[0165] In some embodiments, the modified Fc polypeptide comprises the knob, LALA, and YTE mutations specified in any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183, and has at least 85% identity, at least 90% identity, or at least 95% identity to the respective sequences; or comprises the sequence of any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183. In some embodiments, the Fc polypeptide comprises a hole, LALA, and YTE mutation as specified in any one of SEQ ID NOs: 99-102 and has at least 85% identity, at least 90% identity, or at least 95% identity to the respective sequence; or comprises the sequence of any one of SEQ ID NOs: 99-102. In some embodiments, the modified Fc polypeptide comprises any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183, and the Fc polypeptide comprises any one of SEQ ID NOs: 99-102. In some embodiments, the modified Fc polypeptide and / or the N-terminus of the Fc polypeptide comprises a portion of an IgG1 hinge region (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the modified Fc polypeptide has at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 114, 190, and 191, or comprises the sequence of any one of SEQ ID NOs: 114, 190, and 191.

[0166] In some embodiments, the fusion proteins described herein comprise a first polypeptide chain comprising a modified Fc polypeptide that binds to TfR and comprises T366S, L368A, and Y407V (hole) substitutions; and a second polypeptide chain comprising an Fc polypeptide comprising a T366W (knob) substitution. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises L234A and L235A (LALA) substitutions. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises M252Y, S254T, and T256E (YTE) substitutions. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide further comprises L234A and L235A (LALA) substitutions and M252Y, S254T, and T256E (YTE) substitutions. In some embodiments, the modified Fc polypeptide and / or Fc polypeptide comprises human IgG1 wild-type residues at positions 234, 235, 252, 254, 256, and 366.

[0167] In some embodiments, the modified Fc polypeptide comprises the hole, LALA, and YTE mutations specified in any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189, and has at least 85% identity, at least 90% identity, or at least 95% identity to the respective sequences; or comprises the sequence of any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189. In some embodiments, the Fc polypeptide comprises the knob, LALA, and YTE mutations specified in any one of SEQ ID NOs: 107-110 and has at least 85% identity, at least 90% identity, or at least 95% identity to the respective sequences; or comprises the sequence of any one of SEQ ID NOs: 107-110. In some embodiments, the modified Fc polypeptide comprises any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189, and the Fc polypeptide comprises any one of SEQ ID NOs: 107-110. In some embodiments, the modified Fc polypeptide and / or the N-terminus of the Fc polypeptide comprises a portion of an IgG1 hinge region (e.g., DKTHTCPPCP; SEQ ID NO: 111).

[0168] In some embodiments, the ERT enzyme, e.g., IDS, present in a fusion protein described herein comprises an Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 99-102, or is linked to a polypeptide chain comprising the sequence of any one of SEQ ID NOs: 99-102 (e.g., as a fusion polypeptide). In some embodiments, the ERT enzyme, e.g., IDS, is linked to the Fc polypeptide by a linker, e.g., a flexible linker, and / or a hinge region or portion thereof (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the ERT enzyme comprises an IDS sequence having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 112, 192, and 196, or comprises the sequence of any one of SEQ ID NOs: 112, 192, and 196. In some embodiments, the IDS sequence linked to the Fc polypeptide has at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 113, 115, 193, 194, 197, and 198, or comprises the sequence of any one of SEQ ID NOs: 113, 115, 193, 194, 197, and 198. In some embodiments, the fusion protein comprises a modified Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183, or comprises the sequence of any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183. In some embodiments, the N-terminus of the Fc polypeptide and / or modified Fc polypeptide comprises a portion of an IgG1 hinge region (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the modified Fc polypeptide has at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 114, 190, and 191, or comprises the sequence of any one of SEQ ID NOs: 114, 190, and 191.

[0169] In some embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 113, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 167 and 190 (e.g., SEQ ID NO: 190). In other embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 113, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 131 and 191 (e.g., SEQ ID NO: 191).

[0170] In some embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 193, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 167 and 190 (e.g., SEQ ID NO: 190). In other embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 193, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 131 and 191 (e.g., SEQ ID NO: 191).

[0171] In some embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 197, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 167 and 190 (e.g., SEQ ID NO: 190). In other embodiments, the fusion protein comprises an IDS-Fc fusion polypeptide comprising the sequence of SEQ ID NO: 197, and a modified Fc polypeptide comprising the sequence of any one of SEQ ID NOs: 131 and 191 (e.g., SEQ ID NO: 191).

[0172] In some embodiments, the ERT enzyme, e.g., IDS, present in a fusion protein described herein comprises an Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 107-110, or is linked to a polypeptide chain comprising the sequence of any one of SEQ ID NOs: 107-110 (e.g., as a fusion polypeptide). In some embodiments, the ERT enzyme, e.g., IDS, is linked to the Fc polypeptide by a linker, e.g., a flexible linker, and / or a hinge region or portion thereof (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the ERT enzyme comprises an IDS sequence having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 112, 192, and 196, or comprises the sequence of any one of SEQ ID NOs: 112, 192, and 196. In some embodiments, the IDS sequence linked to the Fc polypeptide has at least 85%, at least 90%, or at least 95% identity to, or comprises the sequence of, any one of SEQ ID NOs: 116, 195, and 199. In some embodiments, the fusion protein comprises a modified Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to, any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189, or comprises the sequence of any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189. In some embodiments, the N-terminus of the Fc polypeptide and / or modified Fc polypeptide comprises a portion of the IgG1 hinge region (eg, DKTHTCPPCP; SEQ ID NO: 111).

[0173] In some embodiments, the ERT enzyme, e.g., an IDS, present in a fusion protein described herein comprises a modified Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183, or is linked to a polypeptide chain that comprises the sequence of any one of SEQ ID NOs: 95-98, 117, 118-123, 130-135, 142-147, 154-159, 166-171, and 178-183 (e.g., as a fusion polypeptide). In some embodiments, the ERT enzyme, e.g., an IDS, is linked to the modified Fc polypeptide by a linker, e.g., a flexible linker, and / or a hinge region or portion thereof (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the ERT enzyme comprises an IDS sequence having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 112, 192, and 196, or comprises the sequence of any one of SEQ ID NOs: 112, 192, and 196. In some embodiments, the fusion protein comprises an Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 99-102, or comprises the sequence of any one of SEQ ID NOs: 99-102. In some embodiments, the modified Fc polypeptide and / or the N-terminus of the Fc polypeptide comprises a portion of an IgG1 hinge region (e.g., DKTHTCPPCP; SEQ ID NO: 111).

[0174] In some embodiments, the ERT enzyme, e.g., an IDS, present in a fusion protein described herein comprises a modified Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189, or is linked to a polypeptide chain that comprises the sequence of any one of SEQ ID NOs: 103-106, 124-129, 136-141, 148-153, 160-165, 172-177, and 184-189 (e.g., as a fusion polypeptide). In some embodiments, the ERT enzyme, e.g., an IDS, is linked to the modified Fc polypeptide by a linker, e.g., a flexible linker, and / or a hinge region or portion thereof (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the ERT enzyme comprises an IDS sequence having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 112, 192, and 196, or comprises the sequence of any one of SEQ ID NOs: 112, 192, and 196. In some embodiments, the fusion protein comprises an Fc polypeptide having at least 85%, at least 90%, or at least 95% identity to any one of SEQ ID NOs: 107-110, or comprises the sequence of any one of SEQ ID NOs: 107-110. In some embodiments, the modified Fc polypeptide and / or the N-terminus of the Fc polypeptide comprises a portion of an IgG1 hinge region (e.g., DKTHTCPPCP; SEQ ID NO: 111).

[0175] V. ERT enzyme linked to an Fc polypeptide In some embodiments, the fusion protein described herein comprises two Fc polypeptides described herein, and one or both of the Fc polypeptides may further comprise a partial or complete hinge region. The hinge region may be from any immunoglobulin subclass or isotype. An exemplary immunoglobulin hinge is an IgG hinge region, such as an IgG1 hinge region, such as the human IgG1 hinge amino acid sequence EPKSCDKTHTCPPCP (SEQ ID NO: 93) or a portion thereof (e.g., DKTHTCPPCP; SEQ ID NO: 111). In some embodiments, the hinge region is present in the N-terminal region of the Fc polypeptide.

[0176] In some embodiments, the Fc polypeptide is joined to the ERT enzyme by a linker, e.g., a peptide linker. In some embodiments, the Fc polypeptide is joined to the ERT enzyme by a peptide bond or by a peptide linker, e.g., a fusion polypeptide. The peptide linker can be configured to allow rotation of the ERT enzyme relative to the Fc polypeptide to which it is joined and / or to be resistant to digestion by proteases. The peptide linker can contain natural amino acids, unnatural amino acids, or combinations thereof. In some embodiments, the peptide linker can be, for example, a flexible linker containing amino acids such as Gly, Asn, Ser, Thr, Ala, etc. Such linkers are designed using known parameters and can be of any length and contain any number of repeat units (e.g., repeat units of Gly and Ser residues) of any length. For example, the linker can have repeats, e.g., 2, 3, 4, 5, or more Gly4-Ser (SEQ ID NO: 201) repeats or a single Gly4-Ser (SEQ ID NO: 201). In some embodiments, the peptide linker can include a protease cleavage site cleavable by an enzyme present, for example, in the central nervous system.

[0177] In some embodiments, the ERT enzyme is joined to the N-terminus of the Fc polypeptide by, for example, a Gly4-Ser linker (SEQ ID NO: 201) or a (Gly4-Ser)2 linker (SEQ ID NO: 202). In some embodiments, the Fc polypeptide may include a hinge sequence or a partial hinge sequence at the N-terminus joined to a linker or directly joined to the ERT enzyme.

[0178] In some embodiments, the ERT enzyme is joined to the C-terminus of the Fc polypeptide, for example, by a Gly4-Ser linker (SEQ ID NO: 201) or a (Gly4-Ser)2 linker (SEQ ID NO: 202). In some embodiments, the C-terminus of the Fc polypeptide is joined directly to the ERT enzyme.

[0179] In some embodiments, the ERT enzyme is conjugated to the Fc polypeptide by a chemical crosslinker. Such conjugates can be produced using well-known chemical crosslinking reagents and protocols. For example, there are numerous chemical crosslinkers known to those skilled in the art that are useful for crosslinking polypeptides with agents of interest. For example, the crosslinker is a heterobifunctional crosslinker that can be used to link molecules in a stepwise manner. Heterobifunctional crosslinkers offer the ability to design more specific coupling methods for conjugating proteins, thereby reducing the occurrence of undesirable side reactions such as homoprotein polymers. A variety of heterobifunctional crosslinkers are known in the art, including N-hydroxysuccinimide (NHS) or its water-soluble analog N-hydroxysulfosuccinimide (sulfo-NHS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS); N-succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), succinimide, methylsuccinimidyl ester (MMS), m- ... These include succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC); 4-succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene (SMPT), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and succinimidyl 6-[3-(2-pyridyldithio)propionate]hexanoate (LC-SPDP). Those crosslinkers with N-hydroxysuccinimide moieties can usually be obtained as N-hydroxysulfosuccinimide analogs, which have higher water solubility. Also, those crosslinkers with disulfide bridges in the linking chain can be synthesized as alkyl derivatives instead to reduce the amount of linker cleavage in vivo. In addition to heterobifunctional crosslinkers, numerous other crosslinkers exist, including homobifunctional crosslinkers and photoreactive crosslinkers. Disuccinimidyl subcrate (DSS), bismaleimidohexane (BMH) and dimethyl pimelimidate.2HCl (DMP) is an example of a useful homobifunctional crosslinker, and bis-[B-(4-azidosalicylamido)ethyl]disulfide (BASED) and N-succinimidyl-6(4'-azido-2'-nitrophenylamino)hexanoate (SANPAH) are examples of useful photoreactive crosslinkers.

[0180] Screening Methods Certain embodiments described herein also include a method of screening a test agent for activity as a treatment for LSD, the method comprising: 1) contacting a cell with a test agent, the cell having a lysosomal storage deficiency; and 2) a) a combination of two or more lipids in a cell, the combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in a cell, where the test agent is being screened for activity as an MPS treatment, and / or c) sTREM2 in cells To measure the concentration of Including, The method provides that a reduction in the concentration of the selected lipid(s) / protein in the cell compared to the concentration of the corresponding lipid(s) / protein in a control cell (e.g., a healthy cell, e.g., a cell not having the LSD mutation) indicates that the test agent has activity as an LSD treatment.

[0181] Certain embodiments described herein include a method of screening a test agent for activity as a treatment for LSD, the method comprising: 1) contacting a cell with a test agent, the cell having a lysosomal storage deficiency; and 2) a) a combination of two or more lipids in a cell, the combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer A combination selected from the group consisting of: b) GlcCer in a cell, wherein the test agent is being screened for activity as an MPS treatment; c) Nf-L in cells, and / or d) sTREM2 in cells To measure the concentration of Including, The method provides that a reduction in the concentration of the selected lipid(s) / protein(s) in the cell compared to the concentration of the corresponding lipid(s) / protein(s) in a control cell (e.g., a healthy cell, e.g., a cell that does not have the LSD mutation) indicates that the test agent has activity as an LSD treatment.

[0182] In certain embodiments, the methods include measuring the concentration of sTREM2.

[0183] In certain embodiments, the method includes measuring the concentration of Nf-L.

[0184] In certain embodiments, the methods involve measuring the concentration of GlcCer, and test agents are screened for activity as MPS treatments.

[0185] In certain embodiments, the methods include measuring the concentration of a combination of two or more lipids, such as a combination described herein.

[0186] In certain embodiments, the methods include measuring the concentration of one or more lipids and the concentration of sTREM2.

[0187] In certain embodiments, the methods include measuring the concentration of one or more lipids and the concentration of Nf-L.

[0188] In certain embodiments, the methods include measuring the concentration of sTREM2 and the concentration of Nf-L.

[0189] In certain embodiments, the methods include measuring the concentration of one or more of lipids, sTREM2, and Nf-L.

[0190] In some embodiments, the cell is from a tissue. For example, in some embodiments, the cell is from the brain, liver, kidney, lung or spleen. In some embodiments, the cell is a brain cell or a cell derived from a brain cell. In some embodiments, the cell is a cell obtained from CSF. In some embodiments, the cell is a cell obtained from serum.

[0191] In certain embodiments, lipid / protein concentrations are measured using the assays described herein (eg, mass spectrometry).

[0192] Methods for isolating enriched CNS cell populations Provided herein are methods for isolating an enriched population of a CNS cell type (eg, an enriched population of neurons, astrocytes, or microglial cells) from brain tissue.

[0193] Thus, certain embodiments provide a method for selecting a population of CNS cells from a tissue sample, comprising: (a) contacting a tissue sample with a primary antibody for a neuron marker, a primary antibody for an astrocyte marker, a primary antibody for a microglia marker, a primary antibody for an endothelial marker, and a primary antibody for an oligodendrocyte marker, each primary antibody being uniquely labeled, providing a labeled tissue sample; and (b) sorting the cells in the labeled tissue sample by flow cytometry; Including, The method provides distinguishable cell populations of neurons, astrocytes, and microglial cells.

[0194] As used herein, the term "distinguishable cell populations" refers to physically separate populations of cells enriched for specific CNS cell types (e.g., neurons, astrocytes, microglia).

[0195] As used herein, the term "neuronal marker" refers to a protein or peptide that is preferentially expressed in the CNS by neurons. In certain embodiments, the neuronal marker is expressed by at least about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.5% of neuronal cells present in the CNS. In certain embodiments, the neuronal marker is expressed by less than about 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of non-neuronal cells present in the CNS. In certain embodiments, the neuronal marker is not expressed by non-neuronal cell types present in the CNS. In certain embodiments, the neuronal marker is Thy1 (see, e.g., UniProtKB P01831 (mouse)).

[0196] As used herein, the term "neuronal marker primary antibody" or "anti-neuronal marker antibody" refers to an antibody capable of binding to a neuronal marker with sufficient affinity such that the antibody is useful for sorting neurons from a mixed population of cells using flow cytometry. In one embodiment, the extent of binding of the anti-neuronal marker antibody to unrelated proteins is less than about 10% of the binding of the antibody to the neuronal marker, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to a neuronal marker has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13M, for example, 10 -9 M~10 -13 M) In certain embodiments, the neuronal marker primary antibody is an anti-Thy1 antibody (e.g., an anti-Thy1 antibody as used herein).

[0197] As used herein, the term "astrocyte marker" refers to a protein or peptide that is preferentially expressed in the CNS by astrocytes. In certain embodiments, the astrocyte marker is expressed by at least about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.5% of astrocytes present in the CNS. In certain embodiments, the astrocyte marker is expressed by less than about 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of non-astrocytes present in the CNS. In certain embodiments, the astrocyte marker is not expressed by non-astrocyte cell types present in the CNS. In certain embodiments, the astrocyte marker is excitatory amino acid transporter 2 (EAAT2) (see, e.g., UniProtKB P43006 (mouse)). In certain embodiments, the astrocyte marker is a glycosylated surface molecule recognized by anti-astrocyte surface antigen-2 (ACSA-2) antibody (see, e.g., Kantzer et al., 2017, Glia, 65:990-1004).

[0198] As used herein, the term "primary astrocyte marker antibody" or "anti-astrocyte marker antibody" refers to an antibody capable of binding to an astrocyte marker with sufficient affinity such that the antibody is useful for sorting astrocytes from a mixed population of cells using flow cytometry. In one embodiment, the extent of binding of the anti-astrocyte marker antibody to a non-related protein is less than about 10% of the binding of the antibody to the astrocyte marker, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to an astrocyte marker has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8M or less, e.g., 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 The astrocyte marker primary antibody has a dissociation constant (Kd) of 1 M. In certain embodiments, the astrocyte marker primary antibody is an anti-EAAT2 antibody (e.g., an anti-EAAT2 antibody used herein). In certain embodiments, the astrocyte marker primary antibody is an anti-ACSA-2 antibody (e.g., ACSA-2-PE (Miltenyi Biotec 130-102-365)).

[0199] As used herein, the term "microglial marker" refers to a protein or peptide that is preferentially expressed in the CNS by microglial cells. In certain embodiments, the microglial marker is expressed by at least about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.5% of the microglial cells present in the CNS. In certain embodiments, the microglial marker is expressed by less than about 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of the non-microglial cells present in the CNS. In certain embodiments, the microglial marker is not expressed by non-microglial cell types present in the CNS. In certain embodiments, the microglial marker is CD11b (see, e.g., UniProtKB P05555 (mouse)).

[0200] As used herein, the term "microglia marker primary antibody" or "anti-microglia marker antibody" refers to an antibody capable of binding to a microglia marker with sufficient affinity such that the antibody is useful for sorting microglia cells from a mixed population of cells using flow cytometry. In one embodiment, the extent of binding of the anti-microglia marker antibody to a non-related protein is less than about 10% of the binding of the antibody to the microglia marker, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to a microglia marker has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 M) In certain embodiments, the microglial marker primary antibody is an anti-CD11b antibody (e.g., an anti-CD11b antibody used herein).

[0201] As used herein, the term "endothelial marker" refers to a protein or peptide that is preferentially expressed in the CNS by endothelial cells. In certain embodiments, the endothelial cell marker is expressed by at least about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.5% of endothelial cells present in the CNS. In certain embodiments, the endothelial cell marker is expressed by less than about 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of non-endothelial cells present in the CNS. In certain embodiments, the endothelial cell marker is not expressed by non-endothelial cell types present in the CNS. In certain embodiments, the endothelial cell marker is CD31 (see, e.g., UniProtKB Q08481 (mouse)).

[0202] As used herein, the term "primary endothelial marker antibody" or "anti-endothelial cell marker antibody" refers to an antibody capable of binding to an endothelial cell marker with sufficient affinity such that the antibody is useful for sorting endothelial cells from a mixed population of cells using flow cytometry. In one embodiment, the extent of binding of the anti-endothelial cell marker antibody to unrelated proteins is less than about 10% of the binding of the antibody to the endothelial cell marker, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to an endothelial cell marker has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 In certain embodiments, the endothelial cell marker primary antibody is an anti-CD31 antibody (eg, an anti-CD31 antibody used herein).

[0203] As used herein, the term "oligodendrocyte marker" refers to a protein or peptide that is preferentially expressed in the CNS by oligodendrocyte cells. In certain embodiments, the oligodendrocyte marker is expressed by at least about 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.5% of the oligodendrocyte cells present in the CNS. In certain embodiments, the oligodendrocyte marker is expressed by less than about 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of the non-oligodendrocyte cells present in the CNS. In certain embodiments, the oligodendrocyte marker is not expressed by non-oligodendrocyte cell types present in the CNS. In certain embodiments, the oligodendrocyte marker is a membrane lipid marker. In certain embodiments, the oligodendrocyte marker is a lipid enriched on mature oligodendrocytes, such as galactocerebroside (GalCer).

[0204] As used herein, the term "oligodendrocyte marker primary antibody" or "anti-oligodendrocyte marker antibody" refers to an antibody capable of binding to an oligodendrocyte marker with sufficient affinity such that the antibody is useful for sorting oligodendrocyte cells from a mixed population of cells using flow cytometry. In one embodiment, the extent of binding of an anti-oligodendrocyte marker antibody to a non-related protein is less than about 10% of the binding of the antibody to oligodendrocytes, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to an oligodendrocyte marker has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 In certain embodiments, the oligodendrocyte marker primary antibody is an anti-O1 antibody (e.g., the anti-O1 antibody used herein) that reacts with a membrane lipid marker (e.g., GalCer).

[0205] In certain embodiments, the tissue sample is contacted with an anti-Thy1 antibody, an anti-EAAT2 antibody, an anti-CD11b antibody, an anti-CD31 antibody, and an anti-O1 antibody. In certain embodiments, the tissue sample is contacted with an anti-Thy1 antibody, an anti-ACSA-2 antibody, an anti-CD11b antibody, an anti-CD31 antibody, and an anti-O1 antibody. In certain embodiments, the primary antibody is included in a composition and the tissue sample is contacted with the composition. In certain embodiments, each primary antibody is uniquely labeled (i.e., each antibody comprises a different label) with a label (e.g., a fluorescent label) suitable for sorting by flow cytometry. In certain embodiments, the tissue sample is further contacted with a viability dye that can be used to distinguish between viable and non-viable cells by flow cytometry (e.g., Fixable Viability Stain BV510). In certain embodiments, the tissue sample is contacted with the viability dye simultaneously or sequentially with the primary antibody. In certain other embodiments, the viability dye is included within a composition that includes the primary antibody, and the tissue sample is contacted with the composition that includes the primary antibody and the viability dye.

[0206] In certain embodiments, cells present within a tissue sample are dissociated and then contacted with a composition comprising a viability dye, a primary antibody, and / or a primary antibody with or without a viability dye.

[0207] In certain embodiments, the tissue sample is contacted with a primary antibody under conditions suitable for the antibody to bind to its corresponding marker and label the cells. In certain embodiments, the labeled tissue sample prior to sorting by flow cytometry contains labeled Thy1 + Cells, labeled EAAT2 + Cells, labeled with CD11b + Cells, labeled CD31 + Cells and labeled O1 + In certain embodiments, the labeled tissue sample prior to sorting by flow cytometry contains labeled Thy1 cells. + Cells, labeled ACSA-2 + Cells, labeled with CD11b + Cells, labeled CD31+ Cells and labeled O1 + In certain embodiments, the cells are further labeled with a viability dye.

[0208] In certain embodiments, cells present within a tissue sample are sorted by flow cytometry into a population of non-viable cells and a population of viable cells (eg, bearing a viability dye).

[0209] In certain embodiments, cells present within a tissue sample are identified by flow cytometry as O1 + Cell population and O1 - A population of cells is selected.

[0210] In certain embodiments, cells present within the tissue sample are identified by flow cytometry as CD31 + Cell populations and CD31 - A population of cells is selected.

[0211] In certain embodiments, cells present within a tissue sample are identified by flow cytometry as Thy + Cell population and Thy - A population of cells is selected.

[0212] In certain embodiments, cells present within the tissue sample are assayed for EAAT2 + Populations of cells and EAAT2 - A population of cells is selected.

[0213] In certain embodiments, cells present within the tissue sample are identified by flow cytometry as ACSA-2 + Cell populations and ACSA-2 - A population of cells is selected.

[0214] In certain embodiments, cells present within the tissue sample are identified by flow cytometry as CD11b + Cell populations and CD11b - A population of cells is selected.

[0215] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , Thy1 + , EAAT2 - A population of cells (i.e., neuronal cells) are sorted.

[0216] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , Thy1 - , EAAT2 + The cells are then sorted into a population of cells (i.e., astrocytes).

[0217] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , CD11b + The cells are then sorted into a population of cells (i.e., microglial cells).

[0218] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , Thy1 + , ACSA-2 - A population of cells (i.e., neuronal cells) are sorted.

[0219] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , Thy1 - , ACSA-2 + The cells are then sorted into a population of cells (i.e., astrocytes).

[0220] In certain embodiments, cells present within the tissue sample are assayed for viability, O1 - , CD31 - , CD11b +The cells are then sorted into a population of cells (i.e., microglial cells).

[0221] In certain embodiments, cells present within a tissue sample are sorted by flow cytometry into a population of non-viable cells and a population of viable cells (e.g., having a viability dye). In certain embodiments, the population of viable cells is O1 + , CD31 + A population of cells (i.e., oligodendrocytes and endothelial cells) and O1 - , CD31 - In some embodiments, the O1 - , CD31 - The population of cells was determined to be viable, O1 - , CD31 - , Thy1 + , EAAT2 - Cell (i.e., neuronal) population, viability, O1 - , CD31 - , Thy1 - , EAAT2 + Cell (i.e., astrocyte) population and viability, O1 - , CD31 - , CD11b + These are then further sorted into a population of cells (i.e., microglial cells).

[0222] In certain embodiments, cells present within a tissue sample are sorted by flow cytometry into a population of non-viable cells and a population of viable cells (e.g., having a viability dye). In certain embodiments, the population of viable cells is O1 + , CD31 + A population of cells (i.e., oligodendrocytes and endothelial cells) and O1 - , CD31 - In some embodiments, the O1 - , CD31 - The population of cells was viable, O1 - , CD31 - , Thy1 + , ACSA-2 -Cell (i.e., neuronal) population, viability, O1 - , CD31 - , Thy1 - , ACSA-2 + Cell (i.e., astrocyte) population and viability, O1 - , CD31 - , CD11b + These are then further sorted into a population of cells (i.e., microglial cells).

[0223] In certain embodiments, cells present within a tissue sample are sorted by flow cytometry into a population of non-viable cells and a population of viable cells (e.g., having a viability dye). In certain embodiments, the population of viable cells is selected from the population of CD31 + A population of cells (i.e., endothelial cells) and CD31 - In some embodiments, the population of cells is further sorted into CD31 - The cell population is CD31 - , Thy1 + , EAAT2 - A population of cells, CD31 - , Thy1 - , EAAT2 + Cell populations, and CD31 - , CD11b + In some embodiments, the population of cells is further sorted into CD31 - , Thy1 + , EAAT2 - cells, CD31 - , Thy1 - , EAAT2 + Cells, and CD31 - , CD11b + The cell population was further sorted to O1 + Cells (i.e., oligodendrocytes) are removed to determine viability, O1 - , CD31 - , Thy1 + , EAAT2 - Population of cells (i.e., neuronal cells); viability, O1 - , CD31 - , Thy1 - , EAAT2 +cell (i.e., astrocyte) population; and viability, O1 - , CD31 - , CD11b + A population of cells (i.e., microglial cells) is provided.

[0224] In certain embodiments, cells present within a tissue sample are sorted by flow cytometry into a population of non-viable cells and a population of viable cells (e.g., having a viability dye). In certain embodiments, the population of viable cells is selected from the population of CD31 + A population of cells (i.e., endothelial cells) and CD31 - In some embodiments, the population of cells is further sorted into CD31 - The cell population is CD31 - , Thy1 + , ACSA-2 - A population of cells, CD31 - , Thy1 - , ACSA-2 + Cell populations, and CD31 - , CD11b + In some embodiments, the population of cells is further sorted into CD31 - , Thy1 + , ACSA-2 - cells, CD31 - , Thy1 - , ACSA-2 + Cells, and CD31 - , CD11b + The cell population was further sorted to O1 + Cells (i.e., oligodendrocytes) are removed to determine viability, O1 - , CD31 - , Thy1 + , ACSA-2 - Population of cells (i.e., neuronal cells); viability, O1 - , CD31 - , Thy1 - , ACSA-2 + cell (i.e., astrocyte) population; and viability, O1 - , CD31 - , CD11b +A population of cells (i.e., microglial cells) is provided.

[0225] In certain embodiments, the microglial cell population comprises a marker profile O1 - / CD31 - / CD11b + are selected based on.

[0226] In certain embodiments, the astrocyte population has marker profile O1 - / CD31 - / Thy1 - / EAAT2 + In certain embodiments, the astrocyte population is selected based on the marker profile O1. - / CD31 - / Thy1 - / ACSA-2 + are selected based on.

[0227] In certain embodiments, the neuronal population comprises marker profile O1 - / CD31 - / Thy1 + / EAAT2 - In certain embodiments, the neuronal population is selected based on the marker profile O1. - / CD31 - / Thy1 + / ACSA-2 - are selected based on.

[0228] In certain embodiments, enriched neuronal cells (e.g., viability, O1 - , CD31 - , Thy1 + , EAAT2 - Cell or viability, O1 - , CD31 - , Thy1 + , ACSA-2 -In some embodiments, the sorted population of enriched neuronal cells (e.g., viable, O1 cells) contains less than about 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of non-neuronal cells. - , CD31 - , Thy1 + , EAAT2 - Cell or viability, O1 - , CD31 - , Thy1 + , ACSA-2 - The sorted population of cells does not contain non-neuronal cells.

[0229] In certain embodiments, enriched astrocytes (e.g., viable, O1 - , CD31 - , Thy1 - , EAAT2 + Cell or viability, O1 - , CD31 - , Thy1 - , ACSA-2 + The sorted population of enriched astrocytes (e.g., viable, O1 cells) comprises less than about 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less non-astrocytes. - , CD31 - , Thy1 - , EAAT2 + Cell or viability, O1 - , CD31 - , Thy1 - , ACSA-2 + The sorted population of cells does not contain non-astrocytic cells.

[0230] In certain embodiments, enriched microglial cells (e.g., viable, O1 - , CD31 - , CD11b +In some embodiments, the sorted population of enriched microglial cells (e.g., viable, O1 cells) comprises less than about 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of non-microglial cells. - , CD31 - , CD11b + The sorted population of cells) does not contain non-microglial cells.

[0231] In certain embodiments, one or more of the enriched cell populations (e.g., one, two, or three of the enriched cell populations) are analyzed for quantification of metabolism or nucleic acid species. In certain embodiments, an enriched neuronal cell population is analyzed for quantification of metabolism or nucleic acid species. In certain embodiments, an enriched astrocyte cell population is analyzed for quantification of metabolism or nucleic acid species. In certain embodiments, an enriched microglial cell population is analyzed for quantification of metabolism or nucleic acid species. In certain embodiments, enriched neuronal, astrocyte, and microglial cell populations are analyzed for quantification of metabolism or nucleic acid species. In certain embodiments, one or more enriched cell populations are analyzed for quantification of metabolic species. In certain embodiments, one or more enriched cell populations are analyzed for quantification of multiple metabolic species (e.g., 2, 3, 4, 5, 10, 25, 50 or more). In certain embodiments, one or more enriched cell populations are analyzed for quantification of nucleic acid species. In certain embodiments, one or more enriched cell populations are analyzed for quantification of multiple nucleic acid species (e.g., 2, 3, 4, 5, 10, 25, 50 or more). In certain embodiments, one or more enriched cell populations are analyzed for quantification of metabolic and nucleic acid species. In certain embodiments, one or more enriched cell populations are analyzed for quantification of multiple metabolic species and multiple nucleic acid species.

[0232] As used herein, the term metabolic species includes macromolecules that are normally degraded by lysosomes. For example, in certain embodiments, the metabolic species is a glycosaminoglycan (GAG) species, such as a GAG species described herein (e.g., D0S0, D0A0, or D0a4). In certain embodiments, the metabolic species is a lipid species, such as a ganglioside, a glycosylceramide (e.g., glucosylceramide), a galactosylceramide, or a bis(monoacylglycerol)phosphate (BMP) species (e.g., a species described herein). In certain embodiments, the metabolic species is a BMP, GlcCer, GD3, GD1a / b, GM2, and / or GM3 species (e.g., those described herein). In certain embodiments, a combination of metabolic species is quantified, such as a combination of lipids described herein. The metabolic species may be quantified using methods known in the art. For example, the metabolic species may be quantified using a liquid chromatography mass spectrometry (LCMS) assay (e.g., see the Examples).

[0233] The nucleic acid can be, for example, RNA or DNA, e.g., genomic DNA, RNA transcribed from genomic DNA, or cDNA generated from RNA. In certain embodiments, the nucleic acid species is RNA. In certain embodiments, the nucleic acid species is DNA. In certain embodiments, the nucleic acid species is genomic DNA. Methods for quantifying nucleic acid species are known in the art. For example, such methods include, but are not limited to, polymerase chain reaction (PCR), including quantitative PCR (qPCR) and real-time quantitative reverse transcription PCR (qRT-PCR); RNAseq; Northern blot analysis, expression microarray analysis; next generation sequencing (NGS); and fluorescent in situ hybridization (FISH). In certain embodiments, the nucleic acid species is quantified using an assay described herein.

[0234] In some embodiments, one or more enriched cell populations are analyzed for quantification of sTREM2. In some embodiments, enriched microglial cell populations are analyzed for quantification of sTREM2. sTREM2 can be quantified using methods known in the art. For example, sTREM2 can be quantified using the assay described in the Examples.

[0235] In some embodiments, one or more enriched cell populations are analyzed for the quantification of Nf-L. In some embodiments, enriched neuronal cell populations are analyzed for the quantification of Nf-L. Nf-L can be quantified using methods known in the art. For example, Nf-L can be quantified using the assay described in the Examples.

[0236] In certain embodiments, one or more enriched cell populations are analyzed for quantification of administered therapeutic agent. In certain embodiments, an enriched neuronal cell population is analyzed for quantification of administered therapeutic agent. In certain embodiments, an enriched astrocyte cell population is analyzed for quantification of administered therapeutic agent. In certain embodiments, an enriched microglial cell population is analyzed for quantification of administered therapeutic agent. In certain embodiments, enriched neuronal, astrocyte and microglial cell populations are analyzed for quantification of administered therapeutic agent. In certain embodiments, the therapeutic agent is an agent capable of reducing one or more symptoms associated with LSD. In certain embodiments, the therapeutic agent is ETV:IDS. Methods for quantifying therapeutic agents are known in the art and described herein. For example, the therapeutic agent may be quantified by the assays described in the Examples.

[0237] Certain embodiments provide a collection of CNS cells comprising three physically distinct cell populations: 1) The first cell population is O1 - / CD31 - / CD11b + comprising an enriched population of cells, 2) The second cell population is O1 - / CD31 - / Thy1 - / EAAT2 + Enriched population of cells or O1 - / CD31 - / Thy1 - / ACSA-2 + comprising an enriched population of cells, 3) The third cell population is O1 - / CD31 - / Thy1 + / EAAT2 - Enriched populations of or O1 - / CD31 - / Thy1 + / ACSA-2 - Contains an enriched population of cells Provide an aggregate.

[0238] Corrected Cells and Related Methods As described herein, LSD is caused by the deficiency of a certain lysosomal enzyme, which leads to the accumulation of metabolic species in a certain cell type (e.g., a certain CNS cell). This accumulation can be corrected by contacting the affected cell with a certain therapeutic agent (e.g., a therapeutic agent described herein). For example, the accumulation of metabolic species in a cell (e.g., a CNS cell) having a lysosomal enzyme deficiency can be reduced by contacting the cell with a fusion protein comprising an enzyme replacement therapy (ERT) enzyme linked to an Fc polypeptide.

[0239] Thus, certain embodiments provide a corrected CNS cell comprising a deficiency in a lysosomal enzyme that causes accumulation of metabolic species in the cell, the cell being corrected by contacting the cell with a protein comprising (i) a first Fc polypeptide linked to a lysosomal enzyme and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide, the protein being capable of binding to a transferrin receptor (TfR), and the correction being a reduction in accumulation of metabolic species. In certain embodiments, the corrected CNS cell is a human cell. In certain embodiments, the corrected CNS cell is a non-human cell. In certain embodiments, the cell is an isolated or purified corrected CNS cell.

[0240] Certain embodiments also provide for a corrected CNS cell comprising a reduced accumulation of a metabolic species, the CNS cell comprising a deficiency of a lysosomal enzyme that causes accumulation of the metabolic species in the cell, comprising: (i) a first Fc polypeptide linked to a lysosomal enzyme, and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. and providing a corrected CNS cell comprising a reduced accumulation of a metabolic species, the protein comprising:

[0241] Certain embodiments also provide corrected CNS cells produced by the methods described herein, for example, the methods described below.

[0242] Certain embodiments also provide a method of correcting a CNS cell having a deficiency in a lysosomal enzyme that causes accumulation of a metabolic species in the cell, the method comprising contacting the cell with a protein comprising (i) a first Fc polypeptide linked to a lysosomal enzyme, and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide to provide a corrected CNS cell having reduced accumulation of the metabolic species, wherein the protein is capable of binding to the transferrin receptor (TfR).

[0243] Certain embodiments also provide a method of reducing accumulation of a metabolic species in a CNS cell having a lysosomal enzyme deficiency, the method comprising contacting the cell with a protein comprising (i) a first Fc polypeptide linked to a lysosomal enzyme, and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide, wherein the protein is capable of binding to the transferrin receptor (TfR).

[0244] In certain embodiments, the cells are contacted with the protein in vitro, ex vivo or in vivo. In certain embodiments, the cells are contacted with the protein in vitro. In certain embodiments, the cells are contacted with the protein ex vivo. In certain embodiments, the cells are contacted with the protein in vivo (i.e., via administration of the protein). In certain embodiments, the cells are from a tissue sample and have been sorted by the methods described herein. In certain embodiments, the cells are contacted with the protein in vivo before being sorted. In certain other embodiments, the cells are contacted with the protein in vitro before or after being sorted.

[0245] In some embodiments, the first Fc polypeptide linked to the lysosomal enzyme is an Fc polypeptide described herein. In some embodiments, the lysosomal enzyme is iduronate 2-sulfatase (IDS), or a catalytically active variant or fragment of wild-type IDS, e.g., wild-type human IDS. In some embodiments, the second Fc polypeptide is a polypeptide described herein. In some embodiments, the protein is ETV:IDS.

[0246] In certain embodiments, the protein has at least 5-fold, 10-fold, 50-fold, 100-fold, 1,000-fold, 10,000-fold, or more affinity for TfR compared to an unrelated target when assayed under the same affinity assay conditions, hi certain embodiments, the protein binds to TfR with an affinity of about 50 nM to about 350 nM. In certain embodiments, the protein binds to TfR with an affinity of about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 275 nM, about 300 nM, about 325 nM, or about 350 nM.

[0247] In some embodiments, the metabolic species is a GAG species, e.g., a GAG species described herein (e.g., D0S0, D0A0, or D0a4). In some embodiments, the metabolic species is a lipid species, e.g., a ganglioside, a glycosylceramide (e.g., glucosylceramide), a galactosylceramide, or a bis(monoacylglycerol)phosphate (BMP) species (e.g., a species described herein). In some embodiments, the metabolic species is a BMP, GlcCer, GD3, GD1a / b, GM2, and / or GM3 species (e.g., those described herein). In some embodiments, the accumulation of a combination of metabolic species, e.g., a combination of lipids described herein, is reduced. Quantification of the amount of accumulation of metabolic species in a cell can be performed using methods known in the art. For example, metabolic species can be quantified using a liquid chromatography mass spectrometry (LCMS) assay (see, e.g., Examples).

[0248] In certain embodiments, the accumulation of at least one metabolic species in the cells is reduced by at least about 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more. In certain embodiments, the accumulation of at least one metabolic species in the cells is reduced to levels in control cells (e.g., corresponding cells that do not include a lysosomal enzyme deficiency). In certain embodiments, the accumulation of multiple metabolic species (e.g., two or more metabolic species, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 50 or more) is reduced.

[0249] In some embodiments, the CNS cell is selected from the group consisting of a neuron, an astrocyte, and a microglial cell. In some embodiments, the CNS cell is a neuron. In some embodiments, the CNS cell is an astrocyte. In some embodiments, the CNS cell is a microglial cell.

[0250] Certain embodiments Embodiment 1. A method for detecting one or more biomarkers in a subject having a lysosomal storage disorder (LSD), the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from the subject, the combination of lipids comprising: a) bis(monoacylglycero)phosphate (BMP), b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) Glucosylceramide (GlcCer) The measuring step is selected from the group consisting of: 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is a mucopolysaccharidosis (MPS) disorder; 3) measuring the concentration of neurofilament light chain (Nf-L) in a sample from the subject; and / or 4) measuring the concentration of soluble triggering receptor expressed on bone marrow cells 2 (sTREM2) in a sample from the subject. The method comprising:

[0251] Embodiment 2. A method of assessing the effectiveness of a treatment in a subject with LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample obtained from the subject after administration of the treatment, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3, d) GD1a / b, and e) GlcCer The measuring step is selected from the group consisting of: 2) measuring the concentration of GlcCer in a sample obtained from the subject after administration of the treatment, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample obtained from the subject after administration of the treatment; and / or 4) measuring the concentration of sTREM2 in a sample obtained from the subject after administration of the treatment. Including, The method, wherein a reduction in the concentration of the selected lipid(s) / protein(s) in the sample obtained from the subject after administration of the treatment compared to the concentration of the lipid(s) / protein(s) in a sample obtained from the subject before administration of the treatment correlates with treatment efficacy.

[0252] Embodiment 3. A method of identifying a subject having an LSD as a candidate for treatment, comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from the subject, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3, d) GD1a / b, and e) GlcCer The measuring step is selected from the group consisting of: 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample from the subject; and / or 4) measuring the concentration of sTREM2 in a sample from the subject. Including, The method, wherein a concentration of the selected lipid(s) / protein(s) in the sample from the subject that is at least as high as a control value identifies the subject as a candidate for treatment.

[0253] Embodiment 4. The method of any one of embodiments 1-3, further comprising administering an LSD treatment to said subject.

[0254] Embodiment 5. The method of any one of embodiments 1-4, further comprising adjusting a treatment regimen for said subject.

[0255] Embodiment 6. A method for treating LSD in a subject, the method comprising: 1) administering an LSD treatment to said subject; 2) a) a combination of two or more lipids in a sample from the subject, the combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer The combination selected from the group consisting of: b) GlcCer in a sample from said subject, wherein said LSD is an MPS disorder; c) Nf-L in a sample from the subject, and / or d) sTREM2 in a sample from said subject Measuring the concentration of 3) adjusting the dosage of the LSD treatment based on the concentration of the selected lipid(s) / protein(s) in the sample from the subject compared to a control value. The method comprising:

[0256] Embodiment 7. The method of any one of embodiments 1 to 6, comprising measuring the concentration of sTREM2.

[0257] Embodiment 8. The method of any one of embodiments 1 to 6, comprising measuring the concentration of Nf-L.

[0258] Embodiment 9. The method of any one of embodiments 1-6, comprising measuring the concentration of GlcCer, wherein the LSD is an MPS disorder.

[0259] Embodiment 10. The method of any one of embodiments 1-6, comprising measuring the concentration of a combination of two or more lipids.

[0260] Embodiment 11. The method of any one of embodiments 1 to 6, comprising measuring the concentration of one or more lipids and the concentration of sTREM2.

[0261] Embodiment 12. The method of any one of embodiments 1 to 6, comprising measuring the concentration of one or more lipids and the concentration of Nf-L.

[0262] Embodiment 13. The method of any one of embodiments 1 to 12, wherein the sample is a tissue sample, a serum sample or a cerebrospinal fluid sample.

[0263] Embodiment 14 The method of embodiment 13, wherein the sample is a tissue sample.

[0264] Embodiment 15 The method of embodiment 14, wherein the tissue is brain, liver, kidney, lung or spleen.

[0265] Embodiment 16 The method of embodiment 13, wherein the sample is a serum sample.

[0266] Embodiment 17 The method of embodiment 13, wherein the sample is a cerebrospinal fluid sample.

[0267] Embodiment 18. A method for treating LSD in a subject, the method comprising administering an LSD treatment to the subject, the subject having: 1) an elevated concentration of a combination of two or more lipids compared to a control, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3, d) GD1a / b, and e) GlcCer The elevated concentration is selected from the group consisting of: 2) an elevated concentration of GlcCer, wherein the LSD is an MPS disorder; 3) elevated levels of Nf-L, and / or 4) Elevated levels of sTREM2 The method of any one of claims 1 to 5, wherein said method comprises:

[0268] Embodiment 19. The method of embodiment 18, wherein said subject has, or has been determined to have, an elevated concentration of sTREM2.

[0269] Embodiment 20. The method of embodiment 18, wherein the subject has, or has been determined to have, an elevated concentration of Nf-L.

[0270] Embodiment 21 The method of embodiment 18, wherein the subject has, or is determined to have, an elevated concentration of GlcCer, and the LSD is an MPS disorder.

[0271] Embodiment 22 The method of embodiment 18, wherein the subject has, or has been determined to have, elevated concentrations of a combination of two or more lipids.

[0272] Embodiment 23 The method of embodiment 18, wherein the subject has, or has been determined to have, elevated levels of one or more lipids and elevated levels of sTREM2.

[0273] Embodiment 24. The method of embodiment 18, wherein the subject has, or has been determined to have, elevated levels of one or more lipids and elevated levels of Nf-L.

[0274] Embodiment 25. The method of any one of embodiments 1 to 24, wherein the combination includes a BMP.

[0275] Embodiment 26 The method of any one of embodiments 1 to 25, wherein the combination includes GlcCer.

[0276] Embodiment 27. The method of any one of embodiments 1 to 26, wherein the combination includes GD3.

[0277] Embodiment 28. The method of any one of embodiments 1 to 27, wherein the combination comprises GD1a / b.

[0278] Embodiment 29. The method of any one of embodiments 1 to 28, wherein the combination includes GM2.

[0279] Embodiment 30. The method of any one of embodiments 1 to 29, wherein the combination includes GM3.

[0280] Embodiment 31. The combination is selected from the group consisting of BMP and GlcCer; BMP and GD3; BMP and GD1a / b; BMP and GM2; BMP and GM3; GlcCer and GD3; GlcCer and GD1a / b; GlcCer and GM2; GlcCer and GM3; GD3 and GD1a / b; GD3 and GM2; GD3 and GM3; GD1a / b and GM2; GD1a / b and GM3; BMP, GlcCer and GD3; BMP, GlcCer and GD1a / b; BMP, GlcCer and GM2; BMP, GlcCer and GM3; B MP, GD3 and GD1a / b; BMP, GD3 and GM2; BMP, GD3 and GM3; BMP, GD1a / b and GM2; BMP, GD1a / b and GM3; BMP GM2 and GM3; GlcCer, GD3 and GD1a / b; GlcCer, GD3 and GM2; GlcCer, GD3 and GM3; GlcCer, GD1a / b and GM2; GlcCer, GD1a / b and GM3; GlcCer, GM2 and GM3; GD3, GD1a / b and GM2; GD3, GD1a / b and GM3; GD3, GM2 and GM3; GD1a / b, GM2 and GM3; BMP, GlcCer, GD3 and GD1a / b; BMP, GlcCer, GD3 and GM2; BMP, GlcCer, GD3 and GM3; BMP, GlcCer, GD1a / b and GM2; BMP, GlcCer, GD1a / b and GM3; BMP, GlcCer, GM2 and GM3; BMP, GD3, GD1a / b and GM2; BMP, GD3, GD1a / b and GM3; BMP, GD3, GM2 and GM3; BMP, GD1a / b, GM2 and GM3; GlcCer, GD3, GD1a / b and GM2; G lcCer, GD3, GD1a / b and GM3; GlcCer, GD3, GM2 and GM3; GlcCer, GD1a / b, GM2 and GM3; GD3, GD1a / b, GM2 and GM3; BMP, GlcCer, GD3, GD1a / b and GM2; BMP, GlcCer, GD3, GD1a / b and GM3; BMP, GD3, GD1a / b, GM2 and GM3; BMP, GlcCer, GD3, GM2 and GM3; BMP, GlcCer, GD1a / b, GM2 and GM3; GlcCer, GD3, GD1a / b, GM2 and GM3;or BMP, GlcCer, GD3, GD1 / b, GM2 and GM3.

[0281] Embodiment 32. The method of any one of embodiments 1 to 24, wherein the combination comprises BMP and GlcCer; BMP and GD3; BMP and GD1a / b; BMP and GM2; BMP and GM3; GlcCer and GD3; GlcCer and GD1a / b; GlcCer and GM2; GlcCer and GM3; GD3 and GD1a / b; GD3 and GM2; GD3 and GM3; GD1a / b and GM2; or GD1a / b and GM3.

[0282] Embodiment 33. The combination is selected from the group consisting of BMP, GlcCer and GD3; BMP, GlcCer and GD1a / b; BMP, GlcCer and GM2; BMP, GlcCer and GM3; BMP, GD3 and GD1a / b; BMP, GD3 and GM2; BMP, GD3 and GM3; BMP, GD1a / b and GM2; BMP, GD1a / b and GM3; BMP, GM2 and GM3; GlcCer, GD3 and GD1a / b; GlcCer, GD3 and GM2; GlcCer, GD3 and GM3; GlcCer, GD1a / b and GM2; GlcCer, GD1a / b and GM3; GlcCer, GM2 and GM3; GD3, GD1a / b and GM2; GD3, GD1a / b and GM3; GD3, GM2 and GM3; or GD1a / b, GM2 and GM3.

[0283] Embodiment 34. The combination is: BMP, GlcCer, GD3 and GD1a / b; BMP, GlcCer, GD3 and GM2; BMP, GlcCer, GD3 and GM3; BMP, GlcCer, GD1a / b and GM2; BMP, GlcCer, GD1a / b and GM3; BMP, GlcCer, GM2 and GM3; BMP, GD3, GD1a / b and GM2; BMP, GD3, GD1a / b and GM3; BMP, GD3, GM2 and GM3; BMP, GD1a / b, GM2 and GM3; GlcCer, GD3, GD1a / b and GM2; GlcCer, GD3, GD1a / b and GM3; GlcCer, GD3, GM2 and GM3; GlcCer, GD1a / b, GM2 and GM3; or GD3, GD1a / b, GM2 and GM3.

[0284] Embodiment 35. The method of any one of embodiments 1 to 24, wherein the combination comprises BMP, GlcCer, GD3, GD1a / b and GM2; BMP, GlcCer, GD3, GD1a / b and GM3; BMP, GD3, GD1a / b, GM2 and GM3; BMP, GlcCer, GD3, GM2 and GM3; BMP, GlcCer, GD1a / b, GM2 and GM3; or GlcCer, GD3, GD1a / b, GM2 and GM3.

[0285] Embodiment 36 The method of any one of embodiments 1 to 24, wherein the combination comprises BMP, GlcCer, GD3, GD1 / b, GM2 and GM3.

[0286] Embodiment 37. The method of any one of embodiments 1 to 36, wherein the LSD is an MPS disorder.

[0287] Embodiment 38 The method of embodiment 37, wherein the MPS disorder is Hunter Syndrome.

[0288] Embodiment 39. The method of any one of embodiments 2 to 38, wherein said LSD treatment comprises hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT), substrate synthesis inhibition therapy, chaperone therapy and / or gene therapy.

[0289] Embodiment 40 The method of embodiment 39, wherein said LSD treatment comprises ERT.

[0290] Embodiment 41 The method of embodiment 40, wherein said ERT is targeted to the brain.

[0291] Embodiment 42. The LSD treatment comprises: (a) a first Fc polypeptide linked to an enzyme replacement therapy (ERT) enzyme, an ERT enzyme variant, or a catalytically active fragment thereof; and (b) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. is a protein comprising 41. The method of embodiment 40, wherein said first Fc polypeptide and / or said second Fc polypeptide do not comprise an immunoglobulin heavy and / or light chain variable region sequence or an antigen-binding portion thereof.

[0292] Embodiment 43 The method of embodiment 42, wherein said ERT enzyme is iduronate 2-sulfatase (IDS), an IDS variant, or a catalytically active fragment thereof.

[0293] Embodiment 44 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 114.

[0294] Embodiment 45 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 131.

[0295] Embodiment 46 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 167.

[0296] Embodiment 47. The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 190.

[0297] Embodiment 48 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 191.

[0298] Embodiment 49. The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 117.

[0299] Embodiment 50. The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 130.

[0300] Embodiment 51. The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 132.

[0301] Embodiment 52 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 166.

[0302] Embodiment 53 The method of embodiment 42, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 168.

[0303] Embodiment 54. A method of screening a test agent for activity as a treatment for LSD, the method comprising: 1) contacting a cell with the test agent, wherein the cell has a lysosomal storage deficiency; and 2) a) a combination of two or more lipids in said cell, said combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer The combination selected from the group consisting of: b) GlcCer in said cells, wherein said test agents are screened for activity as an MPS treatment; c) Nf-L in the cells, and / or d) sTREM2 in the cells To measure the concentration of Including, The method, wherein a decrease in the concentration of the selected lipid(s) / protein(s) in the cells compared to the concentration of the corresponding lipid(s) / protein(s) in control cells indicates that the test agent has activity as an LSD treatment.

[0304] Embodiment 55 The method of embodiment 54, comprising measuring the concentration of sTREM2.

[0305] Embodiment 56. The method of embodiment 54, comprising measuring the concentration of Nf-L.

[0306] Embodiment 57 The method of embodiment 54, comprising measuring the concentration of GlcCer.

[0307] Embodiment 58. The method of embodiment 54, comprising measuring the concentration of a combination of two or more lipids.

[0308] Embodiment 59. The method of embodiment 54, comprising measuring the concentration of one or more lipids and the concentration of sTREM2.

[0309] Embodiment 60. The method of embodiment 54, comprising measuring the concentration of one or more lipids and the concentration of Nf-L.

[0310] Embodiment 61. The method of any one of embodiments 54 to 60, wherein the cell is a brain cell.

[0311] Embodiment 62. A corrected CNS cell comprising a deficiency in a lysosomal enzyme that causes accumulation of a metabolic species within the cell, wherein the cell is contacted with a protein comprising (i) a first Fc polypeptide linked to the lysosomal enzyme, and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide, wherein the protein is capable of binding to a transferrin receptor (TfR), and wherein the correction is a reduction in the accumulation of the metabolic species.

[0312]

[0081] Embodiment 63. A corrected CNS cell comprising a reduced accumulation of a metabolic species, the CNS cell comprising a deficiency of a lysosomal enzyme that causes accumulation of a metabolic species in the cell, (i) a first Fc polypeptide linked to the lysosomal enzyme; and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. wherein the protein is capable of binding to a transferrin receptor (TfR) to provide the corrected CNS cell comprising the reduced accumulation of the metabolic species.

[0313] Embodiment 64. The CNS cell of embodiment 62 or 63, wherein the protein binds to TfR with an affinity of about 50 nM to about 350 nM.

[0314] Embodiment 65. The CNS cell of any one of embodiments 62 to 64, wherein the enzyme is iduronate 2-sulfatase (IDS), or an enzymatically active variant thereof.

[0315] Embodiment 66. The CNS cell of any one of embodiments 62 to 65, wherein the metabolic species is a glycosaminoglycan (GAG) and / or a lysosomal lipid.

[0316] Embodiment 67. The CNS cell of any one of embodiments 62 to 65, wherein the metabolic species is a glycosaminoglycan (GAG).

[0317] Embodiment 68. The CNS cell of any one of embodiments 62 to 65, wherein the metabolic species is a lysosomal lipid.

[0318] Embodiment 69. The CNS cell of embodiment 68, wherein the lysosomal lipid is selected from the group consisting of gangliosides, glucosylceramide, galactosylceramide, and bis(monoacylglycerol)phosphate (BMP).

[0319] Embodiment 70. The CNS cell of any one of embodiments 62 to 69, wherein the CNS cell is selected from the group consisting of a neuron, an astrocyte, and a microglial cell.

[0320] Embodiment 71. A method for selecting a population of CNS cells from a tissue sample, comprising: (a) contacting the tissue sample with a primary antibody for a neuron marker, a primary antibody for an astrocyte marker, a primary antibody for a microglia marker, a primary antibody for an endothelial marker, and a primary antibody for an oligodendrocyte marker, each primary antibody being uniquely labeled, providing a labeled tissue sample; and (b) sorting the cells in the labeled tissue sample by flow cytometry. Including, The method provides distinct cell populations of neurons, astrocytes, and microglial cells.

[0321] Embodiment 72 The method of embodiment 71, wherein said neuronal marker primary antibody is an anti-Thy1 antibody.

[0322] Embodiment 73 The method of embodiment 71 or 72, wherein the microglia marker primary antibody is an anti-CD11b antibody.

[0323] Embodiment 74. The method of any one of embodiments 71 to 73, wherein said astrocyte marker primary antibody is selected from the group consisting of an anti-EAAT2 antibody and an anti-astrocyte surface antigen-2 (ACSA-2) antibody.

[0324] Embodiment 75. The method of any one of embodiments 71 to 74, wherein the endothelial marker primary antibody is an anti-CD31 antibody.

[0325] Embodiment 76 The method of any one of embodiments 71 to 75, wherein the oligodendrocyte marker primary antibody is an anti-O1 antibody.

[0326] Embodiment 77. The method of any one of embodiments 71 to 76, further comprising contacting the tissue sample with a viability dye.

[0327] Embodiment 78. The method of any one of embodiments 71-77, providing a distinct population of microglial cells comprising less than about 20% non-microglial cells, a distinct population of astrocytes comprising less than about 20% non-astrocytes, and / or a distinct population of neurons comprising less than about 20% non-neuronal cells.

[0328] Embodiment 79. The method of embodiment 78, providing a distinct population of microglial cells comprising less than about 20% non-microglial cells.

[0329] Embodiment 80. The method of embodiment 78 or 79, providing a distinct population of astrocytes comprising less than about 20% non-astrocytes.

[0330] Embodiment 81. The method of any one of embodiments 78-80, providing a distinguishable population of neurons containing less than about 20% non-neuronal cells.

[0331] Embodiment 82. The microglial cell population has a marker profile O1 - / CD31 - / CD11b + The astrocyte population was selected based on the marker profile O1 - / CD31 - / Thy1 - / EAAT2 + or O1 - / CD31 - / Thy1 - / ACSA-2 + and / or the neuronal population is selected based on the marker profile O1 - / CD31 - / Thy1 + / EAAT2 - or O1 - / CD31 - / Thy1 + / ACSA-2 - The method of any one of embodiments 71 to 81, wherein the method is selected based on:

[0332] Embodiment 83. The microglial cell population has a marker profile O1 - / CD31 - / CD11b + 83. The method of embodiment 82, wherein the method is selected based on:

[0333] Embodiment 84. The astrocyte population has a marker profile O1 - / CD31 - / Thy1 - / EAAT2 + or O1 - / CD31 - / Thy1 - / ACSA-2 + 84. The method of embodiment 82 or 83, wherein the method is selected based on:

[0334]

[0082] Embodiment 85. The neuronal population has a marker profile O1 - / CD31 - / Thy1 + / EAAT2 - or O1 - / CD31 - / Thy1 + / ACSA-2 - 85. The method of any one of embodiments 82 to 84, wherein the method is selected based on:

[0335] Embodiment 86. The method of any one of embodiments 71 to 85, wherein the enriched cell population is analyzed for quantification of sTREM2, Nf-L, metabolism and / or nucleic acid species.

[0336] Embodiment 87. The method of any one of embodiments 71-85, wherein the enriched cell population is analyzed for metabolic or nucleic acid species quantification.

[0337] Embodiment 88. The method of embodiment 87, wherein the metabolic species is a glycosaminoglycan (GAG) species.

[0338] Embodiment 89. The method of embodiment 87, wherein the metabolic species is a lipid species.

[0339] Embodiment 90. The method of embodiment 89, wherein the lipid species is selected from the group consisting of gangliosides, glucosylceramides, galactosylceramides, and bis(monoacylglycerol)phosphates (BMPs).

[0340] Embodiment 91. The method of embodiment 87, wherein the nucleic acid species is selected from RNA, DNA, and genomic DNA.

[0341] Embodiment 92 The method of any one of embodiments 71 to 91, wherein the enriched cell population is analyzed for quantification of sTREM2.

[0342] Embodiment 93. The method of any one of embodiments 71 to 92, wherein the enriched cell population is analyzed for quantification of Nf-L.

[0343] Embodiment 94 The method of any one of embodiments 71-93, wherein the enriched cell population is analyzed for quantification of an administered therapeutic agent.

[0344] Embodiment 95 The method of embodiment 94, wherein the administered therapeutic agent is ETV:IDS.

[0345] Prescribed definitions The term "control" or "control sample" refers to any sample appropriate for the detection technique employed. A control sample may contain the product of the detection technique employed or the substance being tested. Furthermore, a control may be a positive or negative control.

[0346] As used interchangeably herein, the terms "subject," "individual," and "patient" refer to mammals, including, but not limited to, humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cows, pigs, horses, and other mammalian species. In one embodiment, the patient is a human.

[0347] The term "pharmaceutically acceptable excipient" refers to inactive pharmaceutical ingredients that are biologically or pharmacologically compatible for use in humans or animals, such as, but not limited to, buffers, carriers, or preservatives.

[0348] The term "administering" refers to a method of delivering an agent (e.g., an LSD therapeutic agent, e.g., an ETV therapy described herein), compound, or composition (e.g., a pharmaceutical composition) to a desired site of biological action. These methods include, but are not limited to, oral, topical, parenteral, intravenous, intradermal, intramuscular, intrathecal, colonic, rectal, or intraperitoneal delivery. In one embodiment, the polypeptides described herein are administered intravenously.

[0349] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to a clinical intervention to alter the natural course of the individual being treated, and may be performed for prophylaxis or during the clinical pathology process. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, slowing the rate of disease progression, amelioration or remission of the disease, and remission or improvement of prognosis.

[0350] The phrase "effective amount" refers to an amount of a compound described herein that (i) treats or prevents a particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.

[0351] The "therapeutically effective amount" of a substance / molecule disclosed herein may vary according to factors such as the disease state, age, sex, and weight of an individual, and the ability of the substance / molecule to induce a desired response in an individual. A therapeutically effective amount encompasses an amount in which any toxic or adverse effects of the substance / molecule are outweighed by therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective at dosages and for periods of time necessary to achieve a desired prophylactic result. Typically, but not necessarily, a prophylactically effective amount will be less than a therapeutically effective amount, since a prophylactic dose is used in a subject before or at an early stage of disease.

[0352] The terms "obtaining a sample from a patient," "obtained from a patient," and similar phrases are used to refer to obtaining a sample directly from a patient, and obtaining a sample indirectly from a patient through an intermediary individual (e.g., obtaining a sample from a courier who obtains the sample from a nurse who obtains the sample from the patient).

[0353] "Enzyme replacement therapy enzyme" or "ERT enzyme" refers to an enzyme that is deficient in lysosomal storage disorders. "ERT enzyme variant" refers to a functional variant, including alleles and splice variants, of a wild-type ERT enzyme or a fragment thereof, where the ERT enzyme variant has, for example, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the activity of the corresponding wild-type ERT enzyme or a fragment thereof, when assayed under the same conditions. "Catalytically active fragment" of an ERT enzyme refers to a portion of a full-length ERT enzyme or a variant thereof, where the catalytically active fragment has, for example, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the activity of the corresponding full-length ERT enzyme or a variant thereof, when assayed under the same conditions.

[0354] "Iduronate sulfatase", "iduronate-2-sulfatase", or "IDS" as used herein refers to iduronate 2-sulfatase (EC 3.1.6.13), an enzyme involved in the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Deficiency in IDS is associated with mucopolysaccharidosis II, also known as Hunter syndrome. The term "IDS", as used herein as a component of a protein comprising an Fc polypeptide, is catalytically active and encompasses functional variants, including alleles and splice variants, of wild-type IDS or fragments thereof. The sequence of human IDS isoform I, the human sequence designated as the canonical sequence, is available in UniProt entry P22304 and is encoded by the human IDS gene at Xq28. The full-length sequence is provided as SEQ ID NO:91. "Mature" IDS sequence, as used herein, refers to a form of the polypeptide chain that lacks the signal and polypeptide sequence of the naturally occurring full-length polypeptide chain. The amino acid sequence of a mature human IDS polypeptide is provided as SEQ ID NO: 92, which corresponds to amino acids 34-550 of the full-length human sequence. A "truncated" IDS sequence, as used herein, refers to a catalytically active fragment of a naturally occurring full-length polypeptide chain. An exemplary truncated human IDS polypeptide amino acid sequence is provided as SEQ ID NO: 112, which corresponds to amino acids 26-550 of the full-length human sequence. The structure of human IDS has been well characterized. An exemplary structure is available at PDB accession code 5FQL. The structure is also described in Nat.Comm. 8:15786 doi:10.1038 / ncomms15786,2017. IDS sequences of non-human primates, including chimpanzee (UniProt entry K7BKV4) and rhesus macaque (UniProt entry H9FTX2), have also been described. The mouse IDS sequence is available at Uniprot entry Q08890.An IDS variant has, for example, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the activity of the corresponding wild-type IDS or fragment thereof when assayed under the same conditions. A catalytically active IDS fragment has, for example, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the activity of the corresponding full-length IDS or variant thereof when assayed under the same conditions.

[0355] "Transferrin receptor" or "TfR" as used herein refers to transferrin receptor protein 1. The human transferrin receptor 1 polypeptide sequence is set forth in SEQ ID NO: 94. Transferrin receptor protein 1 sequences from other species are also known (e.g., chimpanzee: Accession No. XP_003310238.1, rhesus monkey: NP_001244232.1, dog: NP_001003111.1, cow: NP_001193506.1, mouse: NP_035768.1, rat: NP_073203.1, and chicken: NP_990587.1). The term "transferrin receptor" also encompasses allelic variants of exemplary reference sequences encoded by genes at the transferrin receptor protein 1 chromosomal locus, e.g., human sequences. The full-length transferrin receptor protein includes a short N-terminal intracellular region, a transmembrane region, and a large extracellular domain. The extracellular domain is characterized by three domains: a protease-like domain, a helical domain, and an apical domain. The apical domain sequence of human transferrin receptor 1 is set forth in SEQ ID NO:200.

[0356] "Fusion protein" or "[ERT enzyme]-Fc fusion protein" as used herein refers to a dimeric protein comprising a first Fc polypeptide linked (e.g., fused) to an ERT enzyme, an ERT enzyme variant, or a catalytically active fragment thereof (i.e., an "[ERT]-Fc fusion polypeptide"); and a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. The second Fc polypeptide may also be linked (e.g., fused) to an ERT enzyme, an ERT enzyme variant, or a catalytically active fragment thereof. The first Fc polypeptide and / or the second Fc polypeptide may be linked to the ERT enzyme, an ERT enzyme variant, or a catalytically active fragment thereof by a peptide bond or a polypeptide linker. The first Fc polypeptide and / or the second Fc polypeptide may be a modified Fc polypeptide containing one or more modifications that facilitate its heterodimerization to other Fc polypeptides. The first Fc polypeptide and / or the second Fc polypeptide can be a modified Fc polypeptide containing one or more modifications that confer binding to the transferrin receptor. The first Fc polypeptide and / or the second Fc polypeptide can be a modified Fc polypeptide containing one or more modifications that reduce effector function. The first Fc polypeptide and / or the second Fc polypeptide can be a modified Fc polypeptide containing one or more modifications that extend serum half-life.

[0357] "Fusion polypeptide" or "[ERT enzyme]-Fc fusion polypeptide" as used herein refers to an Fc polypeptide linked (e.g., fused) to an ERT enzyme, an ERT enzyme variant, or a catalytically active fragment thereof. The Fc polypeptide may be linked to the ERT enzyme, an ERT enzyme variant, or a catalytically active fragment thereof by a peptide bond or a polypeptide linker. The Fc polypeptide may be a modified Fc polypeptide containing one or more modifications that promote its heterodimerization to another Fc polypeptide. The Fc polypeptide may be a modified Fc polypeptide containing one or more modifications that confer binding to the transferrin receptor. The Fc polypeptide may be a modified Fc polypeptide containing one or more modifications that reduce effector function. The Fc polypeptide may be a modified Fc polypeptide containing one or more modifications that increase serum half-life.

[0358] As used herein, the term "Fc polypeptide" refers to the C-terminal region of a naturally occurring immunoglobulin heavy chain polypeptide characterized by an Ig fold as a structural domain. An Fc polypeptide comprises a constant region sequence comprising at least a CH2 domain and / or a CH3 domain, and may contain at least a portion of the hinge region. Generally, an Fc polypeptide does not comprise a variable region.

[0359] "Modified Fc polypeptide" refers to an Fc polypeptide that has at least one mutation, e.g., a substitution, deletion, or insertion, compared to a wild-type immunoglobulin heavy chain Fc polypeptide sequence, but retains the overall Ig fold or structure of a native Fc polypeptide.

[0360] The term "FcRn" refers to the fetal Fc receptor. Binding of an Fc polypeptide to FcRn reduces the clearance and extends the serum half-life of the Fc polypeptide. The human FcRn protein is a heterodimer composed of a protein with a size of about 50 kDa similar to major histocompatibility (MHC) class I proteins and β2-microglobulin with a size of about 15 kDa.

[0361] As used herein, "FcRn binding site" refers to a region of an Fc polypeptide that binds to FcRn. In human IgG, the FcRn binding site, numbered using the EU index, includes T250, L251, M252, I253, S254, R255, T256, T307, E380, M428, H433, N434, H435, and Y436. These positions correspond to positions 20-26, 77, 150, 198, and 203-206 of SEQ ID NO:1.

[0362] As used herein, a "native FcRn-binding site" refers to a region of an Fc polypeptide that binds to FcRn and has the same amino acid sequence as a region of a naturally occurring Fc polypeptide that binds to FcRn.

[0363] As used herein, the terms "CH3 domain" and "CH2 domain" refer to immunoglobulin constant region domain polypeptides. For the purposes of this application, a CH3 domain polypeptide refers to the segment of amino acids from about position 341 to about position 447 as numbered according to EU, and a CH2 domain polypeptide refers to the segment of amino acids from about position 231 to about position 340 as numbered according to the EU numbering scheme, not including the hinge region sequence. CH2 and CH3 domain polypeptides may also be numbered according to the IMGT (ImMunoGeneTics) numbering scheme, where the CH2 domain numbering is 1-110 and the CH3 domain numbering is 1-107 according to the IMGT Scientific Chart Numbering (IMGT website). The CH2 and CH3 domains are part of the Fc region of an immunoglobulin. The Fc region refers to the segment of amino acids from about position 231 to about position 447 as numbered according to the EU numbering scheme, but may include at least a portion of the hinge region of an antibody, as used herein. An exemplary hinge region sequence is the human IgG1 hinge sequence EPKSCDKTHTCPPCP (SEQ ID NO:93).

[0364] "Naturally occurring," "native," or "wild type" are used to describe something that can be found in nature, as distinguished from something that has been artificially produced. For example, a nucleotide sequence that can be isolated from a natural source and is present in an organism (including a virus) that has not been intentionally modified in a laboratory is naturally occurring. Additionally, "wild type" refers to a normal gene or organism found in nature that does not have any known mutations.

[0365] The terms "wild-type," "native," and "naturally-occurring," for example with respect to a CH3 or CH2 domain, are used herein to refer to a domain having a sequence that occurs in nature.

[0366] As used herein, the term "mutant" with respect to mutant polypeptides or mutant polynucleotides is used interchangeably with "variant". Variants relative to a given wild-type CH3 or CH2 domain reference sequence may include naturally occurring allelic variants. A "non-natural" CH3 or CH2 domain refers to a variant or mutant domain of a native CH3 or CH2 domain polynucleotide or polypeptide that is not present in a natural cell and is created by genetic modification, for example, using genetic engineering or mutagenesis techniques. A "variant" includes any domain that contains at least one amino acid mutation relative to the wild type. Mutations may include substitutions, insertions, and deletions.

[0367] The term "amino acid" refers to naturally occurring amino acids, synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.

[0368] Naturally occurring amino acids are those encoded by the genetic code and those amino acids that have been subsequently modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. "Amino acid analog" refers to a compound that has the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. "Amino acid mimetics" refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a naturally occurring amino acid.

[0369] Naturally occurring α-amino acids include, but are not limited to, alanine (Ala), cysteine ​​(Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (Ile), arginine (Arg), lysine (Lys), leucine (Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gln), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr), and combinations thereof. Naturally occurring stereoisomers of α-amino acids include, but are not limited to, D-alanine (D-Ala), D-cysteine ​​(D-Cys), D-aspartic acid (D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe), D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg), D-lysine (D-Lys), D-amino acids (amino acids) and D-amino acids (amino acids). D-s), D-leucine (D-Leu), D-methionine (D-Met), D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln), D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val), D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations thereof.

[0370] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.

[0371] The terms "polypeptide" and "peptide" are used interchangeably herein to refer to a single chain of polymers of amino acid residues. The term applies to naturally occurring and non-naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids. An amino acid polymer can contain all L-amino acids, all D-amino acids, or a mixture of L and D amino acids.

[0372] The term "protein" as used herein refers to either a single polypeptide chain or a dimer (i.e., two) or multimer (i.e., three or more). The single polypeptide chains of a protein can be joined by covalent bonds, e.g., disulfide bonds, or by non-covalent interactions.

[0373] The terms "conservative substitution," "conservative mutation," or "conservatively modified variant" refer to changes that result in the replacement of an amino acid with another amino acid that can be classified as having similar characteristics. Examples of categories of conservative amino acid groups defined in this way may include the "charged / polar group" which includes Glu (glutamic acid or E), Asp (aspartic acid or D), Asn (asparagine or N), Gln (glutamine or Q), Lys (lysine or K), Arg (arginine or R), and His (histidine or H); the "aromatic group" which includes Phe (phenylalanine or F), Tyr (tyrosine or Y), Trp (tryptophan or W), and (histidine or H); and the "aliphatic group" which includes Gly (glycine or G), Ala (alanine or A), Val (valine or V), Leu (leucine or L), Ile (isoleucine or I), Met (methionine or M), Ser (serine or S), Thr (threonine or T), and Cys (cysteine ​​or C). Within each group, subgroups may also be identified. For example, the group of charged or polar amino acids may be subdivided into subgroups including a "positively charged subgroup" including Lys, Arg, and His, a "negatively charged subgroup" including Glu and Asp, and a "polar subgroup" including Asn and Gln. In another example, the aromatic or cyclic group may be subdivided into subgroups including a "nitrogen ring subgroup" including Pro, His, and Trp, and a "phenyl subgroup" including Phe and Tyr. In yet another example, the aliphatic group may be subdivided into subgroups, such as an "aliphatic non-polar subgroup" including Val, Leu, Gly, and Ala, and an "aliphatic slightly polar subgroup" including Met, Ser, Thr, and Cys.Examples of conservative mutation categories include, but are not limited to, amino acid substitutions of amino acids within the above subgroups, such as Arg to Lys or vice versa, such that a positive charge may be maintained; Asp to Glu or vice versa, such that a negative charge may be maintained; Thr to Ser or vice versa, such that a free -OH may be maintained; and Asn to Gln or vice versa, such that a free -NH2 may be maintained. In some embodiments, hydrophobic amino acids are used in place of naturally occurring hydrophobic amino acids, for example, in the active site, to maintain hydrophobicity.

[0374] The terms "identical" or "percent identity" in the context of two or more polypeptide sequences refer to two or more sequences or subsequences that have the same or a certain percentage of amino acid residues that are identical, e.g., at least 60% identity, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or more identical, over a particular region when compared and aligned for maximum correspondence over a comparison window or designated region, as measured using a sequence comparison algorithm or by manual alignment and visual inspection.

[0375] For sequence comparison of polypeptides, typically, one amino acid sequence serves as a reference sequence and is compared with the candidate sequence. Alignment can be performed using various methods available to those skilled in the art, such as visual alignment, or using publicly available software that uses known algorithms to achieve maximum alignment. Such programs include BLAST programs, ALIGN, ALIGN-2 (Genentech, South San Francisco, Calif.) or Megalign (DNASTAR). The parameters to achieve maximum alignment used for alignment can be determined by those skilled in the art. For sequence comparison of polypeptide sequences for this application, the standard protein BLAST of the BLASTP algorithm is used, which aligns two protein sequences using default parameters.

[0376] When used in the context of identifying a given amino acid residue in a polypeptide sequence, the terms "corresponding to," "determined with reference to," or "numbered with reference to" refer to the position of the residue in a particular reference sequence when the given amino acid sequence is compared to the reference sequence with maximal alignment. Thus, for example, an amino acid residue in a modified Fc polypeptide "corresponds to" an amino acid in SEQ ID NO:1 if that residue matches the amino acid in SEQ ID NO:1 when optimally aligned to SEQ ID NO:1. A polypeptide that is aligned to a reference sequence need not be the same length as the reference sequence.

[0377] The terms "polynucleotide" and "nucleic acid" refer interchangeably to a chain of nucleotides of any length, including DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a chain by DNA or RNA polymerase. Polynucleotides can include modified nucleotides, such as methylated nucleotides and their analogs. Examples of polynucleotides contemplated herein include single- and double-stranded DNA, single- and double-stranded RNA, and hybrid molecules having a mixture of single- and double-stranded DNA and RNA.

[0378] As used herein, "binding affinity" refers to the strength of a non-covalent interaction between two molecules, e.g., between a single binding site on a polypeptide and the target to which it binds, e.g., the transferrin receptor. Thus, for example, unless otherwise indicated or clear from the context, the term may refer to a 1:1 interaction between a polypeptide and its target. Binding affinity is measured by the equilibrium dissociation constant (K D ) and the binding rate constant (k a ,time -1 M -1 ) divided by the dissociation rate constant (k d ,time -1 ) refers to K D can be determined by measuring the kinetics of complex formation and dissociation, for example, using surface plasmon resonance (SPR) methods, e.g., the Biacore™ system; kinetic exclusion assays such as KinExA®; and BioLayer interferometry (e.g., using the ForteBio® Octet® platform). As used herein, "binding affinity" refers not only to formal binding affinities, such as those that reflect a 1:1 interaction between a polypeptide and its target, but also to K values ​​that may reflect strong binding. D This also includes the apparent affinity, from which the

[0379] As used herein, the terms "specifically bind" or "selectively bind" to a target, e.g., TfR, when referring to a modified TfR-binding polypeptide, TfR-binding peptide, or TfR-binding antibody described herein, refer to a binding reaction in which the modified TfR-binding polypeptide, TfR-binding peptide, or TfR-binding antibody binds to the target with higher affinity, higher avidity, and / or longer duration than it would bind to a structurally different target. In typical embodiments, the modified TfR-binding polypeptide, TfR-binding peptide, or TfR-binding antibody has at least 5-fold, 10-fold, 50-fold, 100-fold, 1,000-fold, 10,000-fold, or more affinity for a particular target, e.g., TfR, compared to an unrelated target when assayed under the same affinity assay conditions. The terms "specifically bind" a particular target (e.g., TfR), "specifically binds to" a particular target, or "is specific for" a particular target, as used herein, e.g., -4 M or less, e.g., 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, or 10 -12 The equilibrium dissociation constant K for the target binding of M D In some embodiments, the modified TfR-binding polypeptide, TfR-binding peptide, or TfR-binding antibody specifically binds to an epitope on the TfR that is conserved between species (e.g., structurally conserved between species), for example, conserved between non-human primates and human species (e.g., structurally conserved between non-human primates and human species). In some embodiments, the modified TfR-binding polypeptide, TfR-binding peptide, or TfR-binding antibody may only bind to the human TfR.

[0380] The term "variable region" or "variable domain" refers to the domain in an antibody heavy or light chain that is derived from germline variable (V), diversity (D), or joining (J) genes (and not from constant (Cμ and Cδ) gene segments) and confers binding specificity to the antibody for antigen. Typically, antibody variable regions contain four conserved "framework" regions, which are situated between three hypervariable "complementarity determining regions".

[0381] The terms "antigen-binding portion" and "antigen-binding fragment" are used interchangeably herein and refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen via its variable region. Examples of antigen-binding fragments include, but are not limited to, Fab fragments (monovalent fragments consisting of the VL, VH, CL, and CH1 domains), F(ab')2 fragments (bivalent fragments containing two Fab fragments linked by a disulfide bridge at the hinge region), single chain Fvs (scFvs), disulfide-linked Fvs (dsFvs), complementarity determining regions (CDRs), VL (light chain variable region), and VH (heavy chain variable region).

[0382] The following examples are intended to be non-limiting.

[0383] Example 1: IDS KO x TfR muhu Effects of peripheral administration of ETV:IDS on brain GAGs and lysosomal lipids in mice As described below, IDS KO×TfR muhu The effects of peripheral administration of ETV:IDS on brain GAGs and lysosomal lipids in mice were investigated.

[0384] Materials and Methods Animal Care Mice were housed under a 12-hour light / dark cycle and allowed free access to water and standard rodent chow (LabDiet® #25502, Irradiated).

[0385] Mouse strains As previously described, IDS KO mice on a B6N background were obtained from Jackson Laboratories (JAX line 024744). TfR harboring the human TfR apical domain knocked-into the mouse receptor. mu / hu The development and characterization of the KI mouse line has been previously described (U.S. Patent No. 10,143,187). mu / hu Male mice were crossed with female IDS heterozygous mice to generate IDS KO×TfR mu / hu Mice were generated. All mice used in this study were male.

[0386] Dosing and tissue collection 2-month-old IDS KO×TfR mu / hu Mice were intravenously injected with idursulfase (14.2 mg / kg body weight) or ETV:IDS (40 mg / kg body weight) once a week for 4 weeks (n=8). Two-month-old littermates of TfR mice were intravenously injected with saline once a week for 4 weeks. mu / hu Mice (n=5) were used as controls. For the 7-day cohorts, animals were euthanized 7 days after the first injection. For the 28-day cohorts, animals were euthanized 7 days after the fourth weekly dose.

[0387] For final sample collection, animals were deeply anesthetized with an intraperitoneal (ip) injection of 2.5% Avertin. For CSF collection, a sagittal incision was made behind the animal's skull, the subcutaneous tissue and muscle were separated to expose the cisterna magna, and a pre-pulled glass capillary tube was used to perforate the cisterna magna and collect CSF. CSF was then collected in a low-dose 100 mL syringe. The serum was transferred to a Protein LoBind Eppendorf tube and centrifuged at 12,700 rpm for 10 min at 4°C. The CSF was transferred to a new tube and snap frozen on dry ice. The absence of blood contamination in the mouse CSF was confirmed by measuring the absorbance of the sample at 420 nm. Blood was collected by cardiac puncture for serum collection. For serum collection, blood was allowed to clot at room temperature for at least 30 min. The tube was then centrifuged at 12,700 rpm for 7 min at 4°C. The serum was transferred to a new tube and snap frozen on dry ice. The animals were perfused transcardially with ice-cold PBS using a peristaltic pump (Gilson Inc. Minipuls Evolution). The brain and liver were cut and snap frozen on dry ice.

[0388] Tissue preparation: GAG extraction and processing Brain and liver tissue samples and CSF were collected as described above. Brain and liver tissues were homogenized using a TissueLyser from Qiagen. Tissue homogenates were then transferred to a 96-well deep plate and sonicated using a 96-tip sonicator (Q Sonica). A BCA protein assay was performed to quantify total protein, and 20 μg liver and 100 μg brain per sample were subjected to LC-MS / MS sample preparation. For CSF, 3 μL per sample was used. Briefly, heparan and dermatan sulfate-derived disaccharides were generated by digesting tissue homogenates using a combination of heparinase I, II, III, and chondriotinase B. The digest was mixed with acetonitrile and subjected to LC-MS / MS as described below.

[0389] LCMS assay for GAGs A liquid chromatography system (Shimadzu Nexera X2 system, Shimadzu Scientific) coupled to electrospray mass spectrometry (Sciex QTRAP 6500+, Sciex, Framingham, MA, USA) was used. Quantification of GAGs was performed by a HPLC-MS / MS Instrument (Columbia, MD, USA). For each analysis, samples were injected onto an ACQUITY UPLC BEH Amide 1.7 mm, 2.1 × 150 mm column (Waters Corporation) using a flow rate of 0.55 mL / min at a column temperature of 55 °C. Mobile phases A and B consisted of water with 10 mM ammonium formate and 0.1% formic acid, and acetonitrile with 0.1% formic acid, respectively. The gradient was programmed as follows: 80% B from 0.0 to 0.5 min, 80% B to 50% B from 0.5 to 3.5 min, 50% B to 80% B from 3.5 to 4.0 min, hold at 80% B from 4.0 to 4.5 min. Electrospray ionization was performed in negative ion mode applying the following settings: curtain gas at 25; collision gas set to medium; ion spray voltage at -4500; temperature at 600°C; ion source gas 1 at 50; ion source gas 2 at 60. Data acquisition was performed in multiple reaction monitoring mode (MRM) using Analyst 1.6.3 (Sciex) with a dwell time of 50 (ms) for each species, collision energy (CE) set to -30; declustering potential (DP) at -80; entrance potential (EP) at -10; collision cell exit potential (CXP) at -10. GAGs were detected as [MH]- using the following MRM transitions: D0A0 at m / z 378.1 > 87.0; D0S0 at m / z 416.1 > 138.0; D0a4 at m / z 458.1 > 300.0; D4UA-2S-GlcNCOEt-6S at m / z 472.0 (source fragment ion) > 97.0 (Iduron Ltd, Manchester, UK) was used as an internal standard. Individual disaccharide species were identified based on their retention time and MRM transitions using a commercial reference standard (Iduron Ltd). GAGs were quantified by peak area ratios of D0A0, D0S0 and D0a4 relative to the internal standard using MultiQuant 3.0.2 (Sciex). Reported GAG amounts were normalized to total protein levels measured by BCA assay (Pierce).

[0390] Tissue preparation: lipid extract from brain tissue Frozen brain tissue (20±2 mg) was transferred into a dry ice 2 mL Safe-Lock Eppendorf tube (Eppendorf Cat#022600044) and kept on dry ice containing 5 mm stainless steel beads (QIAGEN Cat#69989) and 400 μl MS grade methanol containing internal standard. Tissue was homogenized using a Tissuelyser for 30 seconds at 25 Hz (in a cold room). Samples were then centrifuged for 20 minutes at 21,000×g at 4°C. Methanol supernatant was transferred to a new Eppendorf vial and left at −20°C for 1 hour to further precipitate proteins. Samples were then centrifuged for 10 minutes at 21,000×g at 4°C. 200 uL of the methanolic supernatant was transferred to an LCMS 96-well plate, dried under nitrogen, and then resuspended in 100 uL ACN / IPA / H2O (92.5 / 5 / 2.5) with 5 mM ammonium formate and 0.5% formic acid for GlcCer analysis. The remainder of the supernatant was transferred without disturbing the pellet to a separate LCMS 96-well plate for analysis of BMP and ganglioside species. Samples were either run directly on the LCMS or stored at -80°C.

[0391] LCMS Assays for BMPs and Gangliosides A liquid chromatography system (Shimadzu Nexera X2 system, Shimadzu Scientific) coupled to electrospray mass spectrometry (Sciex QTRAP 6500+, Sciex, Framingham, MA, USA) was used. Analysis of BMPs and gangliosides was performed by a BEH C18 1.7 μm, 2.1 × 100 mm column (Waters Corporation, Milford, Massachusetts, USA) using a flow rate of 0.25 mL / min at 55 °C. Mobile phase A consisted of 60:40 acetonitrile / water (v / v) with 10 mM ammonium acetate, and mobile phase B consisted of 90:10 isopropyl alcohol / acetonitrile (v / v) with 10 mM ammonium acetate. The gradient was programmed as follows: 45% B to 99% B in 0.0–0.01 min, 99% B in 0.1–3.0 min, 45% B in 3.0–3.01 min, and 45% B in 3.01–3.50 min. Electrospray ionization was performed in negative ion mode applying the following settings: curtain gas at 30; collision gas set to medium; ion spray voltage at -4500; temperature at 600°C; ion source gas 1 at 50; ion source gas 2 at 60. Data acquisition was performed using Analyst 1.6.3 (Sciex) in multiple reaction monitoring mode (MRM) with the following parameters: dwell time (milliseconds) for each species reported in Table A, collision energy (CE) at -50, declustering potential (DP) at -80; entrance potential (EP) at -10; and collision cell exit potential (CXP) at -15. BMP and ganglioside species were quantified using the non-endogenous internal standards BMP di14:0 and GM3 (d36:1 (d5)). Quantification was performed using MultiQuant 3.02 (Sciex). BMP and ganglioside concentrations were normalized to either total protein, tissue weight or volume. Protein concentrations were measured using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA).

[0392] Table A. Acquisition parameter information for BMP and ganglioside assays. [Table A-1] [Table A-2]

[0393] LCMS assay for GlcCer and GalCer A liquid chromatography system (Shimadzu Nexera X2 system, Shimadzu Scientific) coupled to electrospray mass spectrometry (Sciex QTRAP 6500+, Sciex, Framingham, MA, USA) was used. Analysis of glucosylceramide and galactosylceramide was performed by a HALO HILIC 2.0 μm, 3.0×150 mm column (Advanced Materials Technology, PN91813-701) using a flow rate of 0.45 mL / min at 45° C. Mobile phase A consisted of 92.5 / 5 / 2.5 ACN / IPA / H2O with 5 mM ammonium formate and 0.5% formic acid. Mobile phase B consisted of 92.5 / 5 / 2.5 H2O / IPA / ACN with 5 mM ammonium formate and 0.5% formic acid. The gradient was programmed as follows: 100% B from 0.0 to 3.1 min, 95% B at 3.2 min, 85% B at 5.7 min, hold at 85% B until 7.1 min, drop to 0% B at 7.25 min and hold until 8.75 min, ramp back to 100% at 10.65 min and hold until 11 min. Electrospray ionization was performed in negative ion mode applying the following settings: curtain gas at 25; collision gas set to medium; ion spray voltage at 5500; temperature at 350 °C; ion source gas 1 at 55; ion source gas 2 at 60. Data acquisition was performed using Analyst 1.6 (Sciex) in multiple reaction monitoring mode (MRM) with the following parameters: residence time (milliseconds) and collision energy (CE) for each species reported in Table B; declustering potential (DP) of 45; entrance potential (EP) of 10; and collision cell exit potential (CXP) of 12.5. Lipids were quantified using a mixture of isotopically labeled internal standards reported in Table B. Glucosylceramide and galactosylceramide were identified based on their retention time and the MRM characteristics of commercial reference standards (Avanti Polar Lipids, Birmingham, AL, USA). Quantification was performed using MultiQuant 3.02 (Sciex). Metabolites were normalized to either total protein, tissue weight or volume.

[0394] Table B: Acquisition parameter information for GlcCer and GalCer assays. [Table B]

[0395] Mass spectrometric analysis of eicosanoids A liquid chromatography system (Shimadzu Nexera X2 system, Shimadzu Scientific) coupled to electrospray mass spectrometry (Sciex QTRAP 6500+, Sciex, Framingham, MA, USA) was used. Eicosanoid analysis was performed by a BEH C18 1.7 μm, 2.1 × 100 mm column (Waters Corporation, Milford, Massachusetts, USA) using a flow rate of 0.6 mL / min at 40 °C. The mobile phase consisted of: A = water + 0.1% acetic acid, and B = 90:10 acetonitrile / isopropyl alcohol (v / v). The gradient was programmed as follows: 25% B from 0.0 to 1.0 min; 1.0 to 8.5 min to 95% B; 8.50 to 8.51 min to 95% B; 8.51 to 10.00 min to 25% B. Electrospray ionization was performed in negative ion mode applying the following settings: curtain gas at 30; collision gas set to medium; ion spray voltage at -4500; temperature at 600°C; ion source gas 1 at 50; ion source gas 2 at 60. Data acquisition was performed using Analyst 1.6.3 (Sciex) in multiple reaction monitoring mode (MRM) with the following parameters: residence time (milliseconds), collision energy (CE), and declustering potential (DP) for each species reported in Table C; entrance potential (EP) of -10; and collision cell exit potential (CXP) of -12. Eicosanoids were quantified using a mixture of non-endogenous deuterated internal standards as reported in Table C. Eicosanoids were identified based on their retention time and the MRM characteristics of commercial reference standards (Avanti Polar Lipids, Birmingham, AL, USA). Quantification was performed using MultiQuant 3.02 (Sciex) and Skyline. Metabolites were normalized to either total protein, tissue weight or volume. Protein concentrations were measured using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA).

[0396] Table C. Acquisition parameter information for the eicosanoid assay. [Table C-1] [Table C-2] [Table C-3]

[0397] Lipidomic analysis Lipid analysis was performed by liquid chromatography (Shimadzu Nexera X2 system, Shimadzu Scientific Instruments, Columbia, MD, USA) coupled to electrospray mass spectrometry (QTRAP 6500+, Sciex, Framingham, MA, USA). For each analysis, 5 μL of sample was chromatographed on a BEH C18 column at 55 °C using a flow rate of 0.25 mL / min. Injection was performed on a 1.7 μm, 2.1 × 100 mm column (Waters Corporation, Milford, Massachusetts, USA). For positive ionization mode, mobile phase A consisted of 60:40 acetonitrile / water (v / v) with 10 mM ammonium formate + 0.1% formic acid; mobile phase B consisted of 90:10 isopropyl alcohol / acetonitrile (v / v) with 10 mM ammonium formate + 0.1% formic acid. For negative ionization mode, mobile phase A consisted of 60:40 acetonitrile / water (v / v) with 10 mM ammonium acetate; mobile phase B consisted of 90:10 isopropyl alcohol / acetonitrile (v / v) with 10 mM ammonium acetate. The gradient was programmed as follows: 0.0–8.0 min from 45% B to 99% B, 8.0–9.0 min at 99% B, 9.0–9.1 min to 45% B, and 9.1–10.0 min at 45% B. Electrospray ionization was performed in either positive or negative ion mode applying the following settings: curtain gas at 30; collision gas set to medium; ion spray voltage at 5500 (positive mode) or 4500 (negative mode); temperature at 250 °C (positive mode) or 600 °C (negative mode); ion source gas 1 at 50; ion source gas 2 at 60. Data acquisition was performed using Analyst 1.6.3 (Sciex) in multiple reaction monitoring mode (MRM) with the following parameters: residence time (milliseconds) and collision energy (CE) for each species reported in Table D (negative mode) or Table E (positive mode); declustering potential (DP) of 80 (positive mode) and -80 (negative mode); entrance potential (EP) of 10 (positive mode) or -10 (negative mode); and collision cell exit potential (CXP) of 12.5 (positive mode) or -12.5 (negative mode). Lipids were quantified using a mixture of non-endogenous internal standards as reported in Tables D and E. Lipids were analyzed by their retention times and by the use of commercially available reference standards (Avanti Polar Metabolites were identified based on their MRM characteristics (Figure 1). Quantification was performed using MultiQuant 3.02 (Sciex). Metabolites were normalized to either total protein or cell number.

[0398] Table D. Acquisition parameter information for lipidomics assays in negative mode. [Table D-1] [Table D-2] [Table D-3] [Table D-4]

[0399] Table E. Acquisition parameter information for lipidomics assays in positive mode. [Table E-1] [Table E-2] [Table E-3] [Table E-4] [Table E-5] [Table E-6] [Table E-7]

[0400] Homogenization of ETV:IDS brain tissue and Trem2 analysis of ETV:IDS brain tissue and CSF 50 mg of tissue was homogenized twice for 3 min at 30 Hz using a Qiagen TissueLyzer II (Cat# / ID:85300) in 500 μL of 1× CST buffer (Cell Signaling Technology 9803S) made with complete protease inhibitors (Roche#04693132001) and PhosStop (Roche#04906837001). The homogenate was incubated on ice for 20 min and spun at 21,100 g for 30 min at 4°C. The resulting lysate was transferred to a clean 96-well deep plate and a BCA was performed to quantify total protein. Samples were then stored at -80°C until use in the assay.

[0401] For Trem2 analysis in brain tissue and soluble Trem2 (sTrem2) analysis in CSF, MSD GOLD 96w small spot streptavidin plates (MSD L45SA) were prepared by coating with 1ug / mL biotinylated sheep anti-mouse antibody (R&D Systems BAF1729) for Trem2 assay overnight at 4°C. The next day, MSD plates were rinsed with Tris-buffered saline with Triton (TBST) and blocked with 3% bovine serum albumin in TBST for 2 hours with shaking at 600 rpm. MSD plates were rinsed again with TBST and brain lysate was diluted 5-fold in blocking solution and added to MSD plates for 1 hour incubation at 600 rpm. After rinsing with TBST, sulfo-tagged sheep anti-mouse antibody (R&D Systems AF1729) was then added to the plate and re-incubated for 1 hour at 600 rpm, followed by a final rinse before the addition of 2x MSD read buffer diluted in water. Plates were then read using an MSD Meso Sector S600. Trem2 signals were normalized to protein concentration and plotted using GraphPad Prism.

[0402] Abbreviation BMP = bis(monoacylglycerol) phosphate; ETV:IDS = enzyme transport vehicle;IDS = iduronate 2-sulfatase;GlcCer = glucosylceramide;GalCer = galactosylceramide;IDS = iduronate 2-sulfatase;KI = knock-in;KO = knock-out;TfR mu / hu = Chimeric human / mouse transferrin receptor.

[0403] result To determine whether the robust GAG reduction observed in the brain resulted in correction of downstream disease-associated pathology, the ability of ETV:IDS to correct secondary lysosomal storage was evaluated. Four weekly active equivalent doses of ETV:IDS or idursulfase were administered to IDS KO;TfR mu / huIDS KO;TfR mice were intravenously administered lysosomal lipids, including gangliosides, glucosylceramide, and bis(monoacylglycerol)phosphate, and levels of a panel of lysosomal lipids were measured using liquid chromatography-tandem mass spectrometry (LCMS). mu / hu Significant lysosomal lipid accumulation was observed in the brains of KI mice compared to wild-type controls. After four weekly doses of 40 mg / kg, ETV:IDS was highly effective in lowering lysosomal lipids in the brain, completely lowering the levels of these lipids to those seen in wild-type mice. However, treatment with an activity-equivalent dose of idursulfase failed to lower the levels of these lysosomal lipids in the brain. Taken together, these data demonstrate that ETV:IDS effectively corrects secondary lysosomal accumulation in addition to its proximate effect on GAG accumulation.

[0404] In particular, Figures 5A-5B show that peripheral administration of ETV:IDS (4 weeks of treatment) corrects GAG accumulation in the brain (Figure 5A) and CSF (Figure 5B) in IDS KO mice. A 58% reduction in brain GAGs was observed with peripheral administration of ETV:IDS compared to a 14% reduction with an activity-equivalent dose of Elaprace. Also, a 66% reduction in CSF GAGs was observed with peripheral administration of ETV:IDS compared to a 27% reduction with an activity-equivalent dose of Elaprace (one outlier omitted for the ETV:IDS group). Figures 14A-14B show the reduction of individual GAG species (D00S0, D00A0, D00a4) in the brain and CSF. In a follow-up study, CSF GAGs were reduced 3-fold relative to WT at a dose of 40 mg / kg ETV:IDS.

[0405] FIG. 6 shows that peripheral administration of ETV:IDS (4 weeks of treatment) corrected lysosomal lipid (ganglioside) accumulation in IDS KO brains.

[0406] 7A-7B show that peripheral administration of ETV:IDS (4 weeks of treatment) corrected lysosomal lipid (GlcCer) accumulation in the IDS KO brain. While peripheral administration of ETV:IDS corrected GlcCer accumulation in the brain, no change in galactosylceramide (GalCer) was observed.

[0407] FIG. 8 shows that peripheral administration of ETV:IDS (4 weeks of treatment) corrected lysosomal lipid (BMP) accumulation in IDS KO brains.

[0408] FIG. 9 shows a heatmap showing lipid levels in the brains of IDS KO mice treated with vehicle, ETV:IDS, or elaprase (idursulfase). This heatmap was generated using modified data from Table 2. Specifically, the data in Table 2 was modified with a cutoff to indicate a difference of more than 10%, and values ​​between 0.9 and 1.1 were converted to 1.

[0409] FIG. 10 shows that peripheral administration of ETV:IDS corrected TREM2 accumulation in the IDS KO brain.

[0410] Figure 11 shows the TfR mu / hu Compared with the KI mouse cohort, IDS KO;TfR mu / hu Elevated sTrem2 levels in the CSF were observed in IDS KO;TfR KI mice. mu / hu It reduced the accumulation of sTrem2 levels in the CSF of KI mice.

[0411] Table 1 provides an overview of the GlcCer species analyzed, with levels expressed as fold relative to WT.

[0412] Table 2 provides data on lipid levels (fold change relative to WT) in the brains of IDS KO mice treated with vehicle, ETV:IDS, or elaplace.

[0413] Example 2. Measurement of brain GAGs, lysosomal lipids, and neurofilament light chain (Nf-L) in 3, 6, and 9 month old IDS KO mice Brain GAG, lysosomal lipid, and neurofilament light chain (Nf-L) levels were examined in 3-, 6-, and 9-month-old WT and IDS KO mice as described below.

[0414] Materials and Methods Animals used in this study were cared for as described herein (Example 1). Tissues were sampled and lipid and GAG levels were measured using the methods described herein (Example 1). Nf-L levels were measured as described below.

[0415] Methods for CSF and serum analysis of Nf-L Cerebrospinal fluid (CSF) was diluted 100-fold and serum was diluted 4-fold using Quanterix Simoa Neurofilament-Light (NF-L) Sample Diluent (Quanterix 102252) before application to a Simoa 96-well microplate (Quanterix 101457). The NF-Light assay was performed using Simoa detection and bead reagents (Quanterix 103159 and 102246, respectively) according to the instructions in the Simoa NF-Light Advantage Kit (Quanterix 1031086). After incubation of samples with detection and bead reagents at 30°C and 800 rpm for 30 min, sample plates were washed in a Simoa Microplate Washer with Simoa Wash Buffer A (Quanterix 103078) according to the Quanterix two-step protocol. SBG reagent (Quanterix 102250) was then added and samples were incubated at 30°C and 800 rpm for 10 min. The two-step wash protocol was continued and sample beads were resuspended twice in Simoa Wash Buffer B (Quanterix 103079) before a final aspiration of buffer. NF-L levels in samples were measured on a Quanterix SR-X instrument using the NF-Light analysis protocol and interpolated against a calibration curve provided with the Quanterix assay kit.

[0416] result Brain HS / DS(GAG) accumulation was measured at 3, 6, and 9 months of age in IDS KO mice compared to age-matched WT controls (Figure 1). GAG accumulation was significantly higher in IDS KO mice at all ages tested.

[0417] We also measured lysosomal lipid accumulation (GM1, GM2, GM3, BMP, GlcCer, and GD3) in the brains of IDS KO mice compared to age-matched WT controls (Figures 2A-2D). GM1 (d36:1) showed similar levels in both IDS KO and WT mice (Figures 2A and 2B), whereas GM2 (36:1), GM3 (36:1), BMP (36:2), GlcCer (34:1), and GD (39:1) levels all showed between a 1.7- and 5.5-fold increase relative to WT animals (Figures 2A-2D). Similar to GD3 (39:1), GD3 (36:1) was also increased in IDS KO (on average, 2-fold).

[0418] We also observed elevated levels of BMPs in the serum of IDS KO mice compared to their age-matched controls, with BMP(36:2) and BMP(44:12) specifically increased in 9-month serum samples collected in IDS KO mice compared to WT controls (Figure 3).

[0419] Elevated levels of lysosomal lipids (Gd1a / b, GM3, BMP, and GlcCer) were observed in the CSF of 9-month-old IDS KO mice compared with WT age-matched controls ( Fig. 4 ).

[0420] Nf-L is a useful marker of neurodegeneration (Norgren et al. 2003. Brain Research 987(1):25-31), but has not been previously associated with Hunter syndrome / MPSII. Nf-L concentrations in serum and CSF of 9-month-old IDS KO mice were elevated compared to age-matched cohorts of wild-type mice (Figure 26A, 26B). The relative difference in Nf-L levels in CSF increased with age of the mouse cohorts, with the greatest difference in Nf-L levels observed in the 9-month-old mouse cohort (Figure 26C). These results indicate that Nf-L may also be useful as a disease-associated and treatment-responsive biomarker in mouse models of Hunter syndrome.

[0421] Example 3. IDS KO x TfR muhu Effect of peripheral administration of ETV:IDS on GAGs and lysosomal lipids in mice IDS KO×TfR muhu The effects of various doses of ETV:IDS on GAGs and lysosomal lipids in mice were examined.

[0422] Materials and Methods Animal Care Mice were housed under a 12-hour light / dark cycle and allowed free access to water and standard rodent chow (LabDiet® #25502, Irradiated).

[0423] Mouse strains IDS KO × TfR used in this study mu / hu The mice are described above in Example 1. All mice used in this study were male.

[0424] Dosing and sample collection 2-3 month old IDS KO×TfR mu / hu Mice were intravenously injected once weekly for 4 weeks with saline, idursulfase (14.2 mg / kg body weight), or ETV:IDS (3, 10, 20, or 40 mg / kg body weight) (n = 5–8). 2- to 3-month-old littermates were intravenously injected with saline once weekly for 4 weeks. mu / hu Mice (n=5) were used as controls. Animals were euthanized 7 days after the last 4 weeks of dosing.

[0425] For final sample collection, animals were deeply anesthetized with an intraperitoneal (ip) injection of 2.5% Avertin. For CSF collection, a sagittal incision was made behind the animal's skull, the subcutaneous tissue and muscle were separated to expose the cisterna magna, and a pre-pulled glass capillary tube was used to perforate the cisterna magna and collect CSF. CSF was then collected in a low-dose 100 mL syringe. The serum was transferred to a Protein LoBind Eppendorf tube and centrifuged at 12,700 rpm for 10 min at 4°C. The CSF was transferred to a new tube and snap frozen on dry ice. The absence of blood contamination in the mouse CSF was confirmed by measuring the absorbance of the sample at 420 nm. Blood was collected by cardiac puncture for serum collection. For serum collection, blood was allowed to clot at room temperature for at least 30 min. The tube was then centrifuged at 12,700 rpm for 7 min at 4°C. The serum was transferred to a new tube and snap frozen on dry ice. The animals were perfused transcardially with ice-cold PBS using a peristaltic pump (Gilson Inc. Minipuls Evolution). The brain was cut and snap frozen on dry ice.

[0426] Tissue preparation and LCMS assay Tissue preparation and LCMS assays were performed using methods similar to those described in Example 1.

[0427] result A dose-dependent decrease in serum brain and CSF GAGs was observed in mice receiving ETV:IDS (FIGS. 12A-12C). Notably, serum GAGs were corrected downward to wild-type levels.

[0428] Importantly, even the lowest ETV:IDS dose tested (3 mg / kg) substantially reduced brain lysosomal lipids (GM3, GlcCer, and BMP) (Figures 13A-13C). Because lipid accumulation in IDS-deficient mice is thought to be a functional consequence of GAG accumulation, these results suggest that functional restoration of lysosomal function in the brain can be achieved even at elevated GAG levels compared to WT mice.

[0429] Example 4. Selection of specific CNS cell types from brain tissue We developed a protocol to isolate enriched populations of neurons, astrocytes, and microglial cells from brain tissue, and then used the enriched populations to investigate IDS KO × TfR mu / huThe effect of administering ETV:IDS in mice was investigated (Example 5).

[0430] Materials and Methods Animal Care Mice were housed under a 12-hour light / dark cycle and allowed free access to water and standard rodent chow (LabDiet® #25502, Irradiated).

[0431] Isolation of CNS cell types To prepare a single cell suspension for sorting CNS cells, mice were perfused with PBS, and brains were sectioned and processed into a single cell suspension using an adult brain dissociation kit (Miltenyi Biotec 130-107-677) according to the manufacturer's protocol. Cells were Fc blocked (Biolegend #101320, 1:100) and stained with Fixable Viability Stain BV510 (BD Biosciences #564406, 1:100) to exclude dead cells, CD11b-BV421 (BD Biosciences #562605, 1:100), CD31-PerCP Cy5.5 (BD Biosciences #562861, 1:100), O1-488 (Thermo / eBio#14-6506-82, 1:37.5), Thy1-PE (R&D#FAB7335P, 1:100), and EAAT2-633 (Alomone#AGC-022-FR, 1:50) for flow cytometry analysis. Cells were washed with PBS / 1% BSA and strained through a 100 μm filter before sorting CD11b+ microglia, EAAT2+ astrocytes, and Thy1+ neurons on a FACS Aria III (BD Biosciences) with a 100 μm nozzle. To obtain pure populations of astrocytes, microglia, and neurons, negative gates were set to eliminate O1+ and CD31+ cells, which are primarily oligodendrocytes and endothelial cells, respectively. Sorted cells were pelleted or collected directly in lysis buffer in preparation for downstream analysis including qRT-PCR, RNAseq, or glycomics as described in the related methods disclosed herein. Cell counts were used to calculate pg GAG / cell.

[0432] FIG. 15A is a schematic diagram of the CNS cell sorting protocol for isolation of pure populations of neurons, astrocytes, and microglial cells as well as downstream endpoints analyzed upon administration of ETV:IDS to mice (Example 5). FIG. 15B is a flow chart of the gating scheme used to isolate enriched populations of cells. FIG. 15C includes representative FACS gates for the sorting procedure. Starting from the top left to the bottom right: forward (FSC) and side (SSC) scatter determines cells from debris, live cells are positively gated, exclusion of CD31 positive endothelial cells is confirmed, EAAT2 positive astrocytes are subgated from CD11b microglia, Thy1 positive neurons are subgated from EAAT2 positive astrocytes, and final removal of O1 oligodendrocyte cells in the CD11b microglia, EAAT2 astrocytes, and Thy1 neuronal cell populations determines the final sorting criteria.

[0433] RNAseq and qPCR analysis of gene expression in isolated CNS cell types To validate the sorting method, sorted cell populations were analyzed for the expression of neuronal, astrocyte, and microglial genes by RNAseq and qPCR. Live cells were sorted directly in 350 μL of RLT-plus buffer (Qiagen, Hilden, Germany) with 1:100 beta-mercaptoethanol. RNA was extracted using an RNeasy Plus Micro Kit (Qiagen, 74034) and resuspended in 14 μL of nuclease-free water. RNA quantity and quality were assessed on a 2100 Bioanalyzer (Agilent) using an RNA 6000 Pico chip (Agilent 5067-1513). For qPCR validation, 1–2 μL of RNA was transcribed into cDNA using SuperScript IV (Invitrogen). Gene expression was assessed on a QuantStudio 6 Flex (Applied Biosystems) using Taqman probes for the target genes and normalized to Gapdh. For QuantSeq library preparation, RNA was processed using the QuantSeq 3'mRNAseq Library Prep Kit FWD for Illumina (Lexogen) with UMI second strand synthesis module to identify and remove PCR duplicates after the "low input" protocol defined by the manufacturer. Barcoded samples were quantified using the NEBNext Library Quant Kit for Illumina (NEB, E7630S). All samples were pooled in equimolar ratios into one sequencing library, which was quantified on a Bioanalyzer using a High Sensitivity DNA chip (Agilent, 5067-4626). 50 bp single-end reads were generated on an Illumina HiSeq 4000 lane at the UCSF Center for Advanced Technology.

[0434] For RNAseq raw data processing, UMIs were extracted from raw sequencing reads using umi2index (Lexogen) and sequencing adapters were trimmed with skewer (Jiang et al. 2014. BMC Bioinformatics 15:182). Reads were aligned to mouse genome version GRCm38_p6. STAR index (version 2.5.3a) was constructed with -sjdbOverhang=50 arguments (Dobin et al. 2013. Bioinformatics 29:15-21). Splice junctions from Gencode gene models (release M17) were provided by the -sjdbGTFfile argument. STAR alignments were generated using the following parameters: -outFilterType BySJout, -quantMode TranscriptomeSAM, -outFilterIntronMotifs RemoveNoncanonicalUnannotated, -outSAMstrandField intronMotif, -outSAMattributes NH HI AS nM MD XS and -outSAMunmapped Within. Alignments were obtained using the following parameters: -readFilesCommand zcat -outFilterType BySJout -outFilterMultimapNmax 20 -alignSJoverhangMin 8 -alignSJDBoverhangMin 1 -outFilterMismatchNmax 999 -outFilterMismatchNoverLmax 0.6 -alignIntronMin 20 -alignIntronMax 1000000 -alignMatesGapMax 1000000 -quantMode GeneCounts -outSAMunmapped Within -outSAMattributes NH HI AS nM MD XS -outSAMstrandField intronMotif -outSAMtype BAM SortedByCoordinate -outBAMcompression 6.Alignments that shared the same UMI and mapped to the same genomic location were collapsed using the collapse_UMI_bam tool (Lexogen). Gene-level counts were obtained using featureCounts (version 1.6.2) from the Subread package (Liao et al. 2013. Bioinformatics 30:923-930). Gene symbol and biotype information were extracted from Gencode GTF files.

[0435] All RNA-seq expression analyses were performed with R (R Core Team 2018; version 3.2) using the voom analysis framework (Law et al. 2014. Genome biology 15:R29) from the limma package (Ritchie et al. 2015. Nucleic Acids Research 43:e47). Gene expression profiles were TMM normalized (Robinson and Oshlack. 2010. Genome Biology 11:R25) to identify low abundance genes and exclude them prior to downstream analyses. Low abundance genes were defined as those that were not expressed higher than 10 counts per million (CPM) in at least four samples.

[0436] For principal component analysis to determine what variance accounts for the major differences between samples, the log-transformed CPM expression values ​​from the 500 genes with the highest variance were used for principal component analysis. Projections of samples onto the first two principal components are shown in Figure 16. Principal components 1 and 2 account for 48% and 26% of the variance in the data, respectively.

[0437] For each cell type, marker genes were identified by combining the results of individual pairwise differential expression tests between itself and the other two cell types. Marker gene p-values ​​for each gene were calculated by combining the nominal p-values ​​from the two "out-of-group" differential expression tests using the Simes method (Simes, RJ 1986. Biometrika 73:751-754). False discovery rates (FDR) were calculated from the combined p-values ​​using the Benjamini-Hochberg method (Benjamini and Hochberg. 1995. Journal of the Royal Statistical Society. Series B (Methodological) 57:289-300). Genes were sorted by reducing the mean log fold change vs. the other two cell types, and the top 20 genes with FDR<0.01 were used as marker genes for the cell. Individual pairwise differential expression tests were performed using limma / voom. To identify genes with strong enrichment of expression in the target cell type versus the remaining cell types, we tested statistical significance against a 5-fold change threshold using the treatment framework in limma (Robinson and Oshlack, supra).

[0438] result To confirm the enrichment and purity of the isolated cell populations, gene expression profiles for each of the sorted populations were analyzed using RNA-Seq and qRT-PCR and compared to known profiles (Figures 16, 17A-17C, and 25). Strong enrichment of corresponding cell type-specific genes in the isolated populations as well as a reduction in endothelial and oligodendrocyte gene markers were observed. This collective data demonstrates that highly pure populations of neurons, astrocytes, and microglia were obtained.

[0439] Figure 17A shows the expression of classical cell-specific markers identified from the literature in purified neurons, astrocytes, microglia, and input cell suspensions as determined by RNA-Seq. Columns are genes specific to cell types: (endo.) endothelium, (oligo.) oligodendrocytes; expression values ​​per gene are shown as the number of standard deviations (z-score) away from its mean; n=4 mice.

[0440] Figure 17B lists and shows the expression of the top 20 enriched genes as determined by fold enrichment >5.0 and FDR <0.01 for each cell type. Heatmap expression values ​​are plotted as gene-level z-scores. Input cells were single cell suspensions from dissociated brains.

[0441] Figure 17C contains representative qRT-PCR data generated from isolated cell populations, confirming that the populations were successfully enriched for neurons, astrocytes, and microglia. Gene classes are grouped on the x-axis: (Astro) astrocytes, (MG) microglia, (Neu) neurons, (Oligo) oligodendrocytes, and (Endo) endothelial cells; n=5 mice. Graphs show mean±SEM.

[0442] Figure 25: Cell type-specific enriched gene set table; information in the table corresponds to the heatmap in Figure 17B. Expression of the top 20 genes for each cell type as determined by fold enrichment >5.0 and FDR <0.01 is listed in ascending order of p-value. The average log fold change (logFC.avg) is relative to the other two "outer" populations, and the rightmost three columns show the average expression of genes within each cell population; n=4 mice.

[0443] Example 5. IDS KO x TfR muhu Effect of peripheral administration of ETV:IDS on GAGs and lysosomal lipids in specific CNS cell types in mice IDS KO×TfR muhuThe effects of various doses of ETV:IDS on GAGs and lysosomal lipids in specific CNS cell types in mice were examined.

[0444] Materials and Methods Animal Care Mice were housed under a 12-hour light / dark cycle and allowed free access to water and standard rodent chow (LabDiet® #25502, Irradiated).

[0445] Mouse strains TfR used in this study mu / hu Mice and IDS KO×TfR mu / hu The mice are described above in Example 1. All mice used in this study were male.

[0446] Dosing and sample collection 2-3 month old IDS KO×TfR mu / hu Mice were intravenously injected with saline or ETV:IDS (40 mg / kg body weight) once per week for 4 weeks (n = 4–6 per treatment). 2–3 month old littermates TfR were intravenously injected with saline once per week for 4 weeks. mu / hu Mice (n = 4-6) were used as controls. Animals were euthanized 7 days after the last 4 weeks of dosing.

[0447] For final sample collection, animals were deeply anesthetized with an intraperitoneal (ip) injection of 2.5% Avertin. For CSF collection, a sagittal incision was made behind the animal's skull, the subcutaneous tissue and muscle were separated to expose the cisterna magna, and a pre-pulled glass capillary tube was used to perforate the cisterna magna and collect CSF. CSF was then collected in a low-dose 100 mL syringe. The serum was transferred to a Protein LoBind Eppendorf tube and centrifuged at 12,700 rpm for 10 min at 4°C. The CSF was transferred to a new tube and snap frozen on dry ice. The absence of blood contamination in the mouse CSF was confirmed by measuring the absorbance of the sample at 420 nm. Blood was collected by cardiac puncture for serum collection. For serum collection, blood was allowed to clot at room temperature for at least 30 min. The tube was then centrifuged at 12,700 rpm for 7 min at 4°C. The serum was transferred to a new tube and snap frozen on dry ice. The animals were perfused transcardially with ice-cold PBS using a peristaltic pump (Gilson Inc. Minipuls Evolution). The brain was cut and snap frozen on dry ice.

[0448] Isolation of CNS cell types CNS cells were sorted as described to obtain pure populations of astrocytes, microglia, and neurons (Example 4). Sorted cells were pelleted or directly collected in lysis buffer and then processed for downstream analysis including qRT-PCR, RNAseq, or glycomics as described in the related methods. Cell counts were used to calculate pg GAG / cell.

[0449] Preparation of cell lysates and LCMS assays for the measurement of GAG, BMP, gangliosides, GlcCer, and GalCer were performed using methods similar to those described in Example 1.

[0450] Distribution analysis of ETV:IDS across CNS cell types Viable cells in sheath fluid (approximately 1.5 ml) were sorted directly into 150 μL of 5% CHAPS lysis buffer (final CHAPS concentration 0.5%). Samples were concentrated with an Amicon Ultra 30KDa filter. 5 μL of sample or recombinant ETV:IDS dilution series was run with the IgG (human) AlphaLISA detection kit (PerkinElmer #AL205C) according to the manufacturer's instructions and read on an EnVision™ plate reader. Sample concentrations were interpolated from a standard curve generated using ETV:IDS and normalized to total cell input.

[0451] result IDS KO;TfR mu / hu The cell type-specific distribution and efficacy of ETV:IDS in the brains of KI mice were evaluated.

[0452] GAG levels in enriched CNS cell populations were quantified by LC-MS / MS as described. Figure 18A shows that GAG levels were significantly higher in IDS KO;TfR mu / hu TfR expression in microglia, astrocytes, and neurons isolated from KI mice mu / hu These results show that IDS expression is elevated compared to KI controls, demonstrating substrate accumulation across all three CNS cell types when IDS expression is knocked out (n=3–5 mice per group). IDS KO;TfR mu / hu KI mice (n=4 mice per group) were dosed intravenously with 40 mg / kg ETV:IDS and enzyme concentrations were assessed across CNS cell populations 2 hours after dosing. Figure 18B shows that significant accumulation of ETV:IDS was observed in neurons, astrocytes, and microglia, demonstrating that ETV:IDS is effectively distributed to the brain parenchyma and taken up by key CNS cell types. All data are presented as mean ± SEM; unpaired Student's t-test p≦0.05*, 0.001***.

[0453] Next, IDS KO;TfR mu / huKI mice were dosed intravenously with 40 mg / kg ETV:IDS once a week for 4 weeks and LC-MS / MS was used to assess the ability of ETV:IDS to reduce GAG ​​accumulation in all three CNS cell types. Figure 19 shows that ETV:IDS treatment reduced GAG levels in neurons, astrocytes, and microglia to levels comparable to those seen in wild-type mice after repeated dosing. Data are presented as mean ± SEM; one-way ANOVA with Tukey's multiple comparison test, *p≦0.05, **p≦0.01. The data demonstrate that ETV:IDS allows IDS to be delivered through the brain endothelium to brain cells and that this delivery is sufficient for efficacy across important CNS cell types.

[0454] ETV:IDS treatment also reduced secondary accumulation of lysosomal lipids including gangliosides (FIG. 20), glucosylceramide (FIG. 21), and bis(monoacylglycerol)phosphate (BMP) (FIG. 22) in CNS cell types of interest (e.g., neurons, astrocytes, microglial cells). These data indicate that treatment with ETV:IDS corrects secondary lysosomal dysfunction in addition to primary GAG accumulation in CNS cell types.

[0455] Example 6. Spatial distribution of accumulated lipid species and correction of lipid accumulation by ETV:IDS IDS KO×TfR muhu The effects of different doses of ETV:IDS on the spatial distribution of lysosomal lipids and microglial activation in mice were examined.

[0456] Mouse strains and treatments TfR used in this study mu / hu Mice and IDS KO×TfR mu / hu Mice were as described in Example 1 above. All mice used in this study were male. Mice were administered saline, idursulfase, or ETV:IDS (40 mg / kg body weight) and euthanized for tissue analysis as described in Example 1.

[0457] Mass spectrometry-based imaging of ganglioside levels Brain tissue was snap frozen on aluminum foil that was gently pressed into liquid nitrogen for approximately 10 seconds. Frozen brains were stored at -80°C until ready for use. Prior to sectioning, brains were placed in a cryostat chamber to allow the tissue to equilibrate to -20°C. Brains were cut into 12 μm thick sections on a cryostat (Leica Biosystems, Buffalo Grove, IL) and thaw-mounted onto indium tin oxide (ITO)-coated slides (Delta Technologies, Loveland, CO). Two brain levels were collected at approximately +0.72 mm and -1.82 mm from bregma. Plates with sections designated for IMS were washed three times with chilled (approximately 4°C) 50 mM ammonium formate and allowed to dry at room temperature before matrix application. Additional sections were obtained for H&E staining. After staining, digital photomicrographs were obtained with a slide scanner (Leica Biosystems, Buffalo Grove, IL). For matrix application, plates were coated with 1,5-diaminonaphthalene (DAN) MALDI matrix by sublimation (Hankin et al. 2007. Journal of the American Society for Mass Spectrometry 18:1646-1652; Thomas et al. 2012. Analytical Chemistry 84:2048-2054). Briefly, 100 mg of recrystallized DAN was placed in the bottom of a glass sublimation apparatus (Chemglass Life Sciences, Vineland, NJ). The apparatus was placed on a metal heating block set at 130°C, and DAN was allowed to sublimate onto the tissue surface for 4 minutes at a pressure of less than 25 mTorr. Approximately 1.8 mg of DAN was applied to each slide, which was determined by weighing the slides before and after matrix application. The coated plates were then placed in a Petri dish, flushed with nitrogen gas, and stored at -80°C for 2 days prior to MS analysis (Yang et al. 2019. International Journal of Mass Spectrometry 437:3-9).

[0458] Plates were equilibrated to room temperature before removal from the sealed Petri dish for imaging mass spectrometry. Brain sections were imaged on a Solarix 15T FT-ICR MS (Bruker Daltonics, Billerica, MA) equipped with a SmartBeam II 2 kHz frequency tripled Nd:YAG laser (355 nm). Images were acquired in negative ion mode with a spatial resolution of 100 μm. Each pixel is the average of 1000 laser shots using a small laser focus setting and random walk within a 100 μm pixel. The mass spectrometer was externally calibrated with a set of phosphorus clusters (Sladkova et al. 2009. Rapid Communications in Mass Spectrometry 23:3114-3118). Data were collected from m / z 600-3,000 using a 1M time-domain file size (FID length = 1.3631 s), resulting in a resolution of 153,000 at m / z 1041. Images were generated using FlexImaging 3.0 (Bruker Daltonics, Billerica, Mass.). Gangliosides were identified by exact mass, typically with a mass accuracy better than 1 ppm.

[0459] immunohistochemistry Fresh frozen mouse brain tissue was sectioned coronally at 10 microns using a Leica cryostat (Leica CM 1950). Sections were mounted directly onto Fisherbrand Superfrost Plus microscope slides and stored at -80°C until processed for immunohistochemistry. Sections were rinsed 3 times for 5 minutes in 1x PBS and then fixed in 4% paraformaldehyde for 15 minutes. Sections were then rinsed 3 times for 5 minutes in 1x PBS and incubated in blocking solution (1x PBS / 5% normal goat serum / 0.3% Triton X-100) for 1 hour at room temperature. Sections were then incubated in primary antibody (BioRad: rat anti-Cd68, 1:500) prepared in blocking solution for 2 hours at room temperature. Sections were rinsed 3 times for 5 min in 1× PBS / 0.3% Triton X-100, followed by incubation in secondary antibody (Invitrogen: goat anti-rat Alexa Fluor 488, 1:500) and DAPI (Invitrogen Molecular Probes D1306: 1:10,000 from a stock solution of 5 mg / mL) prepared in blocking solution for 1 h in the dark at room temperature. Sections were then rinsed 3 times for 5 min in 1× PBS / 0.3% Triton X-100, rinsed quickly in 1× PBS, and coverslipped using polyvinyl alcohol mounting medium with DABCO antifade (Sigma 10981). Fluorescent images were acquired at 20x magnification using a Zeiss Axio Scan Z1. Each fluorophore was imaged individually using the appropriate single channel filter set, using identical exposure times per fluorophore across all tissue samples imaged. Individual images were then tiled using Zeiss Zen software and stitched together with shading correction.

[0460] result IDS KO;TfR mu / huImaging mass spectrometry (IMS) was performed to determine the spatial distribution of lipid accumulation in the brains of KI mice and to assess whether ETV:IDS administration was able to correct lysosomal lipid accumulation throughout the brain. Wild-type and IDS KO;TfR mice were treated with 4 weekly doses of vehicle, idursulfase or ETV:IDS. mu / hu MALDI MS images were acquired from coronal brain sections of KI mice. Representative images for selected ganglioside species are shown in FIG. 23. The middle panel shows the distribution of the signal at m / z 1382.816, which corresponds to GM2 (d36:1), whereas the lower panel shows the distribution of the signal at m / z 1179.738, which corresponds to GM3 (d36:1). Images show the relative intensity of each signal from 0 to 100%.

[0461] As shown in FIG. 23, IDS KO;TfR mu / hu Enrichment of several species of gangliosides in the brains of KI mice was observed compared to wild-type controls, similar to the results observed in the analysis of homogenized tissues (Figure 6). Ganglioside accumulation was region specific, enriched in the hypothalamic and amygdala brain regions. Four weekly doses of ETV:IDS reduced accumulation of these ganglioside species throughout all brain regions evaluated to levels seen in wild-type mice, whereas only a modest reduction in gangliosides was observed with idursulfase treatment. Taken together, these data demonstrate that ETV:IDS can correct lysosomal dysfunction downstream of GAG accumulation in the CNS.

[0462] Neuroinflammation represents a common hallmark of many neuropathic LSDs, and there is an emerging consensus that glial activation, commonly reported in mouse models of MPSII disease and in MPS patients, may contribute to progressive degeneration throughout the brain in MPS disorders. Levels of two markers of microglial activity, CD68 and triggering receptor 2 (Trem2) expressed on myeloid cells, were assessed by immunohistochemical analysis of brain tissue sections or biochemical analysis of brain lysates, respectively. Figure 24 shows the increase in TfR activity in mice treated with vehicle, ETV:IDS or idursulfase. mu / hu KI and IDS KO;TfR mu / hu Representative images of immunofluorescence staining for DAPI and CD68 from KI mouse brains. Magnification is 20x and images represent the hippocampus (upper panel), cortex (middle panel), and striatum (lower panel). Figure 10 shows the levels of Trem2 in treated mice.

[0463] Both CD68 and Trem2 levels were significantly higher in IDS KO;TfR mu / hu In the brains of KI mice, TfR mu / hu Four weekly doses of 40 mg / kg ETV:IDS reduced IDS KO;TfR mu / hu ETV:IDS effectively reduced CD68 signals throughout the brain of KI mice (Figure 21). Trem2 levels in the brain were completely reduced to levels seen in wild-type mice after repeated systemic administration of ETV:IDS (Figure 10). However, four weekly active equivalent doses of idursulfase failed to reduce CD68 and Trem2 levels. ETV:IDS administration also reduced the CD68 signal throughout the brain of treated IDS KO;TfR mice (Figure 22). mu / hu ETV:IDS reduced the accumulation of soluble Trem2 (sTrem2) in the CSF of KI mice (Figure 11). These data demonstrate that ETV:IDS can attenuate microglial activity in addition to GAG and secondary lysosomal lipid accumulation in the brain.

[0464] Example 7. Construction of a fusion protein containing an IDS. Design and Cloning We designed IDS-Fc fusion proteins containing (i) a fusion polypeptide in which the mature human IDS enzyme was fused to a human IgG1 fragment containing an Fc region ("IDS-Fc fusion polypeptide"), and (ii) a modified human IgG1 fragment containing a mutation in the Fc region that confers transferrin receptor (TfR) binding ("modified Fc polypeptide"). In particular, we generated IDS-Fc fusion polypeptides in which the IDS fragment was fused to either the N-terminus or C-terminus of the Fc region of human IgG1. In some cases, a linker was placed between the IDS and the IgG1 fragment to relieve any steric hindrance between the two fragments. In all constructs, the signal peptide from kappa chains V-III, amino acids 1-20 (UniProtKB ID-P01661), was inserted upstream of the fusion to facilitate secretion, and the IDS was truncated to consist of amino acids S26-P550 (UniProtKB ID-P22304). The fragment of the Fc region of human IgG1 used corresponds to amino acids D104-K330 (positions 221-447 (EU numbering) including the 10 amino acids of the hinge (positions 221-230)) of the sequence in UniProtKB ID P01857. In some embodiments, a second Fc polypeptide derived from human IgG1 residues D104-K330 but lacking the IDS fusion was co-transfected with the IDS-Fc fusion polypeptide to generate a heterodimeric fusion protein with one IDS enzyme ("monozyme"). In some constructs, the IgG1 fragment contained additional mutations to facilitate heterodimerization of the two Fc regions. Control IDS-Fc fusion proteins lacking mutations that confer TfR binding were designed and constructed similarly with the difference that these proteins lacked mutations that confer TfR binding. As an additional control, we generated an IDS (amino acids S26 to P550) with a C-terminal hexahistidine tag (SEQ ID NO: 203) to facilitate detection and purification.

[0465] The TfR-binding IDS-Fc fusion protein used in this example is a dimer formed by an IDS-Fc fusion polypeptide and a modified Fc polypeptide that binds to TfR. In the case of a dimer in which an IDS enzyme is linked to the N-terminus of the Fc region, the IDS-Fc fusion polypeptide may have the sequence of any one of SEQ ID NOs: 113, 193, and 197. In these sequences, the IDS sequence is underlined and contains a cysteine ​​to formylglycine modification at position 59 (double underlined). The IDS was joined to the Fc polypeptide by a GGGGS linker (SEQ ID NO: 201). A portion of the IgG1 hinge region (DKTHTCPPCP; SEQ ID NO: 111) was included at the N-terminus of the Fc polypeptide. The CH2 domain sequence begins at position 541 of SEQ ID NOs: 113, 193, and 197.

[0466] The IDS-Fc fusion protein ETV:IDS 35.21 is a dimer formed by an IDS-Fc fusion polypeptide having the sequence of any one of SEQ ID NOs: 113, 193, and 197 and a modified Fc polypeptide that binds to TfR having the sequence of SEQ ID NO: 114. The first 10 amino acids are part of the IgG1 hinge region. The CH2 domain sequence starts at position 11 of SEQ ID NO: 114.

[0467] The IDS-Fc fusion protein ETV:IDS 35.21.17.2 is a dimer formed by an IDS-Fc fusion polypeptide having the sequence of any one of SEQ ID NOs: 113, 193, and 197 and a modified Fc polypeptide that binds to TfR having the sequence of SEQ ID NO: 190. The first 10 amino acids are part of the IgG1 hinge region. The CH2 domain sequence starts at position 11 of SEQ ID NO: 190.

[0468] The IDS-Fc fusion protein ETV:IDS 35.23.2 is a dimer formed by an IDS-Fc fusion polypeptide having the sequence of any one of SEQ ID NOs: 113, 193, and 197 and a modified Fc polypeptide that binds to TfR having the sequence of SEQ ID NO: 191. The first 10 amino acids are part of the IgG1 hinge region. The CH2 domain sequence starts at position 11 of SEQ ID NO: 191.

[0469] The IDS-Fc fusion protein ETV:IDS 35.21.17 is a dimer formed by an IDS-Fc fusion polypeptide having the sequence of any one of SEQ ID NOs: 113, 193, and 197 and a modified Fc polypeptide that binds to TfR having the sequence of SEQ ID NO: 117. The N-terminus of the modified Fc polypeptide can include a portion of the IgG1 hinge region (e.g., SEQ ID NO: 111).

[0470] Recombinant protein expression and purification To express recombinant IDS enzymes fused to Fc regions, ExpiCHO cells (Thermo Fisher Scientific) were transfected with the relevant DNA constructs using the Expifectamine™ CHO transfection kit according to the manufacturer's instructions (Thermo Fisher Scientific). Cells were grown in ExpiCHO™ Expression medium at 37°C, 6% CO2 and 120 rpm in an orbital shaker (Infors HT Multitron). Briefly, logarithmically growing ExpiCHO™ cells were transfected with 0.8 μg of DNA plasmid per mL of culture volume at 6 × 10 6Cells were transfected at a density of 1000000000000000000000 cells / ml. After transfection, cells were returned to 37°C and transfected cultures were supplemented with nutrients as indicated 18-22 hours after transfection. Transfected cell culture supernatants were harvested 120 hours after transfection by centrifugation at 3,500 rpm for 20 minutes. Clarified supernatants were filtered (0.22 μM membrane) and stored at 4°C. Expression of epitope-tagged IDS enzymes (used as controls) was performed as described above with minor modifications. Briefly, IDS enzymes carrying a C-terminal hexahistidine tag (SEQ ID NO: 203) were expressed in ExpiCHO cells.

[0471] IDS-Fc fusion proteins with or without modified Fc regions that confer TfR binding were purified from cell culture supernatants using Protein A affinity chromatography. The supernatant was loaded onto a HiTrap MabSelect SuRe Protein A affinity column (GE Healthcare Life Sciences, using Akta Pure System). The column was then washed with >20 column volumes (CV) of PBS. Bound proteins were eluted using 100 mM citrate / NaOH buffer pH 3.0 containing 150 mM NaCl. Immediately after elution, fractions were neutralized (at a 1:5 dilution) using 1 M arginine-670 mM succinate buffer pH 5.0. The homogeneity of IDS-Fc fusion proteins in the eluted fractions was assessed by reducing and non-reducing SDS-PAGE.

[0472] To purify the hexahistidine-tagged (SEQ ID NO: 203) IDS enzyme, the transfected supernatant was diluted with 15 L of 20 mM HEPES containing 100 mM NaCl. The mixture was dialyzed extensively overnight against pH 7.4. The dialyzed supernatant was bound to a HisTrap column (GE Healthcare Life Sciences, using Akta Pure System). After binding, the column was washed with 20 CV of PBS. Bound proteins were eluted using PBS containing 500 mM imidazole. The homogeneity of the IDS enzyme in the eluted fractions was assessed by reducing and non-reducing SDS-PAGE. The pooled fractions containing the IDS enzyme were diluted 1:10 in 50 mM Tris pH 7.5 and further purified using Q Sepharose High Performance (GE Healthcare). After binding, the column was washed with 10 CV of 50 mM Tris pH 7.5. Bound proteins were eluted using a linear gradient to 50 mM Tris pH 7.5 and 0.5 M NaCl and collected in 1 CV fractions. Fraction purity was assessed by non-reducing SDS-PAGE. Purification produced homogenous IDS-Fc fusion protein and hexahistidine-tagged (SEQ ID NO: 203) IDS enzyme.

[0473] Example 8. IDS KO x TfR muhu Effects of peripheral administration of ETV:IDS on GAG and neurofilament light chain (Nf-L) in mice IDS KO×TfR muhu The effects of a weekly IV dose of ETV:IDS on GAG and neurofilament light chain (Nf-L) in mice were examined.

[0474] Materials and Methods Animal Care Mice were housed under a 12-hour light / dark cycle and allowed free access to water and standard rodent chow (LabDiet® #25502, Irradiated).

[0475] Mouse strains IDS KO×TfR used in this study mu / hu Mice and TfR mu / huKI mice are described above in Example 1. All mice used in this study were male.

[0476] Dosing and sample collection 8-week-old IDS KO;TfR mu / hu KI mice were injected intravenously (IV) via the tail vein with 1 mg / kg or 3 mg / kg ETV:IDS. mu / hu KI mice (IDS WT) were used as non-disease controls. ETV:IDS or vehicle was administered once a week for a period of 13 weeks. All animals were euthanized 7 days after their last dose.

[0477] Viability serum and terminal CSF samples were collected as described in Example 1. Brain and liver tissue samples were also collected as described in Example 1. Urine was also collected and chilled immediately prior to termination. Urine samples were then stored in a freezer set to maintain -60 to -80°C for urinary biomarker analysis.

[0478] Quantification of GAGs Brain and liver tissues were prepared for quantification of GAGs (e.g., heparan sulfate (HS) and dermatan sulfate (DS)) as described in Example 1. Protein lysates (from tissues) or CSF, urine, or serum were mixed with a combination of heparinase I, II, III, and koidriotinase B prior to LCMS assay to quantitate GAGs. Digests were mixed with acetonitrile and analyzed by LCMS. LCMS assay to quantitate GAGs was performed as described in Example 1.

[0479] Methods for CSF and serum analysis of Nf-L Nf-L levels in serum and CSF were measured as described in Example 2.

[0480] result GAGs in brain, CSF, liver, and urine. IDS KO;TfR mu / huGAG levels in the brain from mice were measured 7 days after the last dose of ETV:IDS and after vehicle treatment and TfR mu / hu Consistent with earlier results, brain GAG levels decreased with increasing doses of ETV:IDS, at 1 and 3 mg / kg, respectively, compared with vehicle-treated IDS KO;TfR mice. mu / hu The treatment yielded 64% and 75% efficacy from mice (data not shown). CSF GAG levels also decreased with increasing doses of ETV:IDS, with 1 and 3 mg / kg ETV:IDS compared with vehicle-treated IDS, respectively. KO;TfR mu / hu The treatment yielded 60% and 70% efficacy from 100% and 150% mice (data not shown). Liver GAG levels showed near-complete correction at all dose levels of ETV:IDS (1 and 3 mg / kg, respectively, compared with vehicle-treated IDS KO;TfR mu / hu Mice were treated with ETV:IDS for 13 weekly treatments (98% and 96% treatment efficiency) (Figure 28). Urinary GAG levels were also reduced after 13 weekly treatments with ETV:IDS. Creatinine-normalized GAG levels were treated with ETV:IDS for 1 and 3 mg / kg (78% and 85%, respectively) (Figure 28).

[0481] CSF neurofilament light chain (Nf-L). As shown in Figures 26A-26C, elevated levels of Nf-L in CSF and serum were observed in a mouse model of Hunter syndrome. A weekly dose of ETV:IDS over a 13-week period was able to reverse these changes, and ETV:IDS-treated IDS KO;TfR mu / hu Complete normalization of CSF Nf-L was observed in IDS WT controls. Treatment efficiencies for Nf-L correction were 82% and 117% at 1 and 3 mg / kg, respectively, lowering the levels of Nf-L to those observed in IDS WT controls (Figure 27).

[0482] table Table 1. Summary of GlcCer levels in the brains of IDS KO mice treated with ETV:IDS (fold over WT). [Table 1]

[0483] Table 2. Lipid levels in the brain of IDS KO mice treated with vehicle, ETV:IDS, or Elaprace (fold change relative to WT). [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6]

[0484] Unofficial sequence listing [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8]

Table 3-9

Table 3-10

Table 3-11

Table 3-12

Table 3-13

Table 3-14

Table 3-15

Table 3-16

Table 3-17

Table 3-18

Table 3-19

Table 3-20

Table 3-21

Table 3-22

[0485] All publications, patents, and patent documents are incorporated by reference herein as if individually incorporated by reference. The disclosure has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention. The present invention provides, for example, the following items. (Item 1) 1. A method for detecting one or more biomarkers in a subject having a lysosomal storage disorder (LSD), the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample from the subject, the combination of lipids comprising: a) bis(monoacylglycero)phosphate (BMP), b) GM2 ganglioside and / or GM3 ganglioside, c) GD3 ganglioside, d) GD1a / b gangliosides, and e) Glucosylceramide (GlcCer) The measuring step is selected from the group consisting of: 2) measuring the concentration of GlcCer in a sample from the subject, wherein the LSD is a mucopolysaccharidosis (MPS) disorder; 3) measuring the concentration of neurofilament light chain (Nf-L) in a sample from the subject; and / or 4) measuring the concentration of soluble triggering receptor expressed on bone marrow cells 2 (sTREM2) in a sample from the subject. The method comprising: (Item 2) 1. A method for assessing the efficacy of a treatment in a subject having a LSD, the method comprising: 1) measuring the concentration of a combination of two or more lipids in a sample obtained from the subject after administration of the treatment, the combination of lipids comprising: a) BMP, b) GM2 ganglioside and / or GM3 ganglioside, c) GD3, d) GD1a / b, and e) GlcCer The measuring step is selected from the group consisting of: 2) measuring the concentration of GlcCer in a sample obtained from the subject after administration of the treatment, wherein the LSD is an MPS disorder; 3) measuring the concentration of Nf-L in a sample obtained from the subject after administration of the treatment; and / or 4) measuring the concentration of sTREM2 in a sample obtained from the subject after administration of the treatment. Including, The method, wherein a reduction in the concentration of the selected lipid(s) / protein(s) in the sample obtained from the subject after administration of the treatment compared to the concentration of the lipid(s) / protein(s) in a sample obtained from the subject before administration of the treatment correlates with treatment efficacy. (Item 3) 3. The method of item 1 or 2, further comprising administering a LSD treatment to said subject. (Item 4) The method of any one of items 1 to 3, further comprising adjusting a treatment regimen for the subject. (Item 5) 1. A method for treating LSD in a subject, the method comprising: 1) administering an LSD treatment to said subject; 2) a) a combination of two or more lipids in a sample from the subject, the combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer The combination selected from the group consisting of: b) GlcCer in a sample from said subject, wherein said LSD is an MPS disorder; c) Nf-L in a sample from the subject, and / or d) sTREM2 in a sample from said subject To measure the concentration of 3) adjusting the dosage of the LSD treatment based on the concentration of the selected lipid(s) / protein(s) in the sample from the subject compared to a control value. The method comprising: (Item 6) The method of any one of items 1 to 5, further comprising measuring a concentration of a combination of two or more lipids. (Item 7) The method according to any one of items 1 to 5, comprising measuring a concentration of sTREM2. (Item 8) 6. The method according to any one of items 1 to 5, comprising measuring a concentration of the Nf-L. (Item 9) 6. The method according to any one of items 1 to 5, comprising measuring a concentration of the GlcCer, and the LSD is an MPS disorder. (Item 10) The method of any one of items 1 to 5, comprising measuring the concentration of one or more lipids and the concentration of sTREM2. (Item 11) The method according to any one of items 1 to 5, comprising measuring the concentration of one or more lipids and the concentration of Nf-L. (Item 12) 7. The method of any one of items 1 to 6, wherein the combination comprises a BMP. (Item 13) 7. The method according to any one of items 1 to 6, wherein the combination comprises GlcCer. (Item 14) 7. The method of any one of items 1 to 6, wherein the combination includes GD3. (Item 15) 7. The method of any one of items 1 to 6, wherein the combination comprises GD1a / b. (Item 16) 7. The method of any one of items 1 to 6, wherein the combination includes GM2. (Item 17) 7. The method of any one of items 1 to 6, wherein the combination includes GM3. (Item 18) The combinations include BMP and GlcCer; BMP and GD3; BMP and GD1a / b; BMP and GM2; BMP and GM3; GlcCer and GD3; GlcCer and GD1a / b; GlcCer and GM2; GlcCer and GM3; GD3 and GD1a / b; GD3 and GM2; GD3 and GM3; GD1a / b and GM2; GD1a / b and GM3; BMP, GlcCer and GD3; BMP, GlcCer and GD1a / b; BMP, GlcCer and GM2; BMP, GlcCer and GM3; BMP, GD3 and GD1a / b; B MP, GD3 and GM2; BMP, GD3 and GM3; BMP, GD1a / b and GM2; BMP, GD1a / b and GM3; BMP, GM2 and GM3; GlcCer, GD3 and GD1a / b; GlcCer, GD3 and GM2; GlcCer, GD3 and GM3; GlcCer, GD1a / b and GM2; GlcCer, GD1a / b and GM3; GlcCer, GM2 and GM3; GD3, GD1a / b and GM2; GD3, GD1a / b and GM3; GD3, GM2 and GM3; GD1a / b, GM2 and GM3; BMP, GlcCer, GD3 and GD1a / b;BMP, GlcCer, GD3 and GM2;BMP, GlcCer, GD3 and GM3;BMP, GlcCer, GD1a / b and GM2;BMP, GlcCer, GD1a / b and GM3;BMP, GlcCer, GM2 and GM3;BMP, GD3, GD1a / b and GM2;BMP, GD3, GD1a / b and GM3;BMP, GD3, GM2 and GM3;BMP, GD1a / b, GM2 and GM3;GlcCer, GD3, GD1a / b and GM2;GlcCer, GD3, GD1a / b and GM3;GlcCer, GD3, G any of items 1 to 6, including M2 and GM3; GlcCer, GD1a / b, GM2 and GM3; GD3, GD1a / b, GM2 and GM3; BMP, GlcCer, GD3, GD1a / b and GM2; BMP, GlcCer, GD3, GD1a / b and GM3; BMP, GD3, GD1a / b, GM2 and GM3; BMP, GlcCer, GD3, GM2 and GM3; BMP, GlcCer, GD1a / b, GM2 and GM3; GlcCer, GD3, GD1a / b, GM2 and GM3; or BMP, GlcCer, GD3, GD1 / b, GM2 and GM3. Either one of the methods. (Item 19) 19. The method of any one of items 1 to 18, wherein the LSD is an MPS disorder. (Item 20) 20. The method of item 19, wherein the MPS disorder is Hunter Syndrome. (Item 21) 21. The method of any one of items 2 to 20, wherein said LSD treatment comprises hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT), substrate synthesis inhibition therapy, chaperone therapy and / or gene therapy. (Item 22) 22. The method of item 21, wherein the LSD treatment comprises brain-targeted ERT. (Item 23) The LSD treatment comprises: (a) a first Fc polypeptide linked to an enzyme replacement therapy (ERT) enzyme, an ERT enzyme variant, or a catalytically active fragment thereof; and (b) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide. is a protein comprising 23. The method of item 22, wherein the first Fc polypeptide and / or the second Fc polypeptide does not comprise an immunoglobulin heavy and / or light chain variable region sequence or an antigen-binding portion thereof. (Item 24) 24. The method of item 23, wherein the ERT enzyme is iduronate 2-sulfatase (IDS), an IDS variant, or a catalytically active fragment thereof. (Item 25) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 114. (Item 26) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 131. (Item 27) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 167. (Item 28) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 190. (Item 29) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 191. (Item 30) 24. The method of item 23, wherein the first Fc polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 113, 193, and 197, and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 117. (Item 31) 1. A method for screening a test agent for activity as a treatment for a LSD, the method comprising: 1) contacting a cell with the test agent, wherein the cell has a lysosomal storage deficiency; and 2) a) a combination of two or more lipids in said cell, said combination of lipids comprising: i) BMP, ii) GM2 ganglioside and / or GM3 ganglioside, iii) GD3, iv) GD1a / b, and v) GlcCer The combination selected from the group consisting of: b) GlcCer in said cells, wherein said test agents are screened for activity as an MPS treatment; c) Nf-L in said cells, and / or d) sTREM2 in the cells To measure the concentration of Including, The method, wherein a decrease in the concentration of the selected lipid(s) / protein(s) in the cells compared to the concentration of the corresponding lipid(s) / protein(s) in control cells indicates that the test agent has activity as an LSD treatment. (Item 32) 32. The method of item 31, comprising measuring a concentration of sTREM2. (Item 33) 32. The method of item 31, comprising measuring a concentration of Nf-L. (Item 34) 32. The method of item 31, comprising measuring the concentration of GlcCer. (Item 35) 32. The method of item 31, comprising measuring the concentration of a combination of two or more lipids. (Item 36) 32. The method of item 31, comprising measuring the concentration of one or more lipids and the concentration of sTREM2. (Item 37) 32. The method of item 31, comprising measuring the concentration of one or more lipids and the concentration of Nf-L. (Item 38) 38. The method of any one of items 31 to 37, wherein the cell is a brain cell. (Item 39) A corrected CNS cell comprising a reduced accumulation of a metabolic species, the CNS cell comprising a deficiency of a lysosomal enzyme that causes the accumulation of the metabolic species in the cell, (i) a first Fc polypeptide linked to the lysosomal enzyme; and (ii) a second Fc polypeptide that forms an Fc dimer with the first Fc polypeptide; wherein the protein is capable of binding to a transferrin receptor (TfR) to provide the corrected CNS cell comprising the reduced accumulation of the metabolic species. (Item 40) 40. The CNS cell of item 39, wherein the protein binds to TfR with an affinity of about 50 nM to about 350 nM. (Item 41) 41. The CNS cell of item 39 or 40, wherein the enzyme is iduronate 2-sulfatase (IDS) or an enzymatically active variant thereof. (Item 42) The metabolic species include glycosaminoglycans (GAGs) and / or gangliosides, glycoproteins, and glycoproteins. 42. The CNS cell of any one of items 39 to 41, wherein the lysosomal lipid is selected from the group consisting of sylceramide, galactosylceramide, and BMP. (Item 43) 43. The CNS cell of any one of items 39 to 42, wherein the CNS cell is selected from the group consisting of a neuron, an astrocyte, and a microglial cell. (Item 44) 1. A method for selecting a population of CNS cells from a tissue sample, comprising: (a) contacting the tissue sample with a primary antibody for a neuron marker, a primary antibody for an astrocyte marker, a primary antibody for a microglia marker, a primary antibody for an endothelial marker, and a primary antibody for an oligodendrocyte marker, each primary antibody being uniquely labeled to provide a labeled tissue sample; (b) sorting the cells in the labeled tissue sample by flow cytometry. Including, The method provides distinct cell populations of neurons, astrocytes, and microglial cells. (Item 45) 45. The method of item 44, wherein the neuronal marker primary antibody is an anti-Thy1 antibody. (Item 46) 46. ​​The method of claim 44 or 45, wherein the microglia marker primary antibody is an anti-CD11b antibody. (Item 47) 47. The method of any one of items 44 to 46, wherein the astrocyte marker primary antibody is selected from the group consisting of an anti-EAAT2 antibody and an anti-astrocyte surface antigen-2 (ACSA-2) antibody. (Item 48) 48. The method of any one of items 44 to 47, wherein the endothelial marker primary antibody is an anti-CD31 antibody. (Item 49) 49. The method of any one of items 44 to 48, wherein the oligodendrocyte marker primary antibody is an anti-O1 antibody. (Item 50) 50. The method of any one of items 44 to 49, providing a distinguishable population of microglial cells comprising less than about 20% non-microglial cells, a distinguishable population of astrocytes comprising less than about 20% non-astrocytic cells, and / or a distinguishable population of neurons comprising less than about 20% non-neuronal cells. (Item 51) Microglial cell populations expressed the marker profile O1 - / CD31 - / CD11b + The astrocyte population was selected based on the marker profile O1 - / CD31 - / Thy1 - / EAAT2 + Or O1 - / CD31 - / Thy1 - / ACSA-2 + and / or the neuronal population is selected based on the marker profile O1 - / CD31 - / Thy1 + / EAAT2 - Or O1 - / CD31 - / Thy1 + / ACSA-2 - 51. The method according to any one of items 44 to 50, wherein the method is selected based on the above. (Item 52) 52. The method of any one of items 44 to 51, wherein the enriched cell population is analyzed for quantification of sTREM2, Nf-L, metabolic species and / or nucleic acid species. (Item 53) 53. The method of claim 52, wherein the metabolic species is a glycosaminoglycan (GAG) species or the lipid species is selected from the group consisting of gangliosides, glucosylceramides, galactosylceramides, and BMPs. (Item 54) 54. The method of any one of items 44 to 53, wherein the enriched cell population is analyzed for quantification of the administered therapeutic agent. (Item 55) 55. The method of item 54, wherein the administered therapeutic agent is ETV:IDS.

Claims

[Claim 1] The invention described in this specification.

Citation Information

Patent Citations

  • Biomarkers for lysosomal storage disorders

    WO2013030785A1